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ABSTRACT 
Type 1 diabetes (T1D) is characterised by an absolute insulin deficiency resulting from 
the chronic and progressive destruction of pancreatic β-cells by the immune system cells. 
Continuous subcutaneous insulin infusion (CSII) is becoming a popular technique for 
insulin delivery among T1D patients. Exercise is known to exert anti-inflammatory 
effects and metabolic control. Therefore it was of interest to study this in T1D using CSII. 
The objectives of this thesis were to further understanding of the effect of exercise on 
blood glucose, hemoglobin A1c, lipids, insulin and inflammatory markers in healthy and 
T1D volunteers. Three studies have been investigated where the diabetic volunteers used 
multi daily injections (MDI) or CSII. Firstly a survey was conducted aimed to investigate 
the effect of exercise on T1D patients using CSII therapy. The second study examined the 
acute and chronic effects of resistance and cardio exercise at moderate intensity on 
inflammatory markers such as IL-6, IL-1β, TNF-α and IFN-γ in healthy and T1D using 
MDI or CSII. Finally, a study was undertaken to find out the effects of chronic moderate 
intensity exercise on lipids profile and glycaemic control in healthy and T1D using MDI 
or CSII. 
The statistical analysis of the survey showed that CSII therapy for T1D had a significant 
reduction on A1c, insulin requirement and improvement of lipids profile compared to 
MDI. Moreover, majority of CSII users (63%) rarely suffered from hypoglycemia during 
exercise. The second study demonstrated that acute and chronic exercises have a positive 
impact on the inflammatory markers among CSII users e.g. in CSII users statistically 
significant increase in IL-6 and TNF-α levels were observed (P=0.014 and P=0.001 
respectively). The last study showed that lipids profile, total daily insulin units were 
13 
 
improved and A1c levels were significantly reduced in CSII as well as MDI groups after 
6 weeks of exercise.   
T1D affects major organs e.g. heart, kidneys, blood vessels etc. However, good glycaemic 
control can reduce the risk of diabetes complications. This study suggested that CSII 
therapy along with exercise can maintain the BG level close to normal, as all 5 
participants of the study showed an improvement in their BG levels after exercise. 
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Chapter 1: Introduction 
1. Diabetes Mellitus 
1.1 Overview 
It has been observed that Diabetes Mellitus (DM) has no geographical boundaries and 
become a common disease all over the world. In the UK it represents about 5% of the 
population (see table 1.1) 
Table 1.1: Diabetes (Both Types) Prevalence in UK (2011) 
 Prevalence Number of patients 
Northern Ireland 3.8% 72,693 
Scotland 4.3% 223,494 
Wales 5.0% 160,533 
England 5.5% 2,455,937 
Diabetes causes the glucose levels in blood to rise via insulin deficiency, resistance to 
insulin, or both (Kumar and Kumar 2005). Insulin dependent DM is known as Type1 
(T1D) and non-insulin dependent is referred to as type2 (T2D). DM of either type can 
be treated but it cannot be cured and statistically causes sufferers to die at a younger age 
than non- sufferers (Kumar and Clark 2002). The number of people who have diabetes 
(either type) varies from region to region and country to country.  
Recently in an international league table compiled and published in Diabetes UK 
(January 2013) it was stated that the UK (24.5 T1D cases per 1000) and Saudi Arabia 
(31 cases of T1D per 1000) has one of the highest world’s rate of T1D in children aged 
14 and below (5
th
 and 3
rd
 highest, respectively in the world). Key statistics on diabetes 
show that, in UK, in 2012, 10% of adult diabetic patients suffers from T1D and when 
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children are included, 15% of diabetic patients are diagnosed with T1D (Diabetes April 
2012).(Table 1.1 shows prevalence of diabetes both types) 
It has been estimated that in UK more than 5%of population is suffering from diabetes, 
some are diagnosed while others are undiagnosed and are sleep walking into the 
diabetes trap (Hex, Bartlett et al. 2012)T1D may become apparent at any age; however 
it is most commonly known to appear before the age of twenty, with children aged 12 
years old being most at risk. The average age that T2D appears is 40 years old. 
However, people from ethnic groups such as Afro Americans are at risk of T2D at a 
younger age.  
1.2 Diagnosing Diabetes 
Diagnosis of T1D and T2D is usually triggered by symptoms of frequent urination 
(polyuria) extreme thirst (polydipsia) and weight loss. These symptoms increase day by 
day and week by week. Around a quarter of people who have recently developed type 1 
diabetes have developed worse symptoms by the time their diabetes is diagnosed. 
Diagnosis of other forms of diabetes is usually made with other procedures, such as; 
screening, looking for hyperglycemia during health checks and through the detection of 
secondary symptoms such as changes in eyesight and extreme tiredness (WHO 2006).  
Sometimes diabetes is only noticed when a person experiences a health problem that has 
been caused by diabetes, such as a heart attack, a stroke, neuropathy, a foot ulcer that 
will not heal, problems with eyes, fungal diseases, neonatal macrosomia and or 
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hyperglycemia. A person with diabetes will have relentless hyperglycemia and they will 
be diagnosed if they are showing any of the following symptoms: 
1. A level of fasting plasma glucose at or above 126mg/dL (7.0mmol/l). 
2. The WHO states that a person will be diagnoses with diabetes if they have a 
plasma blood glucose level at or above 200mg/dL (11.11mmol/l) two hours 
after having a 75mg dose of glucose. 
3. If they show symptoms of hyperglycemia and a casual plasma glucose which 
is at or above 200mg/dL (11.1mmol)  
If a person shows a positive result when there is not unequivocal hyperglycemia present 
then any of the procedures mentioned above should be carried out again on a different 
day. Most clinicians use the fasting glucose level and glucose tolerance test (which 
takes two hours) to confirm the diagnosis of diabetes mellitus. Two samples giving 
fasting glucose measurements above (126mg/dl or 7.0 mmol/l) are considered to be a 
confirmation of the diagnosis of diabetes mellitus (ADA 2012). People who have a 
fasting glucose level between 100 and 126 mg/dL (6.1 and 7.0 mmol) are described as 
having an impaired fasting glucose and may need an oral glucose tolerance test to 
exclude overt diabetes. Those who have a plasma glucose from 7mmol (126mg/dL) and 
11.0mmol/L (200mg/dL) two hours after receiving 75g of glucose are classified as 
having a low glucose tolerance and they should have an oral glucose tolerance test 
(ADA 2012). People who have a lowered tolerance to glucose are considered to be at a 
very high risk of developing overt diabetes (ADA 2012). An increased level of glucose 
permanently bonded to hemoglobin (glycated or glycosylated hemoglobin or A1c) of 
6.0% or more (the 2003 revised U.S. standard) is seen as abnormal by most labs; A1c is 
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mainly used as a tracking test that reflects average blood glucose levels over the 
previous 90 days. However, some doctors may order this test at the time of diagnosis of 
diabetes. The current suggested target for A1c in patients with diabetes is <7.0%, which, 
although higher than the normal healthy level is an indicator of fairly good glycaemic 
control in the diabetic subject. Some authorities are stricter (<6.5%) but imposition of 
this by compliant patients may risk some hypoglycaemic episodes. In the ACCORD and 
ADVANCE programmes, T2D patients were randomised to intensive or standard 
regimens but there were excess deaths in the intensive group in which patients were 
encouraged to aim for A1c levels below 6% but there is dispute to whether this was 
actually because of hypoglycemia (Bloomgarden 2008). Patients who have diabetes and 
have A1c levels that fall below 7% have a considerably fewer problems caused by 
diabetes. 
1.3 Impact of diabetes 
1.3.1. Epidemiology and Complications of Diabetes 
Whiting, Guariguate et al. (2011) reported that in 2011 there were almost 280 million 
diabetic patients around the globe and this number rose to 371 million in 2012. It is 
expected that the number will go pass 500 million mark by the end of 2030 (Whiting, 
Guariguata et al. 2011). While Diabetes UK (Diabetes April 2012) claimed that in 2011 
around8.3% of adults (i.e. 366 million) worldwide were suffering from diabetes and it 
has been projected that by 2030 this figure will rise 552 million. The American Diabetes 
Association (ADA) has claimed that around 1 in every 3 people born in 21
st
 century (i.e. 
after 2000), in America, will be diagnosed with diabetes at some point in their lives 
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(Weiss and Sumpio 2006). In 2011 ADA estimated that the number of people with DM 
in US were 25.8 million (children and adults) and that means 8.3% of US population 
live with DM. Diabetes UK 2012 reported that this disease is slightly more common in 
men (6.3 per cent) than in women (5.3 per cent) in England (Table 1.2).  
Table 1.2: Prevalence of diabetes by age group in England (2010) 
Age group Female Male 
16–34 2.1% 1.8% 
35–54 6.6% 9.4% 
55–64 8.0% 11.1% 
65–74 12.2% 15.2% 
75+ 13.2% 15.9% 
 
Controlling of medical conditions related to diabetes has been shown to reduce the risk 
of complications (Stratton, Adler et al. 2000; Diabetes April 2012). However, serious 
complications occur when diabetes is not well managed particularly stroke, cardio 
vascular disease, renal failure, blindness and amputation of limbs (especially lower 
limbs) leading to permanent disability and mortality. Microvascular and macrovascular 
problems can be caused by inefficient glycaemic control.  Macrovascular problems are 
characterised by blocking of the main arteries which in turn can lead to stroke and 
myocardial infarction. Among diabetic sufferers stroke is the most common cause of 
death (Diabetes April 2012). In 2013 ADA data shows that, stroke risk and adult heart 
disease death are 2 to 4 times higher among people with diabetes. NHS data shows that 
in UK 10% of all hospital admissions are associated with diabetes (Diabetes April 
2012). 
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As mentioned above one of the major causes of mortality and morbidity in patients with 
diabetes is cardiovascular disease (CVD) (Martins, Fonseca et al. 2013). CVD may 
increase insulin resistance in T1D patient (Cleland, Fisher et al. 2013). Moreover, 
Diabetes Control and Complications Trial (DCCT), recruited 1441 T1D sufferers (13 to 
39 years old) from 29 medical centres across North America (i.e. US and Canada), 
concluded the “absolute risk for fatal CVD events per 1,000 person-years to be 1.37 and 
2.51 in intensive and conventional diabetes treatment groups, respectively” (Lung, 
Clarke et al. 2013). In recent research it has been observed that CVD is increased by a 
minimum of two- to fourfold and in diabetes it is the main reason behind the death rate 
in both types of diabetes (Martins, Fonseca et al. 2013). It is worth noting that poor 
glycaemic control and its secondary derangement of biochemistry, is the main cause of 
CVD in youth with T1D (Dobrovolskiene, Mockeviciene et al. 2013). 
CVD is a major cause of death and so a public health concern in the UK (Allender, Peto 
et al. 2012). It has been reported that in 2010, almost 147,000 deaths i.e. almost third of 
all deaths were caused by one or other form of CVD. In the US is considered to be the 
main cause of death and it has been reported that 813,000 deaths were caused by CVD 
(Allender, Peto et al. 2012). It is also worth noting that in the US around 82.6 million 
people aged over 20 years are affected by CVD (Roger, Go et al. 2011). There are four 
different types of CVD:  
i. coronary heart disease,  
ii. stroke,  
iii. peripheral arterial disease; and  
iv. aortic disease. 
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T1D is associated with a high risk of coronary heart disease (Salem, AboElAsrar et al. 
2010). In adults, aerobic exercise coupled with a restricted diet regime, is a very 
efficient way of improving total cholesterol (TC) to high-density lipoprotein cholesterol 
(HDL) ratio, low-density lipoprotein cholesterol (LDL) and triglycerides (TG) (Kelley, 
Kelley et al. 2011). Exercise enhances glycemic control and reduces the risk of 
developing cardiovascular problems (Kelley, Kelley et al. 2011). Aerobic exercise 
training decreases hepatic and visceral lipids in obese people without weight loss 
(Johnson, Sachinwalla et al. 2009). Furthermore, resistance training decreased TC, 
TC/HDL-C ratio, non-HDL, LDL and TG in adults (Kelley and Kelley 2009). 
T1D is caused by cellular-mediated obliteration of the pancreatic β-cells that causes a 
loss of the ability to secrete insulin (Groop and Pociot 2013). Moreover, T1D is a result 
of a progressive autoimmune process, where β-cells in the islets of Langerhans are 
destroyed or damaged. Clinical onset and β-cell destruction mechanisms leading to T1D 
are still unclear (Bonifacio 2013). This process causes insulin deficiency and 
hyperglycemia. Nonetheless, this condition is potentially treatable by effective 
interventional therapy (Ahmed, Akirav et al. 2013). In recent years many researchers 
highlighted the role of T cells as pathogenic effectors cells in T1D. Recently, it has been 
established that two types of T-Cells are the main contributor to T1D progression. 
i. Treg Cells (Regulatory T cells): These are commonly known as suppressor T 
cells. On one hand these cells control the immune system, while on the other 
hand these cells abrogate autoimmune disease and maintain tolerance to self-
antigens. In summary these cells control the activity of auto reactive and 
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inflammatory cells, the implication being that either their frequencies or 
suppressive function are altered in T1D (Brusko and Atkinson 2007). 
ii. TH-17:  These cells are a subtype of CD4+ helper T cells. These cells provide 
protection against extracellular bacteria and mediate pathological responses in 
autoimmune disease (Ryba-Stanislawowska, Skrzypkowska et al. 2013).  
These two types of T cells are responsible for the appropriate function of the immune 
system and control inflammation. The decrease of Tregs and/or increase of TH-17 may 
provoke local inflammation and destruction of β cells. It has also been observed that 
diabetic complications are speeded by the inflammatory effects of the disease which 
means the complications, as well as the disease, are inflammatory in nature (Ryba-
Stanislawowska, Skrzypkowska et al. 2013).  
T1D is characterized by the presence of autoantibodies recognizing islet antigens 
(Diana, Gahzarian et al. 2011). Despite the critical role of antibodies for the diagnosis of 
the disease in patients, many data suggest that T cells are the key players in the 
autoimmune attack of β-cells (Bluestone, Herold et al. 2010). Medical research shows 
that in the development of T1D, infection can have either inhibitory or potentiating role 
(Lehuen, Diana et al. 2010). 
In addition hyperglycemia itself  induces inflammation in T1D complications (Jiang, 
Wei et al. 2012). In the recent past (2010), attempts have been made to study the role of 
insulin resistance (IR) in T1D and observed that IR plays a greater role in T1D process 
than commonly known (Dib 2006). Dib (2006) also suggested that “IR may reflect more 
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aggressive form of autoimmune disease mediated by immune-inflammatory factors that 
also mediate β-cell destruction (TNF-alpha and IL-6)”. 
Furthermore, hyperglycemia increases nuclear factor kappa B (NF-κB) p65, interleukin-
l beta (IL-1β) and TNF-α levels (Jiang, Wei et al. 2012). Additionally, IFN-γ is playing 
an important role in the autoimmune pathogenesis in patients with T1D (Lee, Kwon et 
al. 2012; Yi, Li et al. 2012). 
1.3.2. Death Rates of Diabetes 
In 2008 the World Health Organisation (WHO) reported diabetes as the ninth cause of 
death in the world. However, in National Vital Statistics Reports 2012 by Donna, 
diabetes was the seventh cause of death with 3.4% (Ventura, Curtin et al. 2012).   
According to NHS information centre for Health and Social Care, Leeds the mortality 
analysis 2007-2008 by National Diabetes Audit (2011) it is estimated that 15-16 % of 
the 460 000 deaths occurring in England in 2009 were attributable to diagnosed diabetes 
(Duncan and Goldacre 2012). 
The number of death certificates, where diabetes is a cause of death or a contributory 
factor, was increased 5-fold between 1995 and 2010 (Duncan and Goldacre 2012). 
Furthermore, according to NHS diabetes care in England and Wales, 24,000 people with 
diabetes deceased earlier than expected. In a report published by NHS on their website 
it is claimed that the death risk for T1D patients is 2.6 times higher than that of the 
general population and for T2D it is 1.6 times higher. The report further claimed that in 
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younger people with T1D the mortality rate is even higher (e.g. 15-34 year old female 
patients with T1D are 9 times more likely to die than non-T1D females in same age 
group) (NHS, 2011). 
In summary, cardiovascular disease and kidney disease are the main causes of the death 
among diabetic patients. (de Zeeuw, Remuzzi et al. 2004; Ley, Tsiami et al. 2011) 
(Roglic, Unwin et al. 2005). A drop in the mortality caused by prolonged diabetes 
related medical complications was observed in the early onset group. While in the late 
onset cohort no such effect was observed (Harjutsalo, Forsblom et al. 2011).  
1.3.3. Finance and Economic Problem 
Globally in 2012, the equivalent to 11% of the total healthcare budget was spent on 
diabetes i.e. USD 471 billion in 2012 and this may rise to USD 595 billion by 2030 
(Guariguata 2012). 
According to Diabetes UK records in 2012 it is estimated that above £10 billion were 
spent by NHS on diabetes which is 10% of NHS budget (with a 2010/2011 total NHS 
expenditure of approximately £103 billion). This translates to £192 million per week, 
£27 million daily, £1 million per hour, £17,000 per minute and £286 every second. In 
UK the cost of diabetes (direct care and indirect costs) stands at £23.7 billion and is 
estimated to rise to £39.8 billion by 2035; £ 16.9 billion in direct costs (£ 1.8 billion for 
T1D and £ 15.1 billion for T2D) and £ 22.9 billion in indirect costs (£ 2.4 billion and £ 
20.5 billion) (Hex, Bartlett et al. 2012; Diabetes April 2012). In March 2013 ADA 
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stated that, based on 2012 data, in US total cost of diagnosed diabetes stands at $245 
billion, while direct medical cost of DM stands at $176 billion. 
1.4. Diabetes Mellitus Classification 
In 1979 the National Diabetes Data Group (NDDG) was the first worldwide accepted 
classification scheme for diabetes. They classified diabetes based on the pharmacologic 
therapy applied into two major groups (Maraschin Jde 2012). These types are insulin-
dependent diabetes mellitus (IDDM) otherwise known as type 1 diabetes (T1D) and 
non-insulin-dependent diabetes mellitus (NIDDM) which is type 2 diabetes (T2D). 
While the insulin criterion remains technically true, the fact is that at least 40% of T2D 
sufferers use insulin (although are not dependent on it), thus the terminology has moved 
to T1D and T2D. T1D is often known as childhood-onset diabetes (Rother 2007). T2D 
can be described as adult onset diabetes and obesity-related diabetes (Krentz 2012). 
1.4.1. Type 1 Diabetes (Insulin Dependent) 
As explained, multiple autoimmune attack underlies the patho-mechanism of T1D 
(Hermann, Krikovszky et al. 2005). About 80% of β-cell destruction occurs before T1D 
becomes clinically evident. The islet cell autoantibodies (ICAs) are responsible for this 
destruction (Shriver 2011). 
It has been mentioned before that T1D is characterised by the presence of 
autoantibodies and the T-cells (Tregs &TH-17) are considered to be responsible for the 
T1D and the T1D and its complications are inflammatory in nature. In a study of 
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recently diagnosed children with T1D,insulitis was confirmed to involve the infiltration 
of CD8+ and CD4+ T-cells, macrophages and β-cells (In't Veld 2011). CD4+ T helper 
(TH) cells as well as CD8+ cytotoxic T (Tc) cells are responsible for the T-cell mediated 
immunity in T1D (Liblau, Wong et al. 2002; Shao, He et al. 2012). These T-Cells 
release cytokines and chemokines which are responsible for the β-cell destructive 
functions of these T-Cells. Nonetheless, we are still unclear about how the β-cells are 
destroyed, which means the immune activity depends upon the structure of the 
inflammatory proteins. Current theories involve T helper (TH-1) cells such as 
lymphocytes which cause the cell-mediated immunity by production of IFNγ alongside 
TNF, enhanced activity of cytotoxic T (Tc) cells and initiation of macrophages, 
together leading to improve the levels of inflammatory cytokines (e.g. IL-6 and IL-1β) 
(Ryden and Faresjo 2013). IL-1β, and TNF- were played a central role of β-cells 
destruction, TNF- secretion was inhibited by IL-6, and this may have some protecting 
effects (Hermann, Krikovszky et al. 2005).  
It is worth mentioning that the major causes of T2D are insulin resistance and metabolic 
syndrome (Brooks-Worrell, Narla et al. 2012).  
1.5. Management, Lifestyle and Diet of diabetes patients 
T1D has a 90 year history of insulin treatment (Hirsch and Skyler 2012) and it is 
important to support people with diabetes to understand their condition so that they gain 
optimum benefit from the treatment. 
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In UK there are two education programmes which are nationally designed to help 
people with diabetes to gain the skills and confidence to manage their condition. One of 
is for T1D, a scheme called the Dose Adjustment for Normal Eating (DAFNE) was 
designed to help people to adjust their insulin injections to fit their lifestyles. The other 
one is designed for T2D sufferers and is known as The Diabetes Education and Self-
Management for On-going and Newly Diagnosed (DESMOND) and not necessarily 
focused on insulin. 
To achieve near normal glycemia, T1D needs intensive diabetes management and the 
care of T1D patient either child or adult should be under specialists supervision team 
qualified in the care of diabetes (Care 2011). T1D children are different from T1D 
adults in many respects such as ability to provide self-care, insulin sensitivity, and 
unique neurological weakness to hypoglycemia and Diabetic ketoacidosis (DKA)(Care 
2011). 
In 1980 attempts were made to achieve glycemic control, by developing new techniques 
and instruments, such as usage of human insulin, CSII therapy, A1c to assess integrated 
glycemic control and home self-monitoring of blood glucose (SMBG) (Hirsch 2009; 
Hirsch and Skyler 2012). This aligned with the later DCCT findings that showed a 
strong relationship between controlled blood glucose and the neuropathic and micro 
vascular complications in T1D patients(Hirsch and Skyler 2012) 
It has been shown that eating healthily, exercising frequently, not smoking and not 
drinking alcohol are effective in treating both forms of diabetes i.e. T1D and T2D (Hu, 
Manson et al. 2001). 
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Diets and reducing energy intake (low in carbohydrate) for twelve weeks cause a 
reduction in the amount of fasting plasma glucose in the body by 25.7%, decrease blood 
pressure by 8.1%, cholesterol 9.2% and triglycerides by 26.7% (Anderson, Kendall et 
al. 2003). The Nutrition Subcommittee of the Diabetes Care Advisory Committee of 
Diabetes UK (2011) suggests various lifestyle changes, such as having food that has a 
low glycaemic index and monounsaturated fats instead of foods high in saturated fats 
and doing exercise (Dyson, Kelly et al. 2011).  
Diabetes UK suggests that people with diabetes should have a healthy, balanced diet, as 
everyone should; a diet that low in fat, sugar and salt, with lots of fruit and vegetables. 
Meals should contain high levels of starchy foods such as bread, potatoes, cereals, pasta 
and rice (Anderson, Kendall et al. 2003). Diets that contain 55-60% carbohydrate, 15-
20% protein and 20-30% fat have shown to be the most effective in improving 
glycaemic control and lipid management when used with an optimum insulin regimen.  
Regular exercise is considered to play a key role in the management of diabetes, as it 
improves control of blood glucose, reduce risk of cardiovascular disease, cause weight 
loss, and enhance overall well-being (American Diabetes Association) (ADA 2012).  
1.6. Diabetes and glucose 
1.6.1. Overview 
Under regular physiological conditions, glucose is the main energy source for the cells. 
It also acts as a precursor to various metabolites in nearly all tissues. Glucose is 
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discharged into the blood by the liver in the fasting state due to glycogen being broken 
down and used (oxidised) for the energy requirements of cells, while the insulin 
controls the postprandial removal of excess glucose from the blood. Glucose is carried 
into most cells by specific proteins or transporters that cover the cell membrane and 
permit the connecting and transferring of glucose across the hydrophobic lipid layer 
(Scheepers, Joost et al. 2004).  
1.6.2. Glucose transport pathways 
Glucose is transported around the body by a group of membrane proteins that aid the 
carrying of glucose over a plasma membrane. Two common types of glucose carriers 
have been identified in cells are:  
i. The facilitative glucose transporters (GLUT) family are a protein family that is 
found in most mammalian cells (Scheepers, Joost et al. 2004).  
ii. Sodium-Glucose linked transporters are found in small intestine and the 
proximal tubule of the nephron (Scheepers, Joost et al. 2004). 
In people without diabetes, the blood glucose remains at a normal level which is 3.5–5.5 
mmol/l before meals and less than 8 mmol/l, 2 hours after meals (Diabetes April 2012). 
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1.6.3. Glucose control 
In healthy human beings, when glucose is released during food digestion insulin is 
released into the portal bloodstream from the pancreatic islet β-cells as will be discussed 
in detail below (section 1.6). Now due to insulin signalling GLUT 4 glucose 
transporters move from cytoplasm into the plasma membrane, this movement allows 
glucose to enter the cell. (1, 2 and 3 are the movements of GLUT4) (see figure 1.1), it 
starts a cascade ending in the uptake of glucose by recruiting glucose carrier proteins on 
the cell surface. Within the cell, glucose is metabolised i.e. being utilised as energy or 
kept in the muscle and liver glycogen (Lin and Accili 2011).  
 
Figure 1.1: How insulin is delivered to cells Insulin receptor substrate 1 (IRS-1), 
phosphoinositide 3-kinase (PI-3), glucose transporter type 4 (GLUT4) see text.. 
 
On the other hand, insulin decreases blood glucose in the fasting state by stopping the 
production of hepatic glucose from glycogen (i.e. suppressing the gluconeogenesis) 
(Ramnanan, Edgerton et al. 2010). The exact pathway of gluconeogenesis by insulin in 
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Insulin signalling leads to the movement of GLUT4 glucose transporters from the cytoplasm into the plasma 
membrane, allowing glucose to enter the cell. 
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humans remains a debateable issue (Lin and Accili 2011). However, the brain is an 
insulin-sensitive organ and uses glucose in a way that is not reliant on insulin (Levin 
and Sherwin 2011).  
Insulin encourages glycogen and lipid creation in the cells of muscles, while stopping 
lipolysis and gluconeogenesis from muscle amino acids. In summary, the insulin is 
central to regulating and controlling many metabolic processes which also include the 
production of carbohydrates from other sources including structural protein 
(Timmerman, Lee et al. 2010). In healthy tissues this is closely and locally controlled 
but in T1D patients artificially administered insulin hinders the breakdown of muscle 
protein (Dunn 2013). 
1.6.4. Glycogen metabolism 
The body stores glucose for later use by conversion to the branched polymeric form, 
glycogen. A raised level of blood glucose concentration is required for glycogenesis to 
be stimulated (Xu, Morgan et al. 2011). Glycogen serves as an accessible storage depot 
of energy mainly in the liver but also in the muscle and fat cells (Villarroel-Espindola, 
Maldonado et al. 2013). The liver and muscles change excess glucose into glycogen so 
that it can be used for glycogenesis in the future. Glycogen breaks down 
(glycogenolysis) when glucose levels drop, particularly if gaps between meals are 
lengthy.  
There are various enzymes and controlling proteins engaged in the synthesis of 
glycogen (Xu, Morgan et al. 2011). In the liver, the GLUT-2 transporter controls the 
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transfer of glucose into hepatocytes (Leturque, Brot-Laroche et al. 2009), whilst in the 
skeletal muscle; GLUT-4 is the main glucose carrier (Leto and Saltiel 2012). 
1.6.5. Effect of diabetes on glycogen stores 
As the main places of storage of glycogen are the liver and skeletal muscles, most 
studies that researched into the effect of diabetes on glycogen stores were carried out 
with these tissues. Diabetes is considered to be responsible for weakening of glycogen 
synthesis (GS) in skeletal muscles (Krause, Riddell et al. 2011). In T1D sufferers an 
inverse correlation between GS and above normal level of glycogen synthase kinase 3 
(GSK3) proteins and movement in human skeletal muscles was found (RH 2011; 
Villarroel-Espindola, Maldonado et al. 2013). 
In diabetes sufferers (T2D) weakened glucose transport and raised levels of plasma fatty 
acids are considered to be responsible of decline in disposal of glycogen (Kleinert, 
Sylow et al. 2013).  In diabetics hyperglycemia is considered to be the result of faults in 
GS (Pratipanawatr, Cusi et al. 2002; Tanabe, Liu et al. 2011). Impaired glucose 
transport coupled with increased plasma fatty acids and faulty GS leads to reduction in 
glycogen synthesis. Furthermore, the decline in the suppression of hepatic glucose 
production, as seen in diabetes sufferers, is associated with the over expression of a 
catalytic subunit of the enzyme glucose 6 phosphatase (6GPC) (Marcolongo, Fulceri et 
al. 2013).  
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1.7. Insulin 
1.7.1. Definition 
Insulin is a peptide hormone that is secreted by the β-cells and permits cellular glucose 
uptake and regulates levels of glucose in the blood stream. Insulin performs its function 
by controlling the metabolism of lipids, carbohydrate and protein and encouraging cell 
division (Preza, Pinon et al. 2013; Strachan and Frier 2013). 
1.7.2. Synthesis and release of Insulin 
Insulin is synthesised as its precursor, proinsulin as in figure 1.2. Proinsulin is created 
from mRNA as pre-proinsulin in the ribosomes of the rough endoplasmic reticulum 
(rRERs). The production of pre-proinsulin is a complex process in which the B chain, 
signal peptide, the connecting (C-) peptide and then the A chain are sequentially 
synthesised (Lindahl, Nyman et al. 2010). The three dimensional structure of proinsulin 
is engineered within the endoplasmic reticulum. Proinsulin is carried by secretory 
vesicles from the rRERs to the Golgi apparatus. The Golgi apparatus contains aqueous 
zinc and calcium saturated environment which provides perfect conditions for the 
production of soluble zinc-containing proinsulin hexamers (Lemaire, Chimienti et al. 
2012). As under developed storage vesicles are created by the Golgi, enzymes that 
perform outside the Golgi change proinsulin to insulin and C-peptide hexamers 
(Haataja, Snapp et al. 2013). When developed granules are delivered into circulation by 
exocytosis, insulin and an equimolar ratio of C-peptide are released into plasma. 
Consequently the presence of C-peptide indicates endogenous synthesis of insulin and 
therefore, in T1D, C-peptide is decreased or absent (Haidet, Cifarelli et al. 2012). 
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Figure 1.2: Insulin synthesis and secretion process involving the rough endoplasmic 
reticulum (rRERs) and Golgi complex (see text) 
1.7.3. Mechanism of action of insulin secretion 
Heightened levels of glucose encourage the first phase of the glucose-mediated insulin 
secretion by releasing insulin from the secretory granules in the β-cell as in figure 1.2. 
Glucose entry into the β-cell through Glucose Transporter-2 (GLUT2) triggers 
glucokinase (GK) (Porat, Weinberg-Corem et al. 2011; Coate, Kraft et al. 2013), which 
phosphorylates glucose to glucose-6-phosphate (G6P) by GK, producing ATP. Shutting 
off  the K+/-ATP dependent channels (see figure 1.3) causes membranes to depolarize 
and launching of voltage dependent calcium channels Ca
2+
 causes a rise in intracellular 
calcium concentrations; this activates pulsatile insulin emission (Porat, Weinberg-
Corem et al. 2011). It is evident from figure 1.3 that glucose enters into β-cells through 
40 
 
GLUT2 then phosphorylated to G6P by GK. G6P enters into glycolysis pathway and 
electrons are transported through the electron transport chain in mitochondria yielding 
ATP. Increased ATP/ADP ratio and closure of ATP sensitive K+ channels lead to 
membrane depolarization. Change in membrane potential opens up voltage gated Ca
2+
 
channels causing influx of Ca
2+
 into β-cells. Increased cytosolic Ca2+ concentration 
facilitates the synthesis of insulin-containing secretory vesicles with plasma membrane 
releasing insulin.   
 
Figure 1.3: Molecular mechanism of glucose induced insulin secretion. Glucose 
transporter 2 (GLUT2), glucokinase (GK), glucose 6-phosphate (G6P) see text. 
Counter-regulation works against insulin action and leads to raised blood glucose (BG) 
levels in response to hypoglycemia (Szepietowska, Zhu et al. 2012). The glucagon, 
epinephrine (also known as adrenaline), cortisol, and growth hormone are main counter-
regulatory hormones (Chen, Sheng et al. 2012). In diabetes the counter-regulatory 
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hormones are released in the middle of the night and are responsible for hyperglycemia 
often mistaken for the superficially similar so-called Dawn Phenomenon i.e. very high 
level of BG in the early morning (Mandujano, Thomas et al.). Glucagon gene 
expression is associated with insulin signalling in the alpha cells and regulates both 
high- and low-glucose conditions (Kawamori, Kurpad et al. 2009). 
In healthy people hypoglycemia is countered by the natural defence mechanisms. This 
defence mechanism, firstly, decreases insulin secretion from pancreas (which causes 
increase in BG level), and secondly, releases more glucose from the liver by secreting 
the counterregulatory hormone glucagon by alpha cells of the pancreas. Later, the liver 
and kidneys produce more glucose under the influence of the sympathetic autonomic 
nervous system and epinephrine directly secreted from the adrenal glands. Epinephrine 
is a classical stress hormone, which stimulates α and β adrenergic receptors (Ziegler, 
Elayan et al. 2012). It controls tissue needs in terms of releasing glucagon to the 
bloodstream and takes action to reduce insulin secretion and mobilise the conversion of 
glycogen. When epinephrine and glucagon fail to raise the levels of blood glucose, 
growth hormones and cortisol are released by the body to increase glucose level in 
blood stream. 
As mentioned above hypoglycemia in healthy people is avoided by the portal insulin-to-
glucagon ratio (McCrimmon and Sherwin 2010), but in T1D sufferers this glucagon 
counter regulation (GCR)is often impaired and may fail to trigger the necessary 
protection mechanism to avoid hypoglycemia (Farhy, Chan et al. 2012). Insufficient 
glucagon secretion has been reported in T1D (Karimian, Qin et al. 2013) and is 
considered to be responsible for the impairment of counter regulation during 
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hypoglycemia in T1D sufferers. Glucagon raises glutamine uptake and plays an 
important role to this response.  However, in T1D patients, in case of hypoglycemia 
epinephrine and glucagon fail to response effectively (Battezzati, Benedini et al. 2009). 
In people with T2D the impairment of GCR may cause hypoglycemia, particularly in 
those who inject insulin, but it is less severe and common (Davis, Mann et al. 2009). In 
T2D patients age plays no role in the counterregulatory responses to the hypoglycemia 
with older and younger patients showing the same level of GCR (Bremer, Jauch-Chara 
et al. 2009). 
1.7.4. Insulin resistance 
Insulin resistance (IR) is a pathologic condition where target cells (in liver and muscle) 
do not respond to regular amounts of circulating insulin and therefore provide a 
weakened biological response. Insulin resistance is known as an impaired sensitivity to 
glucose removal by insulin. It has been reported that T2D sufferers, young and old, 
develop cardiopulmonary fitness problems, which affect their ability to do exercise and 
cardiovascular functions. However, IR is not typically considered a contributory factor 
in cardiovascular dysfunction in T1D sufferers (Nadeau, Regensteiner et al. 2010). In 
T2D, patients may be managed conservatively with diet, exercise and then subsequently 
by oral agents that may ameliorate resistance or which may increase pancreatic response 
(secretogogues). Some type 2 people may receive insulin as a first line treatment, 
particularly if they have suffered myocardial infarct. However, for type 1, injected 
insulin must always be instituted immediately to avoid DKA and death. IR may also, in 
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fact, be applicable to T1D with intensive insulin therapy and bad glycaemic control  
(Fauci 2008) 
1.7.5. Type of therapeutic insulin 
1.7.5.1. Injectable insulin 
For T1D insulin is needed as a continual replacement therapy. It is a protein that breaks 
down when taken by mouth and therefore it needs to be injected subcutaneously. At 
present, most therapeutic insulin is human but bacterially derived and developed 
through genetic engineering, therefore the negative effects of immunogenic reactions 
and religious beliefs about beef or pork insulin have been eliminated. 
T1D patients can use insulin pump. In which a cartridge stores the insulin as either 
regular or fast acting insulin analogs; such as insulin lispro (Humalog), insulin as part 
(NovoLog), or insulin glulisine (Apidra). The analogs have a quicker onset of 
performance (5 to 15 minutes versus 20 to 30 for Regular) and an earlier peak in 
performance (90 minutes versus 150 minutes). Table 1.3 lists the insulin actions, peak 
activity, onset and duration of insulin, while appendix (A) highlights the various insulin 
types in the market. 
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Table 1.3: Insulin actions, onset, peak activity and durations 
Insulin Onset begins 
Peak activity 
occurs 
Duration after 
injecting 
Analogue rapid Within 15 min 15 min to 1 hour 3 to 4 hours 
Human short Within 30 min 1 to 3 hours 6 to 8 hours 
Animal short Within 1 hour 2 to 5 hours 6 to 8 hours 
Human intermediate Within 2 hours 2 to 12 hours 18 to 24 hours 
Animal intermediate Within 2 hours 6 to 12 hours 18 to 24 hours 
Analogue long Within 1 hour No peak as such 18 to 24 hours 
Source: diabetes.co.uk 
1.7.5.2.Administering insulin by insulin pump 
The insulin pumps were first developed in the late 1970s to imitate the way in which a 
normal pancreas delivers insulin by avoiding multiple doses in favour of continuous 
administration. In medical term administering insulin by pump is called Continuous 
Subcutaneous Insulin Infusion (CSII). CSII is an alternative to Multi Daily Insulin 
injections (MDI) by syringes or insulin pens. 
The insulin pump is a device marketed by a range of companies but fundamentally can 
be used independently by a diabetes patient to administer insulin continuously instead 
of as discrete volumes during the day. The pump administers insulin solution at an 
appropriate rate for the patient’s blood glucose status and predicted changes for meals. 
A cannula with insulin-compatible tubing is used to connect the pump and its cartridge 
of contents to the subcutaneous layer, usually on the abdomen or hip. The patient must 
change the injecting unit every few days to keep it clean and functioning properly. 
Sophisticated inserters make this easy. The patient can stop when they have a wash or 
do exercise. When choosing a pump, several things need to be considered, such as the 
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size and weight of it, how long the batteries last, model of infusion sets, alarms and 
special features (Appendix B shows a table of insulin pumps on the market).  
1.7.5.2.1. World use of insulin pumps 
In March 2012 Canadian Institute of Health Economics (IHE) published a report on the 
acceptance of CSII among T1D patient. This report claimed that the usage of CSII 
therapy is gaining worldwide popularity, mainly in US. The report further stated that 
there are wide spread differences in the acceptance of CSII therapy among medical 
practitioners around the world.  
In 2005, in US it was estimated that 270,000 of T1D sufferers were treated with insulin 
pump compared with over 180,000 in Europe. Recently, in US, this had grown to more 
than 375,000 patient using insulin pump to manage their diabetes (McCrea 2013).  
In 2006 IHE reported that in US about 8% to 15% of individuals with T1D aged above 
12 years are using insulin pump, while the take up of insulin pump among younger 
people i,e. less than 12 years, vary from 15% to 50%.  
In April 2012 Diabetes.co.uk reported that the number of insulin pump users is 
significantly lower in the UK, it is estimated that only around 1% of people with T1D 
have an insulin pump. These data were not changed since 2006 according to IHE report 
“notable low-use countries (such as the UK and Denmark, where about 1% of T1D use 
an insulin pump)”. In the UK the significant low in use of insulin pump is related to the 
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cost as reported by the Scottish Government when they announced to spend £1.5 
million to allow 480 young T1D to have insulin pump therapy. 
The financial cost is the main reason behind the discrepancies in the usage of insulin 
pump, as the insulin pump cost is covered in some countries (e.g. United States, 
Sweden, and the Netherlands) by insurance companies or state and in some other 
countries (e.g. United Kingdom and Denmark) individuals have to cover the cost of the 
pump (Selam 2006). Moreover, training availability for the healthcare professionals and 
lack of knowledge on part of individual T1Ds may also lead to this variation, (Charles, 
Sadri et al. 2009).  
Finally, the International Society for Pediatric and Adolescent Diabetes, European 
Society for Pediatric Endocrinology and Lawson Wilkins Podiatric Endocrine Society 
signed an agreement which was later endorsed by the American Diabetes Association 
and the European Association for the Study of Diabetes claimed that there is no lower 
age limit for prescribing CSI therapy and recommended that all T1D diagnosed 
paediatric patients should be put on CSII insulin therapy. (St Charles, Lynch et al. 
2009). 
1.7.5.2.2. How insulin pumps work 
Nowadays, the pumps are becoming more and more sophisticated, technologically 
advanced and smaller in size i.e. size of a phone or credit card and can be worn 
discreetly. These pumps consist of a pump, which is operated by a battery, and insulin 
cartridge reservoir. Insulin is administered from pump to the body via a cannula, which 
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is kept in place with the help of adhesive tape. Every 2 to 3 days the cannula is moved 
to different site on the body to avoid infection or skin irritation, while once a week the 
tubing  is changed (Hindmarsh, Peters et al. 2013). 
These pumps are programmed to deliver small amounts of insulin throughout the day to 
ensure basal blood insulin levels using rapid-acting insulin and delivering it to the 
patient continuously. Based on the insulin requirements of the user during the day 
insulin infusion rate could be changed or modified (Pickup 2012). Before taking a meal, 
pump user need to program the pump manually to deliver a larger amount of insulin as a 
bolus dose (i.e. supplemental dose) of fast-acting insulin. The amount of insulin in bolus 
dose depends on the pre-meal BG level and the amount of carbohydrate he is planning 
to consume. 
1.7.5.2.3. Insulin Pump versus Multi Daily Injection 
Insulin pump therapy and MDI users both need to measure their blood glucose levels 4-
6 times, at a minimum, every day. Nevertheless, insulin pump allows more flexibility 
precise dose of insulin as compared to MDI (basal bolus regime) and is considered to be 
a closest replica of the physiologic method of insulin administration (IHE, 2012, p. 83).  
The main advantage of insulin pump therapy over MDI is its ability to significantly 
reducing the risk of hyperglycemia and hypoglycemia. It has been observed that insulin 
pump users have fewer events of post-exercise hyperglycemia as compared with MDI 
users (Yardley, Iscoe et al. 2013). Furthermore, T1D sufferers who use insulin pump, 
children and adults, reported lowering of A1c (Battelino, Phillip et al. 2011).  
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The insulin pump users invasively insert a delivery needle once every three days while 
MDI users do this more frequently i.e. not fewer than 3 times in a day. Additionally, 
with insulin pumps the total insulin requirement during the day is, usually, decreased by 
15% to 30%.  
The stability of BG level and insulin in the body is better maintained by an insulin 
pump as compared with the MDI. Moreover, users can adjust the basal and bolus doses 
more accurately, which means pump user can easily adjust their insulin dose around 
times requirements such as meals and physical activities. 
Comfort and convenience are two very important features to all pump users especially 
younger children (for example, during school, or day-care time). Delivering very small 
amounts of insulin is difficult to administer with MDI while the pump can be made to 
deliver required amount of insulin as and when required. Using CSII in T1D will not 
significantly change the body weight while increase in MDI patients (Kordonouri, 
Hartmann et al. 2006).  
Despite above mentioned advantages insulin pumps are still slow to gain popularity 
among the wider public as such pumps are very expensive, especially for patients who 
do not have health insurance and need to pay from their own pocket. Moreover, techno 
phobia coupled with pump complications and faults, infections at the cannula site, 
reactions, and tube blockage are also hindering the widespread usage of these pumps. It 
is worth noting that insulin pens have made MDI a simplified, flexible and portable 
alternative to the costly insulin pumps.  
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The main disadvantages of the insulin pump is the hypoglycemia and DKA events 
which can occur when the user failed to recognise that the right amount of insulin is not 
delivered to the body or insulin infusion is hampered. Furthermore, for some patients, 
such as pregnant, attaching the pump all the time can become a psychological barrier.  
Selection of an appropriate insulin pump is very important to meet the individual 
patient’s needs and circumstances, i.e. physiological and financial. 
1.8. Exercise 
A physical activity which maintains or boosts physical overall health and fitness is 
called an exercise. People perform physical exercises for different reasons such 
enhancing cardiovascular system, strengthening muscles and the weight loss or 
maintaining weight, as well as for the purpose of enjoyment. It is well researched and 
documented fact that regular physical exercise enhances the immune system, and helps 
to prevent cardiovascular disease, obesity and T2D (Simpson, Lowder et al. 2012).  
It is recommended that a person aged between 18 and 64 years, should spend 30 
minutes, at least 5 days a week, to do moderately intense exercise (see table 1.4). 
However, for diabetics, 150 minutes of exercise per week is recommended (SIGN, 
2010; Department of Health, 2010). Following a regular regime of physical exercise a 
person with T1D can enhance their quality of life and also their psychological well-
being (Guelfi, Jones et al. 2005). Moreover, they can decrease the chance of having life-
threatening cardiovascular problems (Bracken, West et al. 2011). Diabetes patients 
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should be encouraged to follow these recommendations and achieve at least 2.5 hours of 
exercise every week (Kilbride L. 2011). 
However, there is not much evidence available that can be used to provide advice to 
people who have T1D with regards to strategies that they can use to self-manage the 
illness and maintain appropriate glycaemic control when they carry out exercise 
(Charlton 2013). It is widely known that hypoglycemia is caused by inappropriate 
glycaemic control and this stops many diabetics from exercising (Charlton 2013). It is 
worth saying that one of the objectives of this research is to develop a strategy to fill 
this gap in the literature. 
1.8.1. Resistance and aerobic exercise 
Some forms of physical exercises, such as lifting weights, have a significantly different 
effect on the body than low intensity exercise such as walking. These two types of 
exercises are called resistance and aerobic exercises respectively (Lucotti, Monti et al. 
2011). Under some circumstances, exercise may be anaerobic and this can well be 
associated with resistance exercise because of its short and intense nature. 
Anaerobic exercises are non oxygen consuming high intensity exercises (a brief, 
infrequent, and intense physical activity) and, after the first few seconds, normally 
activate lactic acid production. They can cause the secretion of hormones that work 
against insulin, often resulting in high levels of blood glucose during and after exercise. 
Conversely, aerobic exercises are generally less intense (termed mild and moderate) 
exercise performed for longer periods of time and may actually lower blood glucose 
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levels (Delvecchio, Zecchino et al. 2009). The intention in this project was to include 
some anaerobic component in the protocol, such that the exercises would differ, not 
only in type (cardiovascular and resistance) but also in metabolic result. In trained 
athletes, the anaerobic condition is reached at 80-90% of the VO2max but for untrained 
individuals such as were planned for this study, it occurs at 50-60% VO2max and it 
seemed that this was a reachable goal without risking the welfare of individuals 
undertaking the exercise (Cerretelli, Ambrosoli et al. 1975; Farrell, Wilmore et al. 
1979). For diabetic people this threshold is reached at even lower intensity levels. So for 
example, Komatsu compares trained athletes and found a lower anaerobic threshold in 
his diabetic cohort. The reasons for this are probably that diabetes is a disease of 
oxidative stress (Yamagishi, Maeda et al. 2012; Yokota, Kinugawa et al. 2013). The 
complications of diabetes are related to this via the glycation products but the 
immediate effects may be that aerobic metabolic processes are compromised and the 
anaerobic component of exercise may be increased at a given intensity level. This might 
manifest itself in the lactate levels, depending on conditions (Soultanakis, Mandaloufas 
et al. 2012). Because it was realised that the anaerobic threshold must have differed in 
the cohorts being compared and thus the resistance exercise a mixture of aerobic and 
anaerobic (though likely the latter predominating in these untrained individuals), the 
term anaerobic has now not been used for this study, but rather resistance. 
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Table 1.4:Exercise intensity classifications, based on physical activity lasting up to 60 
min (Zinman, Ruderman et al. 2003). 
Relative Intensity 
Intensity VO2max(%) % Of Maximal Heart Rate
**
 RPE
* 
Very light <20 <35 <10 
Light 20-39 35-54 10-11 
Moderate 40-59 55-69 12-13 
Hard 60-84 70-89 14-16 
Very hard >85 >90 17-19 
Maximal 100 100 20 
*Borg rating of perceived exertion(RPE)6-20scale. 
**Maximal heart rate = 220 – Age. As exampled below  
Age 
35 
HR at rest 
71 
Intensity  
55 
Maximum HR 
220-35=185 
HR reserve  
185-71=114 
Target HR for 
experiment 
114×0.55+71=134 
When a person has been doing aerobic physical activity two or three times a week their 
use of blood glucose (insulin sensitivity) will change (Yoshida, Ishikawa et al. 2010). 
Doing consistent exercise improves the fat use which lessens the need for blood 
glucose. Nevertheless, for diabetic people, in long lasting aerobic exercise, 
hypoglycemia may occur and as a result, there is less of a need for alteration to regimen 
(Kakleas, Kandyla et al. 2009). Moreover, muscle grows as a result of training and a 
person may become more sensitive to insulin which may decrease the basal and bolus 
insulin requirements (Heinemann 2009). 
Non-diabetic healthy people, who do regular exercise will also become more sensitive 
to insulin and it can prevent them from developing T2D (Sigal, Kenny et al. 2007). A 
meta-analysis of diabetic sufferers T2D showed that staying active seems to improve 
A1c (Boulé, Haddad et al. 2001) and a systemic review of studies that researched 
mainly dietary advice to patients with T2D also showed the same effect of exercise 
(Nield, Moore et al. 2007). A range of types of exercises showed benefit (A1c decreased 
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by 0.8%) for T2D (Snowling and Hopkins 2006). Resistance exercises (RE) are 
prescribed in diabetes because of the aforementioned increase in insulin sensitive 
muscle mass that can result in enhanced endurance and muscular strength. These along 
with improved body composition and flexibility reduce the risk of cardiovascular 
disease (Cohen, Dunstan et al. 2008).  
The American College of Sports Medicine (ACSM) and the American Diabetes 
Association (ADA) have outlined general clinical practice guidelines for exercise and 
diabetes for people who use CSII. The guidelines state diabetes sufferers should not 
exercise if beforehand their fasting blood glucose level is more than 13.8mmol/l and/or 
if there is a raised level of ketones in their blood or urine. A blood glucose level over 
16.6mmol/l with no ketones present should be taken with “caution”. A third guideline is 
to eat carbohydrates if one’s blood glucose level before doing exercise is lower than 
5.5mmol/l. People with diabetes should therefore assess their pre-exercise blood 
glucose level. However, in contrast to the ACSM and ADA principles, people who use 
pumps and have a blood glucose level lower than  5.5mmol/l before doing exercise may 
not need to eat carbohydrates snacks as they can just lower or stop the basal insulin 
whilst doing exercise (Colberg 2013). Levels of counterregulatory hormones drop later 
on in the day and, in most of the users, the amount of insulin that is delivered from the 
pump will need to be changed 60 to 90 minutes before exercise that is going to last for 
30 to 45 minutes. Basal rates may also need to be decreased whilst carrying out the 
exercise, to lower insulin levels. To maintain control, bolus reductions of insulin will 
often need to be done immediately after exercise to eliminate the risk of hypoglycemia 
(Zisser and Riddell 2010). This reduction is dependent on the type, intensity and 
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duration of exercise. For example, resistance exercise increased BG level after one or 
two sets/repetitions (Leelarathna, Little et al. 2013). Even when a person has a pump, 
the metabolic control with exercise can get worse in some circumstances (Hovorka, 
Allen et al. 2010; Elleri, Dunger et al. 2011). When the blood glucose level is raised 
(13.8 mmol/L) or more and there are ketones in the blood or urine, it is evident that they 
do not have enough insulin in the system and are in danger of diabetic ketoacidosis 
(DKA) which can be fatal. Taking part in high intensity exercise like resistance will 
raise the blood glucose level in both diabetes sufferers and healthy people (Simpson, 
Florida-James et al. 2006). In a healthy person natural glycaemic control mechanism 
will pump more insulin in the system. However, if a T1D sufferer takes part in a 
resistance activity while his/her BG level is higher than normal i.e. not enough insulin 
in the blood, the blood glucose level may increase further and as a result risk of DKA is 
increased (Hanas and Ludvigsson 2006; Wolfsdorf, Craig et al. 2007). In this condition 
a CSII user may need to raise the level of basal insulin whilst exercising and/or 
afterwards (Jeandidier, Riveline et al. 2008). 
In summary, individuals with T1D should take special care when taking part in physical 
activity. Although regular and systematic exercise regime is advantageous for all 
patients, yet high intensity exercise can disturb the BG levels. It has been observed that 
the glycemic response depends mainly on the type, duration and intensity of the 
physical activity, along with the insulin in the system and glucose counterregulatory 
hormone concentrations. 
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1.8.2. Exercise and Immunity 
Though recently voluminous literature has been produced to find a link between 
exercise and immunity and it can be argued that exercise immunology is a fairly new 
area of scientific study (Shephard 2010). It has been suggested that exercise may act as 
a model of numerous clinical stresses as it generates comparable hormonal and 
immunological alterations (Gillum, Kuennen et al. 2011). These manifest themselves as 
acute and beneficial inflammatory effects as muscles adapt to exercise and also useful 
longer term anti-inflammatory changes that benefit the causes and effects of some 
diseases such as diabetes. The chronic anti-inflammatory effect of exercise has both 
clinical and public health consequences (Nieman 2012). In a recent study it was 
observed that acute aerobic exercise enhances insulin sensitivity and cardiovascular 
fitness in individuals who are insulin-resistant T2D subjects (Musi 2013).  
Many studies documented the fact that a modest exercise has a positive and favourable 
impact on the human body. It has been observed that a six week regime of moderate 
exercise can elevate activity of NK cells (Nieman, Nehlsen-Cannarella et al. 2008). 
Furthermore, moderate exercise enhances immunoglobulins, which result in a positive 
influence on the immune system (Karacabey, Saygin et al. 2005). Frequent moderate 
exercise has been linked with decreased occurrence of infection (respiratory infection) 
in comparison to an entirely sedentary state in healthy (Walsh, Gleeson et al. 2011). 
Moderate aerobic exercise leads to a temporary increase in both innate (monocytes, 
macrophages, neutrophils, NK cells) and specific (B and T lymphocytes) cells in a 
person’s immune system (Gillum, Kuennen et al. 2011). Light observed that 25 minutes 
of modest exercise leads to swift upsurges in gene expression for receptors detecting 
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muscle metabolites and for sympathetic nervous system and immune system in 
leukocytes in individuals with Chronic Fatigue Syndrome (Light, White et al. 2009) 
with a decrease in the obliterations of T cell numbers.  Similarly, Shephard (2010) 
showed that levels of both CD4 + and CD45 + cells improved in people who exercise 
(Shephard 2010). There was also an increase in the latter cell sub-set which was 
exceptionally significant when taking into consideration its potential to trigger 
production of CD8 + cytotoxic cells (Shephard 2010). 
It is well documented fact that T1D and T2D patients suffer from impaired immune 
system and aforementioned studies provide enough evidence to suggest that T1D and 
T2D sufferers can benefit from a moderate exercise regime (Christiansen, Bruun et al. 
2013; Ho, Dhaliwal et al. 2013; Kennedy, Nirantharakumar et al. 2013; Musi 2013; 
Yardley, Kenny et al. 2013).  
1.8.3. Effects of Acute exercise on the Immune System 
A single session of exercise is considered as acute exercise (Ploeger, Takken et al. 
2009). In contrast to a moderate exercise regime, as discussed above, a single, excessive 
exercise session can have a short-term influence on the immune system (Gleeson 2007). 
It is also associated with bodily reactions that are very comparable (in many aspects) to 
those that are brought about by trauma, sepsis or infection. These reactions cause 
significant upsurge in the level of leukocytes (mainly lymphocytes and neutrophils) in 
the blood stream. The scale of this upsurge is associated with the length and intensity 
exercise session (Gleeson 2007).  
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Cytokines do not only increase during inflammatory disease such as diabetes; acute 
exercise also affects cytokine reactions and inflammation in healthy people (Ploeger, 
Takken et al. 2009). Moreover, the plasma concentrations of a range of substances, 
which are known to have an effect on leukocyte functions (i.e. inflammatory cytokines, 
e.g. TNF-, anti-inflammatory cytokines IL-6 and macrophage inflammatory - IL-1β 
and protein-1) also increases (Gleeson 2007). The heightened levels of plasma IL-6 
concentration are seen in people, when they exercise, and this increase is attributed to 
the release of this cytokine from the contracting muscles (Gleeson 2007). In a study 
carried out by Christiansen et al. (2013) severe exercise generated an increase in the 
presence of inflammatory markers (e.g., IL-6, IL-8, and TNF-α) in people who were 
classed as overweight and obese (Christiansen, Bruun et al. 2013) . Nevertheless, IL-6 
generation by monocyte and IFN-γ generation by T lymphocytes are constrained during 
a period of extended exercise and also for many hours afterwards (Gleeson 2007). The 
immune system is affected by severe exercise both during and after the exercise session 
(Pedersen and Hoffman-Goetz 2000). In acute exercise, IL-6 is released by muscles and 
the levels IL-6 may increase significantly (Petersen and Pedersen 2005). Leukocyte 
subgroups, by way of neutrophils, lymphocytes subsets NK, B, T cells and monocytes, 
in addition to plasma concentrations of anti-inflammatory and pro-inflammatory 
cytokines IL-1, TNF-α and sTNF-r, may increase significantly during a period of 
exercise (Ploeger, Takken et al. 2009). In 2009, a review of 19 studies were carried out 
to investigate the effects of acute exercise on inflammatory markers on subjects with  a 
chronic inflammatory disease and found no conclusion evidence of trend from one 
exercise session (Ploeger, Takken et al. 2009).  
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1.8.4. Chronic Effects of Exercise on Immune System 
Chronic exercise is defined as an exercise regime which lasts for 6 weeks or more 
(Ploeger, Takken et al. 2009; Al-Nassan, Fujita et al. 2012). It has been reported that the 
chronic exercise may affect the chronic inflammatory diseases, such as diabetes, by 
affecting the immune parameters (Petersen and Pedersen 2005). 
Exercise is recommended to be used as an anti-inflammatory therapy as it affects basal 
levels of inflammatory markers in T2D (Bruunsgaard 2005; Petersen and Pedersen 
2005). It has been shown that chronic exercise may improve (back to normal) or re- 
imposed the resting levels of TNF-α and IL-1β in healthy children (Stewart, Flynn et al. 
2007). In a study carried out by Ho et al. (2013) a 12-week exercise programme of 
mixtures of exercise regimes (mainly moderate-intensity resistance and aerobic) 
lowered TNF-α in obese and overweight people. Thus, combination exercise may help 
to lower the risk of contracting chronic diseases (Ho, Dhaliwal et al. 2013). 
In 2009 six studies were conducted that looked at the impact of chronic exercise in 
adults, which essentially looked at the impact of exercise on resting levels and basal of 
inflammatory markers. One of the studies focused on resistance training while the 
remaining five concentrated on endurance training (Ploeger, Takken et al. 2009). While, 
to date there is no study conducted to examine the effects of exercise, in children 
suffering from inflammatory disease, on inflammatory markers. Nevertheless, the 
impact of chronic exercise on the generation of pro- and anti-inflammatory cytokines 
from the skeletal muscle has yet to be investigated (Lira, Koyama et al. 2009).  
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Finally, for individuals with T1D performing resistance before aerobic exercise is 
suggested to reduce the severity and duration of post-exercise hypoglycemia and 
improving glycemic stability throughout exercise (Yardley, Kenny et al. 2012; Yardley, 
Kenny et al. 2013). Moreover, it is recommended to stretch before (warm-up) and after 
(cool-down) performing any exercise (Petit, Hughes et al. 2010) targeting upper and 
lower muscles by elongating them to their fullest length (Kluemper, Uhl et al. 2006). 
1.9. Overview on the Immune System 
1.9.1. Autoimmunity 
Autoimmunity is an abnormal response to tissue components. Usually, a system of self-
tolerance defends an individual from possible self-reactive lymphocytes. A defect in this 
regulation can cause the triggering of self-reactive clones of B or T cells and 
consequently cause a cell or humoral mediated immune reaction against self-antigens. 
This autoimmune response can seriously harm cells and organs, which can cause 
autoimmune disease to develop which can be life-threatening. 
According to the National Institute of Health Autoimmune Disease (NIAID) on March 
2005, autoimmune diseases are a collection of diseases, which up to 8% of the 
population are affected by. At one end of the spectrum, some of these conditions cause 
symptoms that are less difficult to manage but in many cases, one individual organ can 
be severely affected by an autoimmune disease (organ specific autoimmune disease) 
such as diabetes.  
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1.9.2. Immunology of Type 1 Diabetes 
Before discussing the immunology of T1D it is interesting to note that the biologists use 
a protocol known as the cluster of designation/differentiation (CD) to identify and 
investigate the surface of cell molecules which provides targets for the immuno-
phenotyping of cells. Physiologically CD molecules perform different functions such as 
activate a receptor i.e. act as receptors and cell adhesion (Zola, Swart et al. 2007).  
Since the discovery of islet cell antibodies in 1974, it has been suggested that T1D is 
caused by systematic destruction of insulin-producing ß-cells of the pancreas   there has 
been a perception that T1D is autoimmune in nature (Skyler 2011; Hirsch and Skyler 
2012). T1D is a chronic autoimmune disease and is caused by the destruction of 
pancreatic β-cells on a discriminatory basis. The development of T1D comprises 
complicated collaboration amongst pancreatic β-cells and adaptive immune systems and 
cells in the innate immune systems (Lehuen, Diana et al. 2010). The T1D is considered 
to be a T helper 1 (TH-1) cell-mediated illness that involves both CD8+ T cells and 
innate immune cells (Lehuen, Diana et al. 2010). Leuhen et al. (2010) further claim that 
CD4+ and CD8+ T cells along with macrophages play a role in the destruction of β-
cells (Lehuen, Diana et al. 2010).  
Furthermore, studies that have used animal models, predominantly in non-obese 
diabetic (NOD) mice, have revealed roles for various different immune cell types in β-
cell annihilation. The most widely accepted notion is that antibodies (that characterise 
the humoral section of the immune system) do not contribute the obliteration of β-cell 
destruction but instead act as markers of that annihilation, while the cellular section of 
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the immune system, particularly the T-lymphocytes, facilitate the obliteration of β-cells 
(Skyler 2011). However, the T-lymphocytes do not act independently; they are aided by 
antigen-presenting cells such as dendritic cells and macrophages when instigating the 
reaction, and seem also to be helped by B-lymphocytes (Skyler 2011).  
There are some other cell types that exist in the pancreatic infiltrate and also in the 
pancreatic draining lymph node, where the early appearance of islet antigen by dendritic 
cells (DCs) to islet antigen-specific T cells arises (Turley, Poirot et al. 2003). These 
cells comprise B cells and natural killer (NK) cells, in addition to DC subsets, and they 
may also be responsible for the destruction of β-cells. The generation of chemokines by 
B cells leads to further recruitment of mononuclear cells to the site, and thus increases 
inflammation (Eizirik, Colli et al. 2009). Alternatively targeting or controlling the 
actions of various different immune cell types may also be an effective way of impeding 
β-cell annihilation (Lehuen, Diana et al. 2010). 
Moreover, interferon-gamma (IFN-γ) can trigger macrophages and encourage enhanced 
pro-inflammatory cytokine generation, such as interleukin-1beta (IL-1β) and tumour 
necrosis elements (TNF) (Lehuen, Diana et al. 2010).  
A high level of IL-1 receptors is expressed by β-cells. β-cells expedite high levels of IL-
1 receptor and appear to be more susceptible to IL-1β-induced apoptosis in comparison 
to other endocrine cells that exist in the islet (Lehuen, Diana et al. 2010). This 
interaction between T cells and macrophages indisputably aggravates the immune-
mediated stress on β-cells and aids in their obliteration. Expression of reactive oxygen 
species (RoS) such as nitric oxide by β-cells is also induced by interleukin-6 (IL-6) 
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(Lasota, Penna-Martinez et al. 2013), IFNγ, IL-1β and TNF. While RoS have the 
capacity to facilitate apoptosis (Lehuen, Diana et al. 2010). IL-6 plays a major role in 
the development from acute to chronic inflammation which affects clinical expression 
of T1D (Lasota, Penna-Martinez et al. 2013). 
1.9.3. Autoimmune Mechanisms Related to Type 1 Diabetes 
Before the symptoms of T1D disease become apparent several unnoticeable immune 
events will be triggered (Van Belle, Coppieters et al. 2011). T1D is believed to be a 
chronic immune-mediated illness with a subclinical prodromal period (which is the 
period during which a process of disease has started but the disease is not yet clinically 
diagnosable) where the discriminatory loss of insulin-producing β-cells in the pancreatic 
islets in genetically susceptible individuals. Although auto reactive T cells, both CD4 
and CD8 types, play a key role in β-cell obliteration (Knip and Siljander 2008), the sign 
of autoantibodies is the first obvious sign of emergent β-cell autoimmunity (Knip and 
Siljander 2008). Thus, autoantibodies are generated and self-reactive lymphocytes are 
triggered and penetrate the pancreas to obliterate the insulin-producing β-cells in the 
islets of Langerhans (Van Belle, Coppieters et al. 2011). Various studies have revealed 
that β-cell autoimmunity may be prompted in the early stages of life (Kimpimäki, 
Kupila et al. 2001). Results of the Finnish Diabetes Prediction and Prevention (DIPP) 
(cited in Kukko et al., 2005) reveal that the first autoantibodies may be expressed before 
a child reaches 3 months; approximately 9% of the children in the study were sampled 
from the general population based on elevated human leukocyte antigen (HLA) DQB1 
(Kukko, Kimpimäki et al. 2005). Nevertheless, this tenacious, targeted obliteration may 
go unnoticed for several years, and the initial clinical symptoms only show after most of 
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the β-cells have been obliterated or have become dysfunctional. This leads to the 
individual becoming dependent on insulin in order to survive (Van Belle, Coppieters et 
al. 2011).  
Kupila, Keskinen et al. (2012) observed that the spread of humoral autoimmune 
response from epitope to epitope and from antibody to antibody takes place suddenly 
(Kupila, Keskinen et al. 2002). If this spread does not occur within a time frame of one 
year after the first autoantibodies develop, then it is highly unlikely that it will occur at a 
later date. These, together with other observations suggest that positivity for single 
autoantibody specificity signifies in most cases, undamaging non-progressive β-cell 
autoimmunity (Knip and Siljander 2008). The existence of two or more autoantibodies 
points to a worsening condition (Knip and Siljander 2008; Diana, Gahzarian et al. 
2011). In summary in T1D B cells and resulting immunoglobulins i.e. antibodies 
perform a pathogenic role as antigen-presenting cells and autoantibody secretors which 
led to autoimmune destruction of insulin-producing β cells mediated by T cell. These 
findings have generated great interest to develop treatment for T1D by using B cell 
depletion therapies (Mariño, Silveira et al. 2011). 
1.9.4. Animal models of type 1 diabetes 
Some studies in animal models (NOD mice, BB rats), have focused on the significant 
role of dendritic cells (DC), which are main presenters of antigen, in the production of 
insulitis and diabetes (Lehuen, Diana et al. 2010). The Bio-Breeding (DP-BB) rats and 
NOD mice develop spontaneous type 1 comparable to those in humans with symptoms 
such as hyperglycemia and ketoacidosis. These two animal models may add to 
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knowledge about the causes, issues and medication for of T1D diabetes. The studies 
based on DP-BB rats and NOD mice are facilitating the understanding of the immuno 
genetic aspects of disease susceptibility and highlighting the effector cells which play a 
role in the autoimmune attack on the β-cell. 
Bio-Breeding (DP-BB) rats develop autoimmune diabetes with extreme infiltration of 
the islets and the creation of autoantibodies (Dalberg, Haase et al. 2011). Almost 85% 
of the DP-BB rats expressed symptoms of diabetes by the time they reached 120 days 
old (Dalberg, Haase et al. 2011). 
NOD mice were first described by Makino and colleagues in 1980 (Makino, Kunimoto 
et al. 1980). Insulitis in the NOD mouse appears spontaneously around 3 to 4 weeks of 
age, with progression to overt diabetes in 80% of female mice between 10-30 weeks of 
age. The insulitis lesions mainly contain T cells and numerous abnormalities have been 
observed in suppressive T cell of NOD mice (Shultz, Saito et al. 2010). 
1.9.5. Cytokines and Diabetes 
Gianoukakis and Smith (2004) stated that cytokines are important effectors molecules 
that play key roles in health and disease as they provide a network via which cells can 
have an effect on adjoining and distant tissues. The cytokines are membrane-bound and 
exist in soluble form and operate via attaching themselves to high-affinity receptors on 
the exterior of target cells. Cytokines also play a part in cell-mediated and humoral 
immune responses where they should not be perceived as being isolated factors, but 
rather should be investigated based on their collective affect. For instance, T cells 
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express TH-1type; IFN-γ, TNF-α, and Th2-type cytokines IL-4, IL-5, IL-10 and IL-13. It 
seems that the nature of immune reaction is described by the combination of discharged 
cytokines and the equilibrium between different cytokine types (Gianoukakis and 
Smith, 2004). As explained above, cytokines can destroy β-cells through direct 
cytotoxic effects, potentially acting through the initiation of nitric oxide generation 
(Weir 2013) and stimulate or impede disease development in T1D. For instance, in 
patients with some residual β-cell function (as measured by C-peptide), the systemic 
concentrations of the pro-inflammatory  cytokines IL-6 and TNF-α have been shown to 
be raised in either fasting or meal-stimulated states, while anti-inflammatory agents 
such as IL-1R, IL-10 are lowered. This suggests the provocative role of the β-cell 
membrane markers (Pham, Kolb et al. 2013).Specifically, new evidence proposes that 
the cytokines IL-1β, TNF and IFNγ which are secreted by macrophages and T cells, 
play a bigger role in the growth of T1D than previously thought with a range of impacts 
on β-cells (Vincenz, Szegezdi et al. 2011). Moreover, stress on and obliteration of β-
cells certainly involves the secretion of pro-inflammatory cytokines, for example IL-1ß, 
TNF and IFNγ (Limbert 2012). However, combinations of IL-1β/IFNγ or TNF/IFNγ 
have very powerful, synergistic effects that cause high levels of stress which results in 
the death of cells (Vincenz, Szegezdi et al. 2011). The initiation phase of T1D takes 
place in the pancreas, where conventional dendritic cells (cDCs) capture and process β-
cell antigens. β-cell damage can occur by 'natural' apoptosis or after viral infections. 
Invariant natural killer T (iNKT) cells and plasmacytoid DCs (pDCs) control viral 
replication, preventing subsequent inflammation and T1D (not shown). B cells present 
β-cell antigen to diabetogenic T cells and secrete autoantibodies (not shown). In the 
pancreas, β-cells can be killed by diabetogenic T cells and NK cells through the release 
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of IFNγ, granzymes and perforin, as well as by macrophages through the production of 
TNF, IL-1β and nitric oxide. Lastly, β-cells can inhibit diabetogenic T cells by 
expressing PDL1. This complex crosstalk between innate and adaptive immune cells 
results in the development or the prevention of T1D. APC, antigen-presenting cell; 
TCR, T cell receptor; dendritic cell (DC); Natural killer cells (NK); Programmed cell 
death 1 ligand 1 (PD-L1) (see Figure 1.4). 
 
Figure 1.4: Process of T1D initiation. The initiation phase of T1D takes place in the 
pancreas with a complex signalling that can promote or suppress T1D development. 
Adapted from (Lehuen, Diana et al. 2010) (see text).  
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Furthermore, IL-6 plays an key role in the instigation and acceleration of chronic 
inflammation and may later play a part in the development of microvascular 
complications in patients with T1D (Wegner, Araszkiewicz et al. 2013). 
1.9.5.1.Interleukin-1 beta (IL-1β) 
It is believed that IL-1β plays a pathogenic role in T1D (Dinarello 2011; Limbert 2012). 
Evidence to show that IL-1β is toxic for the insulin-producing β-cell started to appear in 
1985 when studies using anti-human IL-1β immuno affinity chromatography emerged 
(Dinarello 2011). It has been evidenced that the interleukin 1 family (IL-1α, IL-1ß and 
IL-33), a group of 11 cytokines, causes β-cell dysfunction (Limbert 2012); as a result, 
therapeutic IL1 receptor blockade has been carried out in humans with T1D and was 
shown to be successful (Akash, Shen et al. 2012) . IL-1β triggers the death of β-cell in 
patients with T1D; this occurs through NF-kB activation (Ortis, Miani et al. 2012). In 
T1D, the chronic hyperglycemia causes the vascular difficulties of the illness. 
Therefore, if blocking IL-1β-mediated obliteration of β-cell function should lead to 
better management of glycemia (Dinarello 2011). However, initial data from a short-
term pilot study of immunotherapy of T1D showed that the levels of C-peptide were 
unaffected during this therapy (Sanda, Bollyky et al. 2009). Nevertheless, IL-1β 
increases in patients who have been recently diagnosed with T1D and it is more than 
likely that it operates as an early inflammatory signal in T1D development (Grishman, 
White et al. 2012). Paradoxically, Grishman, White et al. (2012) scrutinized the 
provoking effects of hyperglycemia itself on elevating the level of IL-1β in peripheral 
blood mononuclear cells (PBMCs) and islet cells. They failed to achieve consistent 
results and the mechanisms that cause this increase are still not agreed on (Grishman, 
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White et al. 2012). It is interesting to note that in T2D sufferers the gene expression for 
IL-1β was more than 100-fold higher in β-cells as compared to the healthy individuals 
(Dinarello 2011).  
It would appear that results of investigations into pancreatic β-cells suggest that damage 
to islet cells are caused by IL-1βand involve multiple downstream targets (Grishman, 
White, Savani, 2012) but the resulting hyperglycemia reinforces the cycle of events. The 
use of the blockade should elucidate this further. 
1.9.5.2.Interleukin-6 (IL-6) 
IL-6 is a pleiotropiccytokine, affecting many functions. IL-6 is mostly produced by 
endothelial, fibroblast and adipocyte cells (Waetzig and Rose-John 2012). IL-6 is 
involved in infection and inflammation responses of the body. Mihara, Hashizume et al. 
(2012) stated that there is a consensus amongthe biologists that inflammatory reactions 
are mainly regulated by IL-6 (Mihara, Hashizume et al. 2012). This cytokine is also 
considered to be involved in the regulation of neural, regenerative and metabolic 
processes (Scheller, Chalaris et al. 2011). IL-6 has a key role in the initiation and 
acceleration of chronic inflammation and may contribute to the progression of 
microvascular complications in individuals with T1D (Wegner, Araszkiewicz et al. 
2013). Neurath and Finotto (2011) found the serum level of IL-6 is low in T1D 
compared to non-diabetic (Neurath and Finotto 2011).Furthermore, some studies 
propose that IL-6 plays a part in the instigation and acceleration of the chronic 
inflammation procedure and may participate in the development of micro- and 
macrovascular problems in diabetic individuals (Jialal and Kaur 2012; Wegner, 
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Araszkiewicz et al. 2013).  
1.9.5.3.Interferon Gamma (IFN-γ) 
Immune cells, which invade the islets and play a role in dysfunction of β-cell and 
apoptosis, secrete IFN-γ (Eizirik, Colli et al. 2009). The obliteration of pancreatic β-
cells in T1D individuals may be possibly mediated by IFN-γ cytokine (Chan, Biden et 
al. 2012). IFN-γ is an important factor in the induction and maintenance of the 
autoimmune damage to the islet β-cells, and IFN-γ has been linked with the onset of 
T1D in humans and animals (Chentoufi, Gaudreau et al. 2011). Nevertheless, the 
progression of spontaneous β-cell autoimmunity remains unchanged in NOD mice that 
are deficient in IFN-γ or the IFN-γ receptor (IFNγR) (Yi, Li et al. 2012). IFNγ also 
triggers the manifestation of reactive oxygen species (RoS) such as nitric oxide by β-
cells, and RoS have the ability to arbitrate apoptosis (Lehuen, Diana et al. 2010). NK 
cells are both cytotoxic and producers of cytokines, especially IFNγ. Therefore, NK 
cells may have an indirect or direct effect on the obliteration of β-cells (Lehuen, Diana 
et al. 2010). 
IFN-γ has been shown to be a possible constituent of many autoimmune diseases, such 
as multiple sclerosis and autoimmune diabetes.  
1.9.5.4. Tumor Necrosis Factor Alpha (TNF-α) 
TNF-α is a pro-inflammatory cytokine that is connected to several autoimmune 
illnesses. Blocking the TNF-α signalling pathway is an influential approach in the 
treatment of various auto-inflammatory illnesses like as rheumatoid arthritis and 
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inflammatory bowel disease. TNF triggers the death of β-cell death in individuals with 
T1D individuals; this is done via NF-κB (light-chain-enhancer of activated B cells) 
activation (Ortis, Miani et al. 2012). In the progression of T1D however, the role of 
TNF-α is rather abstruse. Whilst the existence of TNF-α appears to quicken the 
development of the illness early on in the process, it has been shown to reduce the levels 
of auto reactive T cells after formation of the illness. Therefore, both methods of action 
may ultimately be targeted in a therapeutic manner (Boettler and von Herrath 2010). 
People who were diagnosed with T1D showed high level of circulating TNF-α (Arend 
and Dayer 2005). 
Lately, promising data has been produced in a clinical trial using etanercept, a soluble 
TNF-α receptor fusion protein, in children who had had a recent onset of T1D 
(Mastrandrea, Yu et al. 2009). In the subjects who were given TNF-α blockade 
treatment, C-peptide levels appeared to significantly increase, whereas insulin doses 
reduced from baseline to week 24 in the non-existence of chronic side effects. In the 
control group C-peptide levels reduced and insulin doses were boosted in the study 
period. The small sample size of 18 people, and the short follow up period (24 weeks) 
limit the findings of the study and therefore further trials are needed to confirm the 
findings (Boettler and von Herrath 2010). 
1.10. Study Objectives 
The objective of this research exercise is to study the effect of exercise on blood 
glucose, hemoglobin A1C, lipids, insulin, metabolic control and inflammatory markers 
in healthy and T1D volunteers. In order to achieve this objective three studies were 
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undertaken. The first study used survey techniques and the aim was to investigate the 
effect of exercise on T1D patients using insulin pump therapy, to cover perception, 
attitudes and opinions about exercise, diet, blood glucose, A1c, lipids and insulin pump 
satisfaction. The second study examined the acute, i.e. one session, and chronic, i.e.  6 
weeks, 2 sessions a week, effect of at moderate intensity resistance exercise and aerobic 
exercise on inflammatory markers such as IL-6, IL-1β, TNF-α and IFN-γ in healthy and 
T1D sufferers using MDI or CSII. While the final study was to examine the effects of 
chronic moderate intensity exercise (resistance and cardio) on lipid profiles and 
glycaemic control in healthy and T1D using MDI or CSII. 
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Chapter 2: Materials and Methods 
2.1. Exercise study, short-term (acute) and long-term (chronic) effects 
The objective of this study was to determine the acute and chronic effects on various 
immunologic and metabolic parameters of combined exercise program (aerobic, using 
the recumbent bicycle, and resistance) in Non-Diabetic (ND) and Type 1 Diabetic 
(T1D) using Multiple Daily Injections (MDI) and using insulin pump as continuous 
subcutaneous insulin infusion (CSII) patients. 
The initial part of the practical research was concerned with investigating the effects of 
acute exercise (resistance and aerobic) on immunological parameters such as 
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF), interferon gamma (IFNγ) and 
interleukin-1 beta (IL-1β). In order for researchers to observe the acute effect, 
volunteers were asked to exercise for one session. Blood samples were collected before 
commencement of exercise, after resistance exercise and after aerobic exercise. 
The second part of this study was concerned with examining the chronic effect of 
exercise (resistance and aerobic) on the physiological and biochemical variables over a 
six-week period. 
2.2. Insulin Pump Surveys 
2.2.1. Surveys Project Aims 
An insulin pump survey was designed to investigate the effects of exercise (aerobic and 
resistance) on Diabetes Mellitus (DM) patients and to discover their attitudes and 
opinions about their current exercise regimens. Survey results would support and 
feedback into the practical part of the study. 
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2.2.2. De Montfort University Insulin Pump Users Survey 2009 
A previous survey (referred to as the 2009 survey) designed by this research group 
asked CSII users about their attitudes and experiences with DM and CSII therapy. That 
survey was preceded and supported by several focus groups, the members of which read 
and criticised the questions, as did the consultant diabetologist in the Leicester General 
Hospital. 
The survey was divided into three sections and examined information about current 
CSII therapy, hypoglycemia and hyperglycemia and respondents’ thoughts towards an 
implantable CSII under development by the research group. 
As part of the current study the responses collected from the earlier survey were 
analysed by researchers to gain an understanding and appreciation of survey analysis, 
this survey has been published (Appendix C). These responses had been collected by 
postal mail (100 responses) and electronically (242 responses) by Survey Monkey®.  
2.2.3. De Montfort University Insulin Pump Users and Exercise Survey 
2011 
The second survey (referred to as the 2011 survey) (Appendix D) was compiled as part 
of the current work and its aim was to determine varying attitudes toward and current 
trends in exercise among patients with DM. This survey had 74 questions and was 
divided into five sections: Background Information, Diabetes, Insulin Pump, Exercise 
and Diet. The survey was designed to collect additional information about exercise and 
diet for CSII users. During the development of the questionnaire, advice was taken from 
health professionals and researchers, especially a statistician who has specialist 
knowledge of questionnaire design. One of the professorial diabetes researchers being 
consulted was herself a diabetic pump user and sports enthusiast and gave first-hand 
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account to enhance and improve the questionnaire. This survey was not trialled in focus 
groups or otherwise piloted because it had been scrutinised in this way 
This survey was collected electronically (245 responses) by Survey Monkey® or by 
postal mail (14 responses). 
2.2.4. Survey Distribution 
Both surveys (2009 and 2012) were distributed by the research group at the Insulin 
Pump Clinic (Leicester Royal Infirmary), Balance magazine, the Insulin Pump and 
Diabetes Technology UK (INPUT) forum and through social network sites such as 
Twitter® and Facebook®. An advert was also placed in the Diabetes UK bulletin, 
which produces a quarterly magazine, Stability, which is distributed to all members of 
the charitable organisation Diabetes UK. Additionally, diabetes exhibitions and events 
in England, such as Diabetes UK and NHS exhibitions and conferences, were used to 
distribute these surveys, as well as an advert in the local newspaper (Leicester 
Mercury).In addition, an internal e-mail and advert were sent to all De Montfort 
University (DMU) staff and students. 
2.2.5. Analysis of survey responses 
All postal mail responses were uploaded into Survey Monkey
®
 manually in order to 
analyse responses in the same way as electronic responses collected in Survey Monkey. 
All responses were then transferred to a Microsoft Office Excel worksheet specifically 
designed for analysis of the surveys. Data and open-ended questions were transferred to 
the IBM Statistical Package for Social Science (SPSS) using standard codification 
methods. All responses were coded using numbers, e.g. 0 corresponded to ‘no 
response’. 
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2.3. Practical study -Ethics Approval 
Ethics approval of the practical study design and procedures was granted by the DMU 
Ethics Committee (Appendix E). The following documents were produced and 
submitted to gain approval of the committee. 
2.3.1. Standard Operating Procedure (SOP) 
The SOP (Appendix F) provides details about preliminary and main experimental 
procedures used in the exercise trial. 
2.3.2. Volunteer Information Sheet (VIS) 
The VIS (Appendix G) describes the purpose of the study for the benefit of volunteers. 
It contains information about what happens to the volunteer if they decide to take part, 
an explanation of the experimental trial, expenses and payments, possible benefits of 
taking part in the trial, dealing with possible problems during the trial, confidentiality, 
withdrawal time and who has reviewed the study. 
2.3.3. Risk Assessment Form 
This document is an assessment of all possible risks associated with the experimental 
study. 
2.3.4. Consent Form 
This form (Appendix H) confirms that the volunteer has read the VIS and understands 
the experimental trial. Before being presented with the consent form, the volunteer was 
made aware that they were free to withdraw at any time. Once the volunteer was 
comfortable agreeing to all information related to the study, they are asked to sign the 
consent form indicating their desire to participate. 
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2.3.5. Volunteers Health Screen 
This form (Appendix I) focuses on details about the volunteer’s health and medical 
history. The health screen is used to enter patient details, medication details and 
healthcare measurements from the past two years before commencement of the practical 
study. All volunteers were asked to consult their GP before participating in this study to 
ensure it was suitable for them to participate. Each volunteer had been provided with an 
information sheet outlining the trial to give to their GP, and a GP approval letter was 
also sought, although it was optional. 
2.3.6. Confidentiality 
Confidentiality was recognised and considered at every stage of the research project. 
Volunteers were made aware that the research team would not disclose any personal 
information in any report or publication that could identify individual volunteers. All 
personal data were stored in a lockable filing cabinet accessible only by the research 
team. 
2.3.7. Volunteer Record Sheet 
Volunteers who returned a signed consent form and  were asked to fill in a Volunteer 
Record Sheet (Appendix J) which includes volunteer name, contact details, type of 
diabetes or non-diabetes, GP contact details, history of acute diabetic complications 
including number of hypoglycemia and hyperglycemia episodes and other medical 
conditions. Each volunteer was given a unique identification number to preserve 
confidentiality and facilitate data collection. These were all stored in a lockable filing 
cabinet.  
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2.4. Volunteers 
2.4.1. Recruitment of Volunteers for Exercise Program 
Recruiting for the study was publicised through internal and external adverts. Poster 
adverts were placed on DMU campus notice boards seeking volunteers, and an internal 
e-mail was circulated. A display panel on the De Montfort University electronic student 
portal and an advert in the local newspaper (Leicester Mercury) were also used to attract 
volunteers. Forums such as Insulin Pump Forums, the Leicestershirediabetes.org.uk 
website, Input Forums, Royal Infirmary Hospital Leicester (insulin pump clinic) and 
diabetes events were also used to recruit CSII volunteers. 
The target population for volunteers (ND, MDI and CSII) were males aged between 18–
55 years who were, ideally, not physically active or engaged in any regular exercise 
programmes. These volunteers were considered suitable for observing and measuring 
metabolic and immunological parameters. However, it was not always possible to select 
volunteers who met the criterion of being physically inactive.  
The total number of volunteers who expressed an interest in participating was 49, of 
whom 18 were excluded for not meeting inclusion criteria, such as being outside the age 
range, participating in regular exercise or other medical reasons. In addition, 12 
participants were unable to attend as a result of the difficulty of making arrangements. 
The eventual sample was 19 participants.  
All volunteers involved in the study were divided into 3 main groups. Group A (N=7) 
were ND, group B (N=7) were T1D on MDI and group C (N=5) were T1Dusing CSII. 
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2.4.2. Volunteer Criteria 
 
Inclusion Criteria: 
Patients who fulfilled the following criteria were selected to participate in this study 
o Males who were aged at admission time between 18 and 55 years old  
o Either healthy or diagnosed with T1D of more than 18 month’s duration 
o Used multiple dose injection or an insulin pump. Followed a stable insulin regimen 
for at least one month prior involving either use of an insulin pump or multiple 
daily injections consisting of insulin glargine and insulin lispro or insulin as part or 
any new or other type of insulin. 
o For volunteers using CSII, their system set with the target of maintaining BG 
between 5 and 6 mmol/l for at least 90 min before the start of exercise. 
o A1c ≤10.0% (were measured with the DCA®2000+ (Bayer Diagnostics, 
Tarrytown, NY). 
o Refrain from any form of training or vigorous physical activity for 2 weeks before 
the beginning of the study. 
o Body mass index (BMI) between the 5th and 95th percentile for age and gender. 
o Small amounts of intravenous glucose will infused, if necessary.  
o Normal thyroid function. 
o No medication or anti-inflammatory agents, steroids, antioxidants or vitamin 
supplements before, during, or after study entry.  
o No recent history of infectious, inflammatory or immune diseases.  
o Signed information sheet and consent form and returned stamped GP form. 
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Exclusion criteria: 
The following exclusion criteria were applied to patients who: 
o had any of heart disease, liver disease, kidney disease, high blood pressure, 
rheumatic, heart murmur, HIV positive or aids, any allergy, hepatitis, asthma, 
tuberculosis (TB), stroke, epilepsy, any injury in head, hand or other injury  and 
tumour (cancer) history. 
o were currently using glucocorticoids or beta blockers. 
o had used pseudoephedrine (used for the temporary relief of stuffy nose and sinus 
pain/pressure caused by infection such as the common cold, flu) within 48 hours. 
o had experienced severe hypoglycemia within prior 2 weeks.  
o had an active infection. 
o anticipated a significant change in exercise regimen between admissions.  
o had another medical condition or were using a medication that in the judgment of 
the investigator could affect completion of the exercise protocol. 
o had blood pressure greater than 160/95 mm Hg. 
o had participated in exercise 2 or more times weekly for 20 minutes or longer per 
session or any resistance training during the previous 6 months . 
o showed restriction in physical activity because of disease. 
o had recent blood loss or hemolytic anaemia. 
o were terminally or mentally ill. 
o had any recent surgery. 
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Inevitably, a study such as this one (and especially as pilot in nature) will be imperfect 
in terms of matching the characteristics of the participants. This will be dealt with in the 
discussion in chapters 4 and 5. 
 
2.5. Study design and Description of Exercise Sessions 
2.5.1. Exercise Physiology Lab 
At the commencement of this study, the Exercise Physiology Lab (EPL) did not exist 
and had to be built from the very beginning. This included finding a suitable laboratory 
location with suitable and easy access and with temperature control. Moreover, EPL 
equipment such as the bicycle ergometer, resistance machine, ADInstruments analyser, 
ELISA plate reader, ELISA equipment, blood monitors (BP, BG, lipids and A1c) and 
other equipment. At this phase of the project necessary advice was taken from the Sport 
Exercise Department at Loughborough University. The specialists were briefed about 
the research project and they provided technical guidance. 
2.5.2. Phlebotomy, First Aid, Defibrillation training and other courses 
In order to standardise the blood collection procedure for the study, a phlebotomist 
carried out all venipuncture. The research team attended and passed a phlebotomy 
course at the Clinical Department University Hospital, Royal Infirmary Hospital in 
Leicester so that they were qualified and competent to undertake this task. 
The Advanced First Aid at Work course provided by the East Midlands Ambulance 
Service NHS, Leicester and a defibrillation course provided by HeartSine Technologies 
were also attended and passed. 
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Other courses for doctoral training, compulsory (18) and optional (11) were attended. 
These courses were provided by School of Pharmacy, Graduate School and DMU 
library.  
2.5.3. Initial EPL Visit 
Before enrolling in the study, all interested volunteers attended a screening visit to 
discuss and complete questionnaires regarding their health, family history and current 
physical activity levels. 
At this visit, all interested volunteers were asked about current treatment of their 
diabetes and other medications they were taking. When a volunteer was not prevented 
from taking part by the exclusion criteria based on information collected on this initial 
visit, an appointment was made for pre-exercise assessment. 
2.5.4. Pre-exercise Visit and Familiarisation with exercise 
All participants were asked to visit to familiarise themselves with the laboratory and 
exercise equipment, testing procedures and exercise protocol. 
During this session, volunteers were instructed on how to perform the exercises using 
the correct technique for resistance routines using the multi gym machine and for 
aerobic exercise with recumbent ergometer bike. Volunteers were then given the 
opportunity to practise each exercise and to ask questions. Additionally volunteers were 
instructed to follow their normal diet, to try to eat very similarly the day before and 
during each study event and to not engage in any extra exercise activities different from 
their normal routines. 
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2.5.5. Determination of intensity levels for aerobic exercise 
As stated earlier, each volunteer would be required to perform each exercise at 50- 60% 
of their estimated maximum heart rate (HRmax). After reviewing of literature related to 
the research, it was decided to use the Karvonen formula method to determine HR 
reserve (Goldberg, Elliot et al. 1988; Shnayderman and Katz-Leurer 2013) (see table 
2.1) as follows 
Karvonen formula: [(220-age)-(resting HR) × intensity] + resting HR 
Table 2.1: Karvonen formula calculations methods  
Age HR at 
rest 
Intensity  Maximum HR HR reserve Target HR for 
experiment 
  0.5 220-Age Maximum HR- 
HR at rest (BPM) 
(HR reserve ×intensity  
(as fraction))+ HR at 
rest (BPM) 
Example 
35 71 0.5 220-35=185 185-71=114 (114×0.5)+71=128 
In order to record heart rate at rest the subjects were given heart rate monitors to take 
three readings when they are in complete rest (sitting or lying down) in the late evening. 
The justification for this will be discussed in chapter 4.  
2.5.6. Determination of One Repetition Maximum (1RM) for RE Exercise 
One repetition maximum (1RM) is the maximum amount of weight that can be lifted in 
a single repetition for resistance exercise. Since this might not be without hazard if 
attempted directly, methods have been devised so that it can be inferred from a lower 
weight that is limiting for the subject if attempted through a stated number of 
repetitions. There are several methods of calculation that converge for some conditions 
but in this case, the value was determined according to the Brzycki (Brzycki 2000) 
formula [1RM=100×repweight/ (102.78 – (2.78×reps))] (see table 2.2) where repweight 
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is the workload value of repetitions performed and reps is the number of repetitions 
performed. Prior to performing a 1RM, a warm-up was required. 
Table 2.2: Example of using Brzycki formula to determine the 1RM for RE exercise. 
The weight for back, triceps and bicep target was converted from pounds to kilograms 
(lbs to kg). 
RE 
exercise 
types 
Repetitions weight 
(kg) (repweight) 
Number 
of 
repetitions 
( reps) 
1RM 
100×repweight (kg)/(102.78-
2.78×reps 
Intensity level 
(50 or 60%)  
1RM× 0.5 or 0.6 
 
Squat 60 10 
100×60/(102.78- (2.78×10)) 
= 80.02 kg 
80.02×0.5= 
40.01kg 
Chest 40 12 57.62  28.81kg 
Back 36.28 15 59.4  29.70 kg  
Triceps 22.67 15 37.13  18.56 kg 
Bicep 27.21 7 32.66 16.33 kg 
 
Later, volunteers were asked to perform each RE exercise, during the weeks they 
participated in this study, at 50 to 60% of their 1RM, this was considered as a safe level 
for diabetic people who are non-trained to do such exercise and who might be at 
additional risk of covert cardiovascular disease. Though some authorities recommend to 
continual assessment of this level, simply for safety reasons in their pilot study, yet in 
this study this level was not continually assessed. 
 
2.5.7. Warm-up 
Warm-up is an essential part of exercise sessions and designed to prepare the body for 
exercise, increase body temperature and reduce the potential for post-exercise injury or 
pain, especially muscle stiffness. 
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In each session, all volunteers were asked to relax for 5–7 min before any measurements 
were taken. The objective of this step was to get baseline measurements of blood 
pressure, blood glucose and respiratory exchange ratio (RER). 
After relaxing, volunteers stretched lower and upper muscle groups left and right for a 
total of 5–7 min, as shown in figure 2.1. Stretching included loosening front and back of 
upper arms, chest, shoulders, middle back, lower arms, wrists, hands, fingers, back, tops 
of shoulders, neck, triceps, waist, quadriceps, inner thighs and groin, as well as hip 
flexor stretches and chest stretches for the pectoral muscles. 
After stretching, volunteers performed 5 min on a recumbent bike as part of the warm-
up session. 
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Figure 2.1: Stretching left and right for lower and upper muscle groups 
Source:http://www.womensheart.org/content/exercise/stretching_exercise.asp 
2.5.8. Resistance exercise (RE) 
At 50 to 60 % of the volunteer’s1RM as described above in section 2.5.6, they were 
asked to perform five different types of RE exercises on the multigym machine 
(Bodycraft, F610.F602.5046.5049B, US). This phase included 3 sets of 10 repetitions 
with 40 seconds of rest between each set. A Polar heart-rate chest sensor (Polar, FT1-
TRA/BLK) was attached to volunteer’s chest during the session. After each set, the HR 
was recorded and the rate of perceived exertion (RPE) on a6-20 scale (table 2.3). The 
loosens upper arm and 
chest muscles 
 
 
 
 
 
 
 
 
Stretching shoulder, 
middle back, arms, 
hands, fingers, wrist 
 
 
 
 
 
 
 
 
Stretching the back and 
shoulder muscles 
Stretching the chest, 
top of shoulder and 
lower arm muscles 
 
 
Stretching the shoulders 
and neck 
 
 
 
 
 
 
 
 
 
Stretches triceps, top of 
shoulders, waist 
 
 
 
 
 
 
 
 
Stretching the 
quadriceps 
 
Hip flexor stretches 
 
 
 
 
 
 
 
 
Chest stretch for pectoral 
muscle 
 
 
 
 
 
 
 
Stretches inner thigh, groin 
 
 
 
 
 
 
 
 
Stretches side of shoulder and 
back of upper arm 
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target muscles and how volunteers were performing the RE exercises in this session are 
explained in figure 2.2. 
Table 2.3: Rated Perceived Exertion chart (RPE) 
Rating of Perceived Exertion (RPE) Scale 
6 
Very, very light 
7 
8 
Very light 
9 
10 
Fairly light 
11 
12 
Somewhat hard 13 
14 
15 
Hard 
16 
17 
Very hard 
18 
19 Very, very hard 
20 Maximum exertion 
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Figure 2.2: Five types of resistance (RE) exercise (3 sets, 10 repetitions each set)  
Type of RE exercises Description Muscles targeted 
Squat 
 
 
Incline bench press 
  
 
lat curl pull-down 
  
 
Triceps 
 
 
Biceps 
  
 
URLS source:http://www.muscle-fitness-tips.net/biceps-training.html 
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2.5.9. Cycling 
Both the volunteer and the bike were attached to an ADInstruments Analysis System 
(ADInstruments) (PL3516/P ADInstruments, 16 channels, Australia). ADI produces an 
instant graphical representation of performance linked to work done and various 
metabolic parameters such as oxygen consumption (VO2), carbon dioxide production 
(VCO2), respiratory exchange ratio (RER), heart rate (HR), bike revolutions per minute 
(RPM) and breath flow and temperature. 
Physiological signals were converted from analog to digital during aerobic exercise by a 
PowerLab data acquisition unit LabChart (LabChart v6.1.3, ADInstruments, springs, 
Colorado) modules provided acquisition and analysis features specific to specialised 
applications. 
Volunteers were attached to the ADI via a breathing mask (breath-by-breath) system, 
Polar chest heart-rate monitor, pulse rate and blood pressure. A 3-lead 
electrocardiograph (ECG) system was linked by electrodes to the ADI during the 
experiment. 
Volunteers were asked to cycle for 20 min at moderate intensity at 50 to 60% of 
predetermined maximum heart rate (HRmax) on a recumbent ergometer bike (Lode, 
Corival Recumbent, US), as described previously in section 2.5.5. 
After 10 min, blood glucose was monitored and volunteers were asked to rate their 
RPE. 
2.5.10. Warm-down 
Finally, all volunteers were asked to stretch the lower and upper muscle groups for 5–7 
min as described previously in section 2.5.7. 
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2.5.11. Long-term (chronic) exercise 
This exercise programme involved 2 visits (48 hours apart) for a total of 150 min each 
week for a 6-week period. All exercise sessions included stretching, warm-up on the 
bike (5 min), five types of RE exercise (3 sets of 10 repetitions), as described previously 
in section 2.5.8 followed by 5 min rest. After that, volunteers exercised aerobically for 
20 min at 50-60% of predetermined maximum heart rate (HRmax), as shown in section 
2.5.5, then cooled down and rested before final observation of volunteers for 
hypoglycemia (BG level). In the event of low BG after final exercise, volunteer was 
asked to stay in the exercise lab and not to move out for final observation for 45min to 2 
hours. 
In order to control the lab temperature, the exercise room was fitted with cold and hot 
air conditioning system. The lab temperature was adjusted at 20°C by a weather station 
(Oregon Scientific, Hong Kong).   
Blood samples were taken after the 1
st
, 2
nd
, 4
th
, 6
th
, 8
th
, 10
th
 and 12
th
 sessions to 
determine the effect of chronic exercise on immunologic and metabolic parameters. 
2.5.12. Acute exercise 
In this phase, volunteers were asked to do the same as in the chronic phase described 
above. However, in this session, three venous blood samples were collected: before 
exercise (baseline), after RE exercise and after aerobic exercise.  
2.6. Visit measurements 
On each visit, the Measurements form (Appendix K) was filled out. This form was 
designed to measure volunteer health during each exercise session.  
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2.6.1. Body fat percentage, weight, height, body mass index (BMI) 
Body composition according to volunteer age was analysed by a bioelectrical technique 
using SECA scales. The scale sends a small, harmless electrical current through the 
volunteer’s body when they step on the scale plate. 
A triple SECA scale (SECA model 808) was used to determine volunteer weight (in 
kilograms) and BMI. Height (in centimetres) was measured using SECA (SECA 
Stadiometer model 217). BMI was calculated as weight (kg)/height (m)
2
. 
Body fat (BF%), weight, height and BMI were measured 3 times: at the beginning of 
the trial, after 6 visits and at the end of the trial (visit12).Table 2.4shows standard BMI 
percentage as used in this study. 
Table 2.4: Standard BMI index 
 Description BMI 
1 Underweight <18.5% 
2 Normal weight =18.5-24.9% 
3 Overweight =25%-29.9% 
4 Obesity >30% 
2.6.2. Lipid profile 
High-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), 
total cholesterol (TC) and triglyceride level (TG) were measured three times: before the 
trial, after 6 visits and at the end of the trial. HDL, LDL, TC and TG were measured by 
a CardioChek analyser (PA Bundle, Health Check Systems, Germany). It is recognised 
that this desk top equipment is not able to produce the accuracy of the bench top 
instrument such as the BioRad, Beckman etc as used in hospitals etc. The kits come 
with calibration solutions, against which the precision can be measured over the time 
period for which the kit is in date. Thus the precision is not in doubt, but the exact level 
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or accuracy can be guaranteed, rather references only in terms of the calibration solution 
which is supplied within a defined range but not an actual value. To test this, we asked 
the supplier, BHR, to cross-test our instrument and strips against their demo instrument 
and strip batch and the differences were small. We were therefore confident that 
readings were close to actual and that significant changes could be picked up. A 
limitation of this study was that many of the volunteers would have been taking lipid 
moderating medication as standard diabetes protective therapy and therefore large 
changes were not expected. 
2.6.3. Blood glucose (BG) and hemoglobin A1c (A1c) 
Blood glucose was measured specifically 4 times for each volunteer: at rest before 
exercise, after RE exercise, after 10 min of aerobic exercise and at the end of each trial. 
BG was measured using a blood glucose kit (Contour, BAYER, Switzerland). Fast-
acting sugar sources were given if required. 
A1c level was measured at the beginning of the trial and after the last visit for ND and 
diabetic volunteers. A1c was measured by A1c Now
® 
and Quo-Test A1c reagent kit 
which we had already tested for reasonable precision and accuracy, although since the 
study it has been replaced. Sample results are available within five minutes and are 
reported in IFCC and DCCT. 
2.6.4. Venous blood sampling 
Volunteers were asked to sit on a comfortable chair in order to collect blood samples. 
An alcohol swab and a disposable latex-free tourniquet (Fisher Thermo Scientific- Cat 
no. 22-040-225) were used to avoid any infection or contamination. Venous blood 
samples from the median basilica or cephalic veins were collected using S-Monovette 
blood collection system needle and 10 ml tube containing EDTA anticoagulant 
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(ethylenediaminetetraacetic acid) (Monovette, SARSTEDT) syringe system. Twenty-
four samples, one for each volunteer, were collected during successive visits and 
labelled with volunteers’ reference numbers and the date. 
In order to collect blood plasma, labelled samples were centrifuged at 3000 rpm for 15 
min at 4°C using a Fisher Thermo Scientific centrifuge (23RSorvall Legend, Thermo). 
Plasma was then separated into labelled 1.5 ml Eppendorf tubes (Eppendorf, Germany) 
and stored in a -80°C freezer until analysis. 
2.6.5. Assessment of caloric intake 
It was important that all volunteers weighed and recorded everything that they ate and 
drank for the day prior to each experimental exercise session, although as explained 
above this approach is imperfect. Food inventory sheets were provided to volunteers 
(Appendix L). Volunteers were asked to try to keep the same food regimen for the 24 
hours before each exercise session and to refrain from alcohol and smoking 24 hours 
before an exercise session if possible. 
2.7. Calibrating, filtering and sterilising the ADInstruments analyser 
At the beginning of each trial, the ADInstruments PowerLab was calibrated with 4% 
CO2 and 16% oxygen/nitrogen (BOC cat no 226927-v-c). To prevent moisture damage 
to the sensors and to remove any possible damaging particulates, an In-line Filter (0.45μ 
hydrophobic membrane) was changed every 2–3 weeks. 
A face mask, nose clips and drying tube were cleaned and sterilised before each 
volunteer commenced exercise. 
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2.8 Statistical analyses 
2.8.1 Survey 
All data were analysed using Statistical Package for the Social Sciences (SPSS) (version 
20 “IBM”, Chicago, IL, US).Microsoft Excel and SPSS were used to for statistical 
analysis. To examine sample characteristics, frequencies were calculated for variables. 
Descriptive statistics were calculated for all patient demographics. Variables were 
described using main values as well as total numbers and relative frequencies. 
Responses and variables were compared using chi-square test. All data were filtered and 
missing data were excluded from the analyses and only valid percentages were 
considered. Cross tabulations were used to explore the relationship between the sections 
of the questionnaire. Data distributions were checked for normality, for normally 
distributed data paired t-test were used while for non-normal distribute data Wilcoxon 
test was used to determine the significant. All test of significance were conducted using 
α = 0.05 i.e. level of significance. 
2.8.2 Practical study 
All data are presented as mean ± standard error of the mean (SEM) unless otherwise 
stated. T-tests were used in practical study to calculate the P value significance were 
conducted to study various relationships among the data and to conduct meaningful 
analysis. 
The data for the acute test were entered into Excel to detect differences in the same 
exercise session (pre, during and post-exercise) and between (acute and chronic) 
exercise sessions. Analysis was carried out using the IBM Statistical Package for Social 
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Science (SPSS), Version 19 software for Windows to determine the significance of 
difference between the mean values. 
A p value less than 0.05 was considered statistically significant. When a significant 
difference was found, comparison was carried out using the T-test.  
2.9 Cytokine detection 
One of the main objectives of this study was to determine the effect of acute and chronic 
exercise on selected inflammatory cytokines on T1D either MDI or CSII users and to 
compare these with ND. Cytokines selected to be examination were IFN-γ, TNF, IL-6 
and IL-1β. To determine the level of these cytokines, the Sandwich Enzyme-linked 
Immunosorbent Assay (ELISA) test was used.  
2.9.1 Enzyme-linked immunosorbent assay (ELISA) 
The ELISA assay was developed using commercial kits (DuoSet ELISA Development 
Kit, R&D systems, US).  
2.9.1.1Capture antibody 
Capture antibody from R&D Systems were diluted to a working concentration 
according to the R&D Catalogue, as shown in table 2.5. 
Table 2.5: Catalog number and dilutions for capture antibody to working concentration, 
PBS (phosphate buffered saline). Dilution e.g. (360/2) = 5000/180=27.77 µL 
Capture Antibody Mouse anti-human 
Dilute to working 
concentration 
Working 
concentration 
IL-6 
(part 840113, 1 via) 
360 μg/mL 2.0 μg/mL 
27.77 µL of IL-6 into 5 
ml of PBS 
IL-1β 
(part 840168, 1 via) 
720 μg/mL 4.0 μg/mL 
27.77 µL of IL-1β into 
5ml of PBS 
TNF- 
(part 840119, 1 via) 
720 μg/mL 4.0 μg/mL 
27.77 µL of TNF- 
into 5 ml of PBS 
IFN-γ  
(part 840101, 1 via) 
720 μg/mL 4.0 μg/mL 
27.77 µL of IFN-γ into 
5ml of PBS 
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2.9.1.2 Detection antibody 
Detection antibody was diluted to a working concentration according to R&D Systems 
Catalogue, as shown in table 2.6. 
Table 2.6: Catalog numbers and dilutions of detection antibody, RD (Reagent Diluent). 
Dilution e.g. (9 µg=9000ng); for IL-6 (9000/50) = 5000/180=27.77 µL. 
Detection Antibody 
Biotinylated goat 
anti-human 
Dilute to working 
concentration 
Working 
concentration 
IL-6 
(part 840114, 1 via) 
9 μg/mL 50 ng/mL 
27.77 µL of IL-6 
into 5ml of RD 
IL-1β 
(part 840169, 1 via) 
36 μg/mL 200 ng/mL 
27.77 µL of IL-1β 
into 5ml of RD 
TNF- 
(part 840120, 1 via) 
45 μg/mL 250 ng/mL 
27.77µL of TNF- 
into5ml of RD 
IFN-γ  
(part 840102, 1 via) 
9 μg/mL 50 ng/mL 
27.77 µL of IFN-γ 
into 5ml of RD 
 
2.9.1.3 Standard Antibody 
A standard curve was conducted with each assay for quantification, as shown in table 
2.7. 
Table 2.7: Dilutions and catalogue numbers of standard antibody. 
Standard Recombinant human 
Dilute to working 
concentration 
Working 
concentration 
IL-6 
(part 840115, 1 via) 
120 ng/mL 600 pg/mL 
5 µL of stand to 
995 µL of distilled 
water 
IL-1β 
(part 840170, 1 via) 
75 ng/mL 250 pg/mL 
3.33 µL of stand to 
996.66 µL of 
distilled water 
TNF- 
(part 840121, 1 via) 
340 ng/mL 1000 pg/mL 
3 µL of stand to 
997 µL RD 
IFN-γ  
(part 840103, 1 via) 
55 ng/mL 1000 pg/mL 
18.18 µL of stand 
to 981.81 µL of RD 
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2.9.1.4 Plate preparation for ELISA 
2.9.1.4.1 Preparation 
ELISA preparation involved several steps: 
1. Capture antibody was diluted to the working concentration as in table 2.5in 
phosphate-buffered saline (PBS) without carrier protein. Immediately, a 96-well 
microplate was coated with 100 µL per well of the diluted capture antibody. The 
plate was sealed and incubated overnight at room temperature. 
2. Each well was aspirated and washed with wash buffer, repeating the process twice, 
for a total of 3washes. Washing was by filling each well with wash buffer (400 µL) 
using a squirt bottle, manifold dispenser or auto washer. Liquid was completely 
removed at each step. After the last wash, any remaining wash buffer was removed 
by aspirating or by inverting the plate and blotting it against clean paper towels. 
3. Plates were blocked by adding 300 µL of reagent diluent to each well. The plates 
were then incubated at room temperature for a minimum of 1 hour. 
4. The plate was washed as in step 2. The plates were now ready for sample addition. 
2.9.1.4.2 Assay procedure 
1. 100 µL of sample or standards were added per well. Then the plates were covered 
with an adhesive strip and incubated for 2 hours at room temperature. 
2. The plate was washed as in step 2. 
3. 100 µL of the detection antibody was added, diluted in reagent diluent, to each well. 
Then the plates were covered with an adhesive strip and incubate 2 hours at room 
temperature 
4. The plate was washed as in step 2. 
5. 100 µL of the working dilution of Streptavidin-HRP were added to each well. Then 
the plates were covered with an adhesive strip and incubate 20 minutes at room 
temperature. 
6. Plate was washed as in step 2. 
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7. 100 µL of substrate solution were added to each well then incubated for 20 min at 
room temperature avoiding placing the plate in direct light. 
8. 50 µL of stop solution were added to each well then gently tapped the plate to 
ensure thorough mixing. 
9. Immediately the optical densities of each well were determined, using a microplate 
reader set to 450 nm (no correction subtraction needed for high concentrations in 
this case). This determination was determined by microplate absorbance readers 
with Manta PC analysis software (Labtech LT-4000) 
2.10 Materials 
 ELISA solutions 
 Phosphate-buffered saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4. Filtered (0.2 μm 
pore size). 
 Wash buffer 
0.05% Tween 20 in PBS, pH7.4. (R&D Systems cat. WA126) 
 Block buffer 
1% BSA, 50% Sucrose in PBS with 0.05% NaN3. 
 Reagent diluent 
0.1% BSA, in PBS, pH 7.2–7.4, 0.2 μm filtered. (R&D Systems cat. DY995) 
 Substrate solution 
1:1 mixture of colour reagent A (H2O2) and colour reagent B (Tetramethylbenzidine). 
(R&D Systems cat. DY999) 
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 Stop solution 
2 NH2SO4.(R&D Systems cat. DY994) 
 Streptavidin-HRP (Part 890803, 1 vial) 
1.0 ml of Streptavidin conjugated to horseradish-peroxidase, stored at 2–8°C for up to 6 
months. Diluted to the specified working concentration by using reagent diluent.  
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Chapter 3: Insulin Pump Survey 
De Montfort University Insulin Pump Users' Diet and Exercise Survey 2012 
3.1. Introduction 
Diabetes mellitus (DM) is a metabolic disorder and recognised since 2000 B.C. Type1 
diabetes (T1D) is known as a permanent lack of insulin production from the pancreas 
due to the destruction of the β cells of the Islets of Langerhans. This results in raising 
the blood glucose concentration in the blood, for the reason that with no insulin, the 
cells will not exchange carbohydrates such as sugars or other foods into energy usable 
by the body.  
T1D is an autoimmune condition and where insulin producing beta cells in pancreas are 
destroyed and body lacks necessary insulin to maintain blood glucose level and 
maintaining the insulin level in the body becomes a difficult challenge. Diabetes 
Control and Complications Trial (DCCT 1993) and the UK Prospective Diabetes Study 
(UKPDS) were established the significance of intensive management in achieving tight 
metabolic control and improving long-term health in patients with diabetes (Turner, 
Holman et al. 1998). Intensive insulin therapy can be implemented using either 
continuous subcutaneous insulin infusion (CSII) with insulin pump therapy or multiple 
daily insulin injection (MDI) regimens. Insulin pumps deliver fast-acting insulin 
continually at a rate that is pre-set according to patients’ needs throughout the day and 
night. After a meal patient can press a button on the pump to get an additional dose of 
the insulin. This capability of delivering insulin as and when required makes the pump a 
replica of pancreas. Recent advancements in sensors and pumps made it possible to 
automate the management of insulin within the given parameters. Further advances of 
insulin pumps are to make them wearable and programmable. 
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Intensive insulin therapy helps to counter the rise in blood glucose and as a result can 
reduce the risk of developing advanced complications, such as cardiovascular disease, 
chronic renal failure, retinal damage, nerve damage, and microvascular damage. Though 
exercise is an important contributor to healthy outcome in intensive (or any) diabetes 
yet managing T1D requires balancing diet, physical activity and medication to keep 
blood glucose as close to normal as possible. 
Physical activities have acute and chronic effects on BG, lipid and immunological 
parameters (cytokines). Regular aerobic exercises reduces visceral fat mass and body 
weight without decreasing lean body mass, improve insulin sensitivity, glucose and 
blood pressure control, lipid profile and reduces the cardiovascular risk. For these 
reasons, regular physical activity must be considered an essential component of the 
treatment of DM. Nonetheless, during physical activity insulin demands of body change 
and T1D may need careful monitoring of their BG levels during and after the exercise. 
Although researchers have conflicting views on effects of exercise on blood glucose 
control in people with T1D yet, given its other numerous benefits, exercise is still an 
important part of living well with T1D. Furthermore, a carefully planned exercise 
regime can help people with T1D better use insulin and reduce their risk of heart 
disease.   
On the other hand in T1D the lack of the physiological inhibition of insulin secretion 
during exercise results in a potential risk of hypoglycemia. While exercise induced 
activation of counterregulatory hormones might also trigger an acute hyperglycaemic 
metabolic derangement in severe insulin-deficient subjects.  
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In summary, T1D patient must discuss their physical exercise plans with the health care 
professional to understand the consequences of physical activity on their blood glucose 
and the appropriate modifications of diet and insulin therapy.  
The aim of this survey was to assess glycemic control on T1D using the insulin pump, 
to assess the satisfaction with this therapy option and to gauge the frequency of 
treatment-related complications among a large group of people with diabetes around the 
world under conditions of routine daily life including diet and exercise. 
3.2. Study Objectives 
T1D is a condition without any cure in sight yet there are efforts made to develop 
strategies to help T1D to better manage their life. The main aim of this research is to 
study the effectiveness of automated device which pumps insulin into the body as and 
when required to keep a balance in the body and avoids the risks of hyperglycemia and 
hypoglycemia. As mentioned above a balanced diet and a suitable regular exercise 
regime also play an important role in managing the condition. Hence this study further 
aims to study the effects of diet and exercise on T1D especially who relies on CSII for 
insulin.  
This study was designed to investigate the effect of exercise on T1D patients using 
insulin pump therapy, to cover attitudes and opinions about exercise, to support and to 
combine with practical study in chapter 4 and 5 and to gain more information about 
insulin pump and it complications. The ethical approval for the study was obtained from 
the Ethical Review Committee, Faculty of Health and Life Science, De Montfort 
University (DMU), Leicester. 
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The respondents were volunteered to take part in this research and were free to 
withdraw from the survey, if they wished to do so. Although no personal information 
was collected in this survey every effort was made to keep the collected information 
strictly confidential. Over 245 insulin pump users responded to the Insulin Pump Users' 
Diet and Exercise Survey from January 2012 till July 2013; and the method to deliver 
these responses were through SurveyMonkey™ and free post service. 
3.3. Materials and Methods 
An international survey of diabetic patients using insulin pump therapy was carried out 
in 2012 and 2013. This survey was distributed as explained in section 2.2.4 to the 
insulin pump volunteers. In total, there were 74 structured questions with five sections.  
3.3.1. Survey Design, Layout and Measures 
In order to achieve the research goals a survey was conducted using a structured 
questionnaire. The questionnaire was divided into following five sections: 
1. Identity: This section helped to understand the demographics of the respondents 
and collect background information such age, gender, weight and height, level 
of education, time of first diagnosed with DM, ethnic group, pump resources and 
country of residence. 
2. Diabetes history: This section was aimed to collect information about the 
diabetes related medical history. This section asked questions about type of 
diabetes, diagnosis details, family history of DM, A1c levels (diagnosed time, 
before using insulin pump, after using insulin pump), and other health check 
(blood pressure, cholesterol, LDL, HDL, eye test, bare feet, kidney disease or 
dialysis, heart attack, angina, stroke). 
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3. Medication section asked questions about insulin pump therapy including type 
of insulin pump, number of years with insulin pump, type of insulin infused into 
insulin pump, basal rates throughout an exercise and non-exercise day, bolus for 
meals on an exercise and non-exercise day, total amount of insulin on an 
exercise and non-exercise day, pre-exercise bolus, BG before and after exercise, 
hypoglycemia after exercise and level of BG pre-exercises. 
4. Exercise section focused on the exercise and lifestyle. The questions were 
aimed to study the effects of exercise on BG, usage of insulin pump (on or off) 
during exercise, level of intensity, type of exercise, exercise amount (times, 
sessions and days), hypoglycemia and hyperglycemia events (decrease or 
increase), symptoms with exercise and ketoacidosis events. 
5. Diet section collected information about number of calories and carbohydrates, 
diabetic food and drink, dietician consultative, medically advised dietary 
programme, diet approach, eating habits, smoking, drink alcohol and symptoms 
after exercise. 
At the end of this survey the respondents were asked for any comments they would like 
to add. 
All responses were administered and completed by the subject themselves. 
3.3.2. Target audience 
As mentioned above the objective of this study was to explore the impact of exercise on 
T1D sufferers who relied on insulin pump to administer required dosage of insulin. 
Hence, the target audience of this study were T1D patients who were using insulin 
pump therapy.  
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3.3.3. Study population and sampling 
Insulin users were invited to represent the wider population. The distribution and uptake 
cannot be claimed as random because the respondents selected themselves and thus had 
certain characteristics such as reading ability, adequate eyesight or other means to 
complete the survey, English language, motivation, understanding, access to selection 
points etc. A total of 245 T1D volunteers who used CSII, male and female, aged 
between 1-80 years old from different ethnic groups and different levels of education 
took part in the survey.  
3.3.4. Survey Distribution and response collection 
In order to collect sufficient responses; this survey was distributed by different channels 
such as Insulin Pump Clinic (Leicester Royal Infirmary Hospital), the Insulin Pump and 
Diabetes Technology UK (INPUT) forums and through social network sites such as 
Twitter
®
 and Facebook
®
. Furthermore, an advert was also placed in the Diabetes UK 
bulletin, which produces a quarterly magazine, Balance, which is distributed to all 
members of the charitable organisation Diabetes UK. Additionally, diabetes exhibitions 
and events in England, such as Diabetes UK and NHS exhibitions and conferences, 
were used to distribute these surveys, as well as an advert in the local newspaper 
(Leicester Mercury). An advert with this survey link was placed on the main home page 
of DMU. In addition, an internal e-mail and advert were sent to all DMU staff and 
students. 
3.3.5. Data collection 
Survey responses were mainly collected by Survey Monkey
®
. However, all postal mail 
responses were uploaded into Survey Monkey
®
 manually in order to analyse responses 
in the same way as electronic responses collected in Survey Monkey. Information 
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collected was gleaned to conduct a statistical analysis. All responses were coded using 
appropriate numeric codes, e.g. number 1corresponded to ‘no response’.  
3.3.6. Statistical analyses (Analysis of responses) 
All data were analysed using Statistical Package for the Social Sciences (SPSS) (version 
20 “IBM”, Chicago, IL, US).Microsoft Excel and SPSS were used to for statistical 
analysis. To examine sample characteristics, frequencies were calculated for variables. 
Descriptive statistics were calculated for all patient demographics. Variables were 
described using main values as well as total numbers and relative frequencies. 
Responses and variables were compared using chi-square test. All data were filtered and 
missing data were excluded from the analyses and only valid percentages were 
considered. Cross tabulations were used to explore the relationship between the sections 
of the questionnaire. Data distributions were checked for normality, for normally 
distributed data paired t-test were used while for non-normal distribute data Wilcoxon 
test was used to determine the significant. All test of significance were conducted using 
α = 0.05 i.e. level of significance. 
3.4. Results 
Following sections describe and discuss the data collected from the survey and analysed 
using SPSS. 
3.4.1. Background information Section 
This section discusses the demographics of the respondents such as country of origin; 
ethnic group, gender and T1D diagnosis (see table 3.1). 
Almost 89% of the respondents live in UK or US and the majority of respondents (i.e. 
83.96%) are white. Approximately 52% of the respondents were female while 48% 
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were male. The data showed that 54.67% of the respondents did not have a family 
history of T1D while 58% of respondents were living with T1D from 1 to 20 years, 
which means they have clear idea of the T1D related health issues and complications.  
Table 3.1: Survey background information regarding participants in the exercise survey 
Background information Responses % 
Countries: 
UK 
US 
Canada 
Australia 
Others (France, Italy, New Zealand and Denmark) 
 
44.64 
44.21 
6.01 
2.15 
2.99 
Ethnic groups: 
White British 
Other white background 
White Irish  
Others ethnic (Asian, Asian British, Indian, Black 
or Black British, African) 
 
41.98 
41.98 
5.35 
10.69 
Gender: 
Female  
Male  
 
52.05 
47.95 
Diagnosis time (years) with T1D: 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-80 
 
30.33 
27.46 
18.03 
9.84 
10.66 
3.28 
0.41 
 
The data show that most of the respondents (i.e. 42.86%) had normal weight as 
describes by body mass index (BMI) (see figure 3.1) while 4.59% of respondents were 
under weight, 27.04% were overweight, with20.92% were classed as obese. 
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Figure 3.1: Frequencies of BMI values in the survey. Underweight = <18.5 %, Normal 
weight = 18.5–24.9 %, Overweight = 25–29.9 %, Obesity = BMI of 30 % or greater. 
 
The lipid level guidelines as set out by NICE (2010) (Table 3.2 A and B) were used to 
analyse the lipid levels in the respondents. Figure 3.2 shows that 75% respondents 
reported “desirable level of total cholesterol” while 52% respondents reported 
“desirable level of LDL and HDL”. Around 10% of respondents reported “Tc and HDL 
in the undesirable region” while less than 5% respondents had an “undesirable level of 
LDL”. 
Table 3.2A: Lipids level (absolute values mmol/l) according to (NICE, 2010) 
 Normal Abnormal Highly abnormal 
Total Cholesterol (Tc) Less than 4.0 4.1-6.0 Greater than 6 
LDL-Cholesterol Less than2.0 2.1-4.0 4.1-4.8 
HDL-Cholesterol >1.4  1.0-1.4  Less than 1.0 
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Table 3.2B: Lipids ratio level (mmol/l)  
Total Cholesterol to HDL ratio 
Risk Men 
Very low (1/2 average) <3.4 
Low risk 4.0 
Average risk 5.0 
Moderate risk (2x average) 9.5 
High risk (3x risk) >23 
LDL to HDL ratio 
Very low (1/2 average) 1 
Average risk 3.6 
Moderate risk (2x average) 6.3 
High risk (3x risk) 8 
Very low (1/2 average) 1 
 
It is worth noting that for some authorities such as the Mayo clinic these figures vary a 
little. 
 
Figure 3.2: Survey respondents’ lipids levels 
In this survey 90.43% respondents who are CSII users were highly educated while only 
9.57% had not had any formal education. This fact was further supported by the fact 
that approximately 63% of CSII users were professionals or skilled workers, while 
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11.98% were retired, 5.21% student, 4.5% were semi-skilled or manual labourer and 5% 
were unemployed.  
3.4.2.  Diabetes section 
This survey was focused on T1D yet some respondents (only 6.44%) turned out to be 
diagnosed with T2D. The vast majority of the respondents (i.e. 89.60%) were diagnosed 
by T1D, while 3.95%were diagnosed with LADA (1.7%) and type 1.5 (2.25%). Only 
the T1D people were included in the results. 
50% of T1D respondents, who were using CSII therapy, reported to be diagnosed by 
General Practitioners or medical centres, while 21% were diagnosed by hospital clinics, 
10.30% were diagnosed in A&E (accident and emergency) and 2.48% during routine 
medical check-ups. In summary the data shows that almost 85% of the T1D cases were 
diagnosed by formal medical diagnostic techniques while 15% reported to be diagnosed 
by friend and family who picked some signs of the disease and led the patient to the 
medical professional. 
Table 3.3 shows 81.70% respondents with T1D reported that at the time of diagnosis 
their A1c was above 10 (DCCT-%) (96% reported A1c levels higher than 7 at the time 
of diagnosis). However, 81% of such respondents reported that before using CSII 
therapy their A1c was above 7, which is considered to be high according to health 
guidelines. It is worth noting that only 39% of these respondents reported A1c level 
higher that 7 after using CSII. The further analysis of the data show that approximately 
52% of such respondents reported A1c level higher than 8 before starting CSII therapy 
as compared to 12% after using CSII. This shows that CSII is a very effective therapy to 
control and manage the A1c level in T1D sufferers (see figure 3.3). 
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Table 3.3: A1c levels reported by respondents 
  
A1c levels (responses %) 
<5  5.1 - 6  6.1 - 7  7.1 - 8  8.1 - 9  9.1 - 10  >10  
A1c at time of diagnosis 0.9%* 0.5%* 2.7% 4.6% 2.3% 7.3% 81.70% 
A1c before using CSII 0.9% 6% 12% 29.2% 23.6% 12.5% 15.8% 
A1c after using CSII 1.35% 18.83% 36.32% 26.91% 5.38% 2.24% 4.04% 
* It seems that 4 out of 245 respondents failed to understand the question or clicked in 
the wrong box. This makes 1.4% of the total sample, which would not statistically 
significantly to alter the results. 
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Figure 3.3: A1c level before and after insulin pump therapy as reported by the 
respondents. 
 
As mentioned above the majority of CSII users were highly educated and professionals 
so it is not surprising that they checked their BG level before every exercise session. 
59% of T1D sufferers who were using CSII reported that they start exercise when their 
BG level was ≥7mmol/L and 88% reported that BG level dropped significantly after 
exercise.  77.30% reported that they took carbohydrates if their BG level was ≤4mmol/L 
111 
 
before exercise and 89% reported that they took carbohydrates in the event of 
hypoglycemia after exercise. 
3.4.3. Insulin Pump Section 
Almost 50% of the insulin pump user in this survey had been on CSII therapy for more 
than 3 years while 26% for less than 1 year. Respondents gave varying reasons for 
selecting CSII therapy. However, 80% of the insulin pump and the infusion sets were 
provided by NHS or health insurance providers. 
When asked about the type of pump being used the respondents mentioned five 
different makes of pumps (Medtronic Paradigm, Animas, Accu-Chek, Omnipod and 
Roche). Medtronic Paradigm pump was among the most popular (55.21%) then Animas 
(22.51%), Accu-Chek Spirit and Roche (14.57%), Omnipod (5.9%) and Smiths 
Medical–Cozmo (1.81%) as in figure 3.4. 
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Figure 3.4: Insulin pumps that had been selected by respondents or their providers 
 
The respondents used six different types of insulin. Novolog® or Novorapid
®
 (Aspart) 
which are considered to be fast acting insulin is most commonly used i.e. by 56.28%, 
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while 31.43% used Humalog® (Lispro),9% used Apidra,2.29% used Actrapid
®
 (regular 
or soluble insulin) and 1% animal insulin (figure 3.5).  
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Figure 3.5: Types of insulin stated by respondents to be infused into their insulin 
pumps being used 
It seems that patients were highly satisfied with CSII treatment when exercising because 
86.71% did not face any problems during and after their exercise sessions while using 
pumps. Furthermore, 77.65% said that they did not change their exercise routine after 
switching from MDI to CSII therapy. 
Almost 83% of the respondents, who were using CSII, reported that they switched on 
their pumps during the exercise sessions while remaining 17% preferred to keep it 
switched off. 10% of the respondents who switched off their pumps did so on a medical 
advice while 50% did it due to fear of hypoglycemia and 20% reported that pump 
interfered with their exercise regime (20% of such respondents did not give any reason). 
41.21% of the respondents, T1D sufferers using CSII, reported that on an exercise day 
their basal rate was 0.5-1 units/hour daily, while 48.95% reported the same basal rate on 
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a non-exercise rate. In 91.44% of cases, the bolus was not used before exercise and a 
standard bolus for a meal was used on an exercise and non-exercise day (55.68% and 
63.16%, respectively).  
Between 21 and 40 units of insulin (total daily) were used on non-exercise day 
(48.68%) and on exercise day (47.8%).  
The data analysis show that in case of elevated BG level (i.e. over 10mmol/L) 95.21% 
of respondents would increase the insulin bolus, while 4.19% would not intervene and 
would wait for the BG level to come down and 0.60% relied on water or any drink with 
low calories. 
A small number of serious adverse events such as hypoglycemia or elevated BG level at 
fasting were recorded. 32 % of participants reported to have more than 3 episodes of 
hypoglycemia per week while 37% reported 2-3 such episodes per week. Almost 41% 
reported that their BG level at fasting was above 10mmol/L more than twice a week. It 
is worth noting that 63.25% very rarely suffered from hypoglycemia during an exercise 
session. However, 52.41% reported to have more than usual episodes of hypoglycemia 
after exercise while 45.18% witnessed no effect on the occurrence of hypoglycemia 
after exercise. 
3.4.4. Exercise Section 
67.35% of respondents, who were using CSII therapy, considered physical activities as 
an important aspect of their life while 25% were indifferent and 7.7% gave exercise no 
importance. Furthermore, 74.17% of respondents indicated that they always lived 
actively. Almost 35% of the participants considered reducing A1c as the main 
motivation behind participating in exercise, while 18% considered weight reduction and 
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16% considered staying motivated as the main reasons (30% gave other reasons e.g. 
burning fat, healthy life style etc.). It is worth noting that only 5.52% of CSII users 
frequently missed an exercise session due to feeling unwell (29% sometimes and 62% 
rarely).  
A majority of pump users i.e. 61.59% were not a regular member of a sport centre or 
physical activity group and only 13.50% were doing exercise with a sport team (e.g. 
football, netball, aerobics, dance, etc.). 46.63% preferred to exercise in open areas and 
20% indoor i.e. at home or office, while only 18% liked to go to gym. When asked 
about the intensity level of exercise 75% were doing moderate exercise while remaining 
25% were on the extreme ends of the spectrum (i.e. 10% high and 15% low) figure 3.6. 
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Figure 3.6: Intensity level during exercise sessions as reported by respondents  
 
40% of the respondents, who were using CSII, were doing a combination of aerobic and 
resistance exercise regime (i.e. walking, cycling, weight lifting, swimming, running and 
team sport), while 55% were relying on aerobic only (see figure 3.7 A and B). 
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Figure 3.7: Types of physical activity reported by respondents. A are the main types of 
exercise and B is the subtype of activities.  
It was observed that the majority of the CSII users were following a regular exercise 
regime with 17% doing exercise more than 5 times every week, almost 45% doing 
exercise 3-5 times every week and almost 38% 1-2 times per-week. Respondents said 
A 
B 
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they exercised once a day (80.25%), twice a day (15.92%), three times or more daily 
(3.83%). A typical exercise session comprised less than 30 minutes (13.58%), more 
than 30 min to 1 hour (42.59%), from 1 to 2 hours (33.33%) and more than 2 hours 
(10.49%). Exercising time was mainly stated in the morning (58.18%), afternoon 
(48.48%), evening (49.09%), after meal (32.73%) and before meal (22.42%). 
Despite the fact that exercise has many health benefits, especially for diabetes mellitus 
(DM), yet it was observed that majority of DM in this survey did not follow a regular 
exercise regime due to fear of negative effects such as muscle cramps, flushing etc. 
46.05% of CSII users in this survey reported that they never witnessed any ill effects of 
exercise. 54% of the respondents muscle cramps (20.39%), breathing shortness 
(11.18%), flushing (7.24%), red face (7.89%), chafing (1.97%) and others (5.26%) ill 
effects of the exercise were observed. On the other hand, when asked about Diabetic 
Ketoacidosis (DKA), 91% of the pump users reported that they had never experienced 
of DKA since they started to exercise.  
3.4.5. Diet Section 
Almost 89% of the responders said that they did not follow any medically approved 
dietary programme and 95.21% did not consume any special diabetic food or drink. 
This is further confirmed by the fact that 64% of the CSII users never consulted a 
dietician, while 28% did so regularly and a small percentage 8% had regular 
consultations with a dietician. However, 99.40% of insulin pump users who participated 
in this survey regularly counted their carbohydrate intake. Furthermore, 70% of such 
respondents reported to eating healthy as a priority, while 25% try to eat healthy food. 
Only a tiny percentage i.e. 2% said that they were too busy to search for healthy food 
options. And 3% described their eating habits as poor. It was observed in this survey 
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that most of the CSII users were conscious of their A1c level (this fact is supported by 
the previously mentioned stats that vast majority of CSII users were highly educated 
professionals). 35% of such respondents follow healthy eating regime to control their 
A1c level.91.62% of CSII users did not smoke while 51.5% consume alcohol.  
As identified in this survey there were other factors that affected their eating habits such 
as trying to eat a healthy diet (63.69%), parents and family (4.46%), school and work 
(3.18%), socialising live (12.10%), not to try to change eating habits (3.18%) and others 
factor (13.38%). The average of calories number was intake in a typical day as listed in 
the table 3.4.  
Table 3.4: The average number of calories intake in a typical day by CSII users as 
reported by respondents 
Average of calories number/ daily  Responses % 
Less than 1500 12.57 
Over 1500 up to 2000 34.13 
Over 2000 up to 2500 19.16 
Over 2500 up to 3000 13.17 
Over 3000 up to 3500 1.20 
More than 3500  0.60 
 
3.4.6. Diabetes complications 
97% of CSII users among the respondents considered themselves as in good health and 
they confirm that they have regular medical check-ups. Table 3.5 provides a brief 
summary of some of the findings: 
Table 3.5: Medical check-ups (responses %) as reflected in survey responses 
Medical  check list  Yes No 
Have had your weight checked by a doctor or nurse? 98.21 1.79 
Blood pressure taken by a doctor or nurse? 96.89 2.67 
Is your blood pressure usually normal? 78.67 20.44 
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Do you take any medication to control your blood pressure? 32.59 67.41 
 A cholesterol test by a doctor or nurse 90.67 9.33 
Are you on lipid lowering medication (for high cholesterol 
or triglycerides)? 
33.78 65.33 
An eye test where a photograph of the back of your eyes 
was taken? 
81.25 17.86 
Has your eyesight suffered as a consequence of your 
diabetes? 
33.33 
 
65.78 
Bare feet were examined 78.22 21.33 
Do you have diabetic kidney disease? 7.11 92.89 
Have you had a kidney transplant? 0.90 99.10 
Do you require dialysis? 0 100 
Have you ever had, or suspected that you had a stroke? 1.79 97.77 
Have you ever had a heart attack? 2.67 96.89 
Do you ever have chest pain due to angina? 1.79 97.77 
Have you ever had heart bypass surgery (coronary artery 
bypass)? 
0.44 99.11 
Have you ever had a balloon angioplasty or a coronary stent 
placed? 
3.11 96.44 
 
3.4.7. Bivariate Analysis (Crosstab Analysis) 
In statistics bivariate data analysis is a technique to study how two variables or 
questions relate to each other. In SPSS, bivariate analysis is called crosstab analysis and 
performed by tabulating them in a two way table. 
CSII therapy relies on a portable pump which constantly delivers insulin throughout the 
day based on a pre-set basal rate. The basal rate can be programmed and changed at 
different times of day according to the need of the patients (figure 3.8) i.e. how much 
background insulin patient received each hour by pressing few buttons on the device. 
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Figure 3.8: Basal and Bolus delivery by insulin pump. (Adapted from Accu-chek 
website) 
In this study the CSII respondents stated that they have a lower basal rate in an exercise 
day compare to a non-exercise day (see table 3.6). 
Table 3.6: Basal rate cross-table on an exercise day and on non-exercise day as reported 
by survey respondents 
Basal rates (Unit/hr) An exercise day 
<0.5  0.5 - 1  1 - 2  >2  
Non-
exercise 
day 
< 0.5 100% 0% 0% 0% 
0.5 – 1 28% 72% 0% 0% 
1 – 2 5% 37% 55% 3% 
>2 0% 0% 31% 69% 
 
For example: when insulin pump users use 1-2 Unit/hr in non-exercise days then 55% 
of them will use the same amount in an exercise day while 37% of them will use less 
than 1 unit/hr and 5% of them will use less than 0.5 unit/hr. 
The insulin pump can also deliver a shot of insulin (bolus), to control the BG levels 
following a meal (see figure 3.8). Insulin pumps are programmable and flexible devices 
which can be set to deliver half doses of required insulin before meal and delivering the 
second half of the required insulin dose one hour later or so. 
In this study the respondents stated that if their bolus types for meal were of the 
following type (standard bolus (spike), combination bolus (spike and square wave) they 
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were slightly adjusted on exercise days compared to non-exercise days on which they 
preferred standard bolus (spike), extended bolus (square wave) and combination bolus 
(spike and square wave). However, extended bolus (square wave) and super bolus 
(increased spike) were not changed on exercise and non-exercise days (see table 3.7). 
Table 3.7: Bolus types on an exercise and non-exercise day (responses %) 
Bolus types for meal 
An exercise day 
Standard 
bolus 
(Spike) 
Extended 
bolus 
(Square 
wave) 
Combination 
bolus (Spike 
and Square 
wave) 
Super 
bolus 
(Increased 
spike) 
Non-exercise 
day 
Standard bolus 
(Spike) 
85% 6% 9% 0% 
Extended bolus 
(Square wave) 
0% 100% 0% 0% 
Combination bolus 
(Spike and Square 
wave) 
14% 8% 78% 0% 
Super bolus 
(Increased spike) 
0% 0% 0% 100% 
 
Table 3.8 shows the total daily amount of insulin (Units/day) infused into the pump on 
the exercise and non-exercise day. Pump users reported that the total daily amount of 
insulin infused into the pump was reduced in an exercise day as compared to non-
exercise day when they use more than 20 units of insulin. However, the total amount of 
daily insulin did not changed in exercise and non-exercise day when pump users used 
less than 20 units of total daily insulin. 
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Table 3.8: Total insulin through an exercise and non-exercise day (responses %). 
*Responders reported sometime when they exercise they eat more than on non-exercise day. 
Total amount of insulin (Units) 
An exercise day 
<20  21 -30  31 - 40  41- 50  51- 60  >61  
Non-exercise day 
<20  100% 0% 0% 0% 0% 0% 
21 -30  29% 69% 0% 0% 0% 2%* 
31 - 40  0% 37% 63% 0% 0% 0% 
41- 50  0% 11% 36% 53% 0% 0% 
51- 60  0% 0% 14% 38% 43% 5%* 
>61  0% 0% 0% 4% 21% 75% 
Data analysis shows that the CSII users who were doing BG tests more than 6 times day 
did not make any adjustments for exercise or non-exercise day. However, 78% of CSII 
users conducted more frequent BG tests on exercise days (49% from 51 to more than 
six times a day and 29% from 21 to 51 times a day) (Table 3.9). 
Table 3.9: Number of BG tests on exercise and non-exercise day 
 Blood glucose test times 
An exercise day (% of responses) 
1-3  4-6  >6  
 Non- exercise day 
1-3  71% 29% 0% 
4-6  0% 51% 49% 
>6  0% 0% 100% 
 
As mentioned previously most of the respondents (i.e. approximately 88%) in the 
survey reported that exercise session reduced their BG level. Table 3.10 summarise the 
data to highlight the effect of exercise on CSII users. It is clear from the data in table 
3.10 that all the respondents who started exercise with BG level higher than 8 mmol/l 
witnessed a significant drop in their BG level.  
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Table 3.10: BG level before exercise and the change after exercise 
 Blood glucose (mmol/l) 
Effect of exercise on BG level (% of responses) 
 Increase in 
BG level 
 Decrease in BG 
level 
 No change 
in BG level 
Pre-exercise 
BG level 
(mmol/l) 
<5 25% 50% 25% 
5.1 - 6 0% 94% 6% 
6.1 - 7 l 11% 86% 3% 
7.1 - 8 7% 84% 9% 
8.1 - 9 0% 100% 0% 
9.1 - 10 0% 100% 0% 
>10 0% 100% 0% 
 
Most of the respondents of this survey were based in UK or US (44.64 and 44.21% 
respectively) and a comparison of data from respondents from these countries reveals 
that:  
 In UK, 71.11 % of insulin pump users are female in contrast to US, 64.38 % are 
male.  
 More than 80% in both countries underwent some form of educational training 
(e.g. vocational or college) or have had a higher education (e.g. university) 
 This research is mainly focused in T1D patients and Type 2 diabetes patients 
who are using insulin pump were excluded from the data analysis. However, 
there were only 2.38% from UK compare to 14.29% from US who are 
diagnosed with T2D and using CSII therapy. 
 In UK 66.67 % did not have a family history of diabetes in contrast to 65.22% in 
US who have a family history of diabetes. 
 26.19% T1D sufferers in UK discovered that they are diabetic when their friend 
or member of family picked some symptoms, while in US 4.29% cases for 
discovered this way.  
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 In UK almost 38% were diagnosed at the age less that 10 while in US 38% were 
diagnosed bet 1-20 years of age (table 3.11).  
Table 3.11: Insulin pump users at diagnosed age. 
First diagnosed age UK US 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
37.78% 
 28.89% 
 20% 
 6.67% 
 4.44% 
 2.22% 
17.81% 
30.14% 
19.18% 
12.33% 
16.44% 
4.11% 
 39% of the respondents from US are using CSII for more than 5 years, while 
only 22.5% in UK are using it for more than 5 years (table 3.12). 
Table 3.12: Insulin pump users on the pump (years). 
Years on pump UK US 
Less than 1 year 
1-3 years  
3-5 years  
More than 5 years 
15% 
32.50% 
30% 
22.50% 
20.31% 
17.19% 
23.44% 
39.06% 
 
 In UK most of the CSII pumps are sourced by NHS (i.e. 97.73%) and a very 
small number i.e. 2.27% are paid for by the patients. While in US the main 
provider for the insulin pump and the infusion set is the capital health plan 
insurance or other insurance (in some cases patient pay 20% of the total cost and 
the insurance cover the rest of the cost) and 14.29% of insulin pump users 
reported that they paid for the pump infusion sets. 
 6.67% of CSII users in UK are retired while in US 19.18% of respondents 
reported to be retired (table 3.13). 
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Table 3.13: Insulin pump users age (years). 
Age years UK US 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-80 
4.44% 
6.67% 
11.11% 
24.44% 
31.11% 
13.33% 
6.67% 
1.37% 
6.85% 
4.11% 
10.96% 
21.92% 
41.10% 
13.70% 
 In the UK 29% of the responders reported their A1c at the time of diagnosis was 
above 9% and almost same of number of respondents from US had the same 
experience (table 3.14). 
Table 3.14: A1c level. 
A1c UK US 
At diagnosed time 
7.1-8 
Above 9 
Before using pump 
6.1-7  
7.1-8  
8.1-9  
9.1-10  
Over 10 
After using pump 
5.1-6 
6.1-7  
7.1-8  
8.1-9 
9.1-10 
Over 10 
 
4.76% 
 28.57% 
 
9.52 
26.19% 
30.95% 
9.52% 
19.05% 
 
4.76% 
35.71% 
38.10% 
7.14% 
2.38% 
7.14 
 
7.14% 
30% 
 
14.49% 
31.88% 
18.84% 
14.49% 
1.45% 
 
28.57% 
40% 
15.71% 
5.17% 
1.43% 
2.86% 
 In UK NHS is offering different types of insulin pumps and Medtronic Paradigm 
(34.15%), Animas (21.95%) and Accu-chek (21.95%) are the most commonly 
supplied devices. While in US the insurance companies are also following the 
same pattern and offering Medtronic Paradigm (62.50%), Animas (15.63%) and 
Accu-chek (4.69%). Moreover, in both countries patients are using almost the 
same type of insulin in their pumps (table 3.15). 
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Table 3.15: Type of insulin. 
Insulin infused into pump UK US 
Humalog® (Lispro)  
Novorapid® or Novolog® (Aspart) 
32.50% 
47.50% 
29.82% 
50.88% 
 
 Basal rate on a non-exercise day for UK based respondents on CSII therapy is 
less than same respondents from US. In UK insulin pump users mainly use less 
than one unit of insulin on non exercise day and less than half unit on an 
exercise day as in the table 3.16. In UK insulin pump users show that they use 
less total daily insulin in exercise and non-exercise day as compared to US based 
respondents. 
Table 3.16: Basal and total amount of insulin daily. 
Basal rates: 
On non-exercise day 
0.5-1 unit  
1-2 units 
On a an exercise day 
Less than 0.5  unit 
0.5-1 unit 
1-2 units 
 
The total amount of daily insulin: 
On non-exercise day 
21-30 units 
31-40 units 
51-60 units 
More than 61 units 
On a an exercise day 
Less than 20 units 
21-30 units 
31-40 units 
41-50 units 
51-60 units 
More than 61 units 
UK 
 
57.50% 
20% 
 
39.47% 
34.21% 
10.53% 
 
 
 
25% 
27.50% 
7.50% 
7.50% 
 
20.51% 
28.21% 
28.21% 
10.26% 
7.69%) 
5.13% 
US 
 
32.81% 
43.75% 
 
15.8% 
39.68% 
25.40% 
 
 
 
18.75% 
25% 
18.75% 
21.88% 
 
9.68% 
29.03% 
17.74% 
9.68% 
19.35% 
14.52% 
 75% of responders from UK and 50% from US reported the acceptable BG level 
before exercise is to be above 7mmol/L. However, same percentages in both 
countries reported the decreased in BG level after exercise. In UK 73% of 
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insulin pump users did not report hypoglycemia during exercise whereas 50% 
from US report hypoglycemia during exercise.  
 In the UK and US (85% and 80% respectively) were switched on their pump 
during exercise and 88% of such respondents from both countries have no pump 
problems during exercise. 
 The exercise hours, intensity and types are almost same in UK and US as show 
in the table 3.17. Importantly, more than 88% in both countries insulin pump 
users did not report any DKA events since they start exercising. 
Table 3.17: Exercise duration, level and types. 
Exercise hours/week: 
1-3 hours 
More than 3 hours 
Level of intensity: 
Light  
Moderate  
Type of exercise: 
Aerobic exercise 
Resistance exercise 
Mixture 
UK 
23.68% 
39.47% 
 
20% 
28.57% 
 
 47.22% 
 2.78% 
36.11% 
US 
30.36% 
48.21% 
 
14.04% 
38.60% 
 
57.14% 
0.0% 
28.57% 
 
 In the UK 100% and 90% from US of T1D using CSII did not take any special 
diabetic food or drink and did not follow a medically approved dietary 
programme while 100% of pump users in US counted intake carbohydrates 
compare to 87% from UK do so as in the table 3.18. 
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Table 3.18: Calories Number. 
Number of calories in a typical day: UK US 
Less than 1500 
1500-2000  
2000-2500  
2500-3000  
3000-3500  
More than 3500 
5.26% 
36.84% 
28.95% 
10.53% 
0.0% 
2.63% 
14.29% 
35.71% 
12.50% 
19.64% 
1.79% 
0.0% 
 
The above analysis shows that T1D sufferers in both countries had almost same 
experience with the CSII therapy and found CSII therapy and exercise helpful to 
manage their BG level and over all quality of life. 
3.5. Discussion 
Diabetes is becoming more and more common across the world. It has been observed by 
different researchers that although insulin is vital for T1D, exercise and diet play an 
important role to manage both types of the condition. For some time now, CSII therapy 
has been an alternative to MDI to manage and control the insulin in T1D (Wu, Graves et 
al. 2010). CSII therapy was first introduced in 1970 and the past few years have 
witnessed significant improvement in the design, ease of use and effectiveness of this 
device (Fuld, Conrad et al. 2010). The aim of this survey was to study the attitude and 
perception of T1D sufferers about the effectiveness of CSII therapy, exercise and diet. 
A questionnaire for this study was published on SurveyMonkey
®
 and different diabetes 
related publications were used to advertise it.  
In total, 273 people completed the survey but only 245 responses were considered in 
this study for analysis. Others were disregarded for the present purpose because some of 
the respondents failed to fully complete the questionnaire while some others were not 
T1D patients rather diagnosed as T2D or LADA. It may be a shortcoming that this 
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survey was not piloted in focus groups or to small recipient audience to trial it. 
However, it had been scrutinised and edited by professionals, one of whom was a 
diabetic sportswoman apart from being a professor of diabetology. One or two questions 
were inadequately posed including asking for lipid level information, although it is hard 
to see how information can be elicited that is not in the respondent’s possession. This 
did blunt the power of the lipid data but inferences could be gained and we did not find 
any obvious contradictions in the data. A survey is just a snapshot, however, and is open 
to many biases such as we discovered in the first survey mentioned earlier. In that study, 
the responses included a large majority of T1D despite being open to T2D subjects as 
well, of whom there are in fact ten times the number. This anomaly turned out to be a 
question of enthusiasm for surveys, access to PCs and the web and the ability to read the 
small print in the Balance magazine advertisement. 
The findings of the current study are discussed in details as below:  
 In this study almost 89% of respondents lived in the UK or US and the majority 
(i.e. 83.96%) were white. Pickup (2011) and Renard (2010) reported that the US 
is the leader in CSII therapy, with 40% of T1D patients on insulin pump (Renard 
2010). Moreover, (Pickup 2011) also stated that in UK less than 5% of T1D are 
using CSII therapy. Only 3% respondents were from mainland Europe 
(excluding UK). This small response could be associated with survey being in 
English and also the lack of formal interest of medical professionals and limited 
research in the field of CSII in large parts of this region. Furthermore, as 
reported by NICE, there are very small numbers of European medical 
professionals who are trained to advise patients about CSII therapy in these 
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countries, as the manufacturers of insulin pump have neglected to invest there in 
research and training, probably due to health insurance in these countries failing 
to routinely underwrite insulin pump use.  
 The data showed that 54.67% of the respondents did not have family history of 
T1D. In the UK 66.67% did not have a family history of diabetes in contrast to 
65.22% in US who did. These findings should be compared with those of Steck 
and Rewers (2011) who reported that in US more than 85% of T1D patients with 
T1D did not have a family history of T1D (Steck and Rewers 2011). However, 
American Diabetes Association (ADA) in a report entitled “Definition and 
Description of Diabetes Mellitus” considered T1D has genetic factors, and this 
claim is supported by some other studies as well (Diabetes Care 2011; ADA 
2013). However, T1D is a complicated disease as the genes which affect T1D 
susceptibility can be a function of 1) β-cell function 2) insulin expression 3) 
immune function (Noble and Erlich 2012) 
 It is a fact that onset of T1D usually occurs in children and young adults. This 
claim was supported by that fact that 58% of respondents in this pump study 
were living with T1D for 1 to 20 years. This result is in line with Renard (2010) 
who reported a sharp rise in CSII usage among children and teenagers (Renard 
2010).  
 The data show that most of the respondents (i.e. 42.86%) have normal weight as 
described by body mass index (BMI) while 4.59% of respondents were under 
weight, 27.04% were overweight and 20.92% were classed as obese. Further 
analysis of data in this respect showed that the female respondents have the 
higher percentages of overweight and obesity as compared to the males. This 
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result is supported by other studies such as Łuczyński, Szypowska et al (2011) 
they compared the BMI of male and female CSII users and found that more 
females are classed as overweight/obese with higher BMI values as compared to 
the boys (Łuczyński, Szypowska et al. 2011). On the other hand, DiMeglio, 
Pottorff et al. (2004) in their study found that CSII therapy had no effect on 
patients’ BMI. They further argued that increased level of insulin to control A1c 
may result in increased BMI in youth with T1D (DiMeglio, Pottorff et al. 2004). 
 In the survey, it was found that 70% of respondents had desired levels of total 
cholesterol while almost 65% respondents reported a desirable level of LDL 
and/or HDL. While it has become widespread practice to use ratios of TC/HDL 
and LDL/HDL, it should be noted that some authorities, such as the Mayo 
Clinic, prefer ratios only for the purposes of diagnosis and not for treatment 
basis. In this survey, the question asked for numbers, giving no prompts and not 
specifying that all values were needed. Many respondents gave insufficient 
information to calculate these ratios e.g. missed one or other value. It is worth 
noting that 65.33% (see table 3.5) respondents were not taking any lipid 
lowering medication which means the majority of the ratio values may well have 
been maintained at normal/acceptable values for the purpose of this study. This 
could well apply to the un-medicated and to the 35% who took statins or their 
alternatives (assuming appropriate prescribing and compliance). The greater 
efficiency of pumped insulin might well affect lipid control. Maahs, Nadeau et 
al. (2011) reported that reduced HDL is associated with lower insulin resistance 
in youths with T1D (rather than T2D resistance and as assessed by lower 
glucose infusion rates in clamp experiments) (Maahs, Nadeau et al. 2011). 
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Meanwhile, Feitosa, Feitosa-Filho et al (2013) showed that intensive insulin 
therapy even with poor glycaemic control may lead to lower LDL than in 
controls, arguing that insulin may control lipids and glucose with different ratios 
of efficiency. Ho, Dhaliwal et al. (2012) found in their study that exercise plays 
an important role to lower the lipids and is therefore likely to have an augmented 
effect for insulin pumpers. This may be associated with weight control and thus 
Guo, Kawano et al. (2011) argued that for non-diabetic Japanese subjects, a drop 
in BMI may cause a drop in LDL level and elevate the HDL level. 
 In this survey 90.43% of CSII users are highly educated, while 63% of CSII 
users are professionals or skilled workers. These findings are in line with Valla 
(2013) claim who suggested that insulin pump users should be able to respond to 
education regarding the functions of the pump to use it effectively and control 
their glycemia 
 In this study it was found that insulin pump therapy is an effective means to 
lower the A1c in T1D (statistically significant with P=0.001) which is consistent 
with other studies such as (Pickup and Sutton 2008; Bergenstal, Tamborlane et 
al. 2010; Misso, Egberts et al. 2010; Hermanides, Nørgaard et al. 2011).This 
study also found that T1D using insulin pump therapy reached the target A1c of 
7.1% or less, and this was achieved by reducing hyperglycemia without 
increasing hypoglycemia these results are in line with Levy-Shraga, Lerner-
Geva et al. (2013). These results are further supported by NICE guidelines 
where CSII therapy is recommended for T1D to improve their diabetes control 
and hypoglycemia and to achieve and maintain target A1c (Hitman 
2012).Moreover, Aberle, Scholz et al. (2009) reported that the A1c is 
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significantly lower in T1D using insulin pump as copmapred to MDI users 
(Aberle, Scholz et al. 2009) as well as Knight, Northam et al. (2009) reported 
that CSII is effective to control A1c (from 8.2% to 7.5%) (Knight, Northam et 
al. 2009). de Vries, Grushka et al. (2011) examined 530 patients with T1D who 
had had insulin pump therapy for 8 years (2000 and 2008), and found that A1c 
was significantly higher in patients discontinuing pump therapy than in the 
controls (p = 0.02) (de Vries, Grushka et al. 2011). It is worth noting that in the 
US, CSII is also prescribed for T2D people who fail to control their A1c (Bode 
2010). Pickup (2011) argued that most of the T2D patients poorly control their 
glycaemic while CSII improved their glycaemic control (Pickup 2011). Hence it 
could be concluded that both types of diabetes could improve their glycaemic 
control after using CSII therapy. 
 In this study 88% reported that BG level was dropped significantly after exercise 
and no hypoglycemia events were recorded. Yardley, Iscoe et al. (2013) also 
reported that, CSII users have less hyperglycemia post-exercise than MDI 
(Yardley, Iscoe et al. 2013). 
 Our study indicates that more than half of T1D on Medtronic Paradigm insulin 
pump. Though the type of pump is mainly selected by NHS or the insurance 
company yet Agrawal, Welsh et al. (2011) study found Medtronic Paradigm 
insulin pump easy to use and the most effective on their criteria (Agrawal, 
Welsh et al. 2011). 
 56.28% of respondents used Novolog® or Novorapid® (Aspart) insulin (figure 
3.5). Garg, Ampudia-Blasco et al. (2010) supporting the choice of this type of 
insulin as rapid-acting insulin analog, lowering incidence of hypoglycemia as 
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well as providing improvements in glycemic control (Garg, Ampudia-Blasco et 
al. 2010). Moreover, this insulin is safe and effective for use with insulin pump 
in T1D patient’s (children or adult) (Weinzimer, Ternand et al. 2008).  
 In this study patients were highly satisfied with CSII treatment because 86.71% 
did not face any problems during and after their exercise sessions while using 
pumps. Furthermore, 77.65% said that they did not change their exercise routine 
after switching from MDI to CSII therapy. 
 In this study it was found that users who take less that 0.5 insulin units/hour did 
not need to change their basal rates. Interestingly, when insulin pump users 
injected more than 0.5 insulin units/hour only about a third reduced the dose for 
exercise. Tildesley, Chan et al. (2012) reported having multiple basal pumped 
rates did not appear to affect A1c reduction (Tildesley, Chan et al. 2012). 
Delivery consistency in basal rates 24/7 days is one of the advantages of using 
CSII to control BG levels, injections being variable for reasons connected with 
skin sites and technique. However, elsewhere it has been reported that the 
variable basal rates and low insulin depots also contribute to pumps’ reported 
clinical superiority (Valla 2013). This makes sense because the variation is 
aimed to control identified times when glucose might be expected to change or 
has changed. 
 63.16% of cases, standard bolus for a meal were used on an exercise and non-
exercise day. The use of standard bolus was supported by Maahs, Horton et al. 
(2010) to correct elevated BG levels after meals (Maahs, Horton et al. 2010) and  
Danne et al. (2008) demonstrated that patients taking more of their daily insulin 
as boluses had significantly lower A1c levels than patients taking fewer boluses 
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(Danne, Battelino et al. 2008). Moreover, Cukierman-Yaffe, Konvalina et al. 
(2011) recommended to use this bolus method to achieve better glucose control 
(Cukierman-Yaffe, Konvalina et al. 2011). The strategic use of bolus dosing is 
associated with better glucose control and improved estimates of carbohydrate 
ingestion.  
 64% of respondents said they very rarely suffered from hypoglycemia during an 
exercise session. However, 52.41% reported to have more than usual episodes of 
hypoglycemia after exercise. Yardley, Iscoe et al. (2013) are supporting this 
statement when they compare the post aerobic exercise (moderate-to-heavy) 
hyperglycemia on CSII and MDI and CSII group reported limited the post-
exercise hyperglycemia but this is not associated with increased risk for post-
exercise late-onset hypoglycemia (Yardley, Iscoe et al. 2013). One of the 
greatest advantages of CSII therapy is to reduce the number of hypoglycemia 
during and after exercise. 
 75% of the respondents preferred to exercise with moderate intensity. Yardley, 
Iscoe et al. (2013) supported this level of intensity for T1D using CSII (Yardley, 
Iscoe et al. 2013). This may further support the finding that majority of the 
insulin pump users are educated and are following the latest American College 
of Sports Medicine (ACSM) guidelines. 
 91%of responders in this study reported no DKA since they started to exercise.  
This is similar to Levy-Shraga, Lerner-Geva et al. (2013) when they reported the 
DKA events were not reported with CSII therapy (Levy-Shraga, Lerner-Geva et 
al. 2013). These results also in line with previously discussed finding of this 
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study and Fredheim, Johannesen et al. (2013) that T1D CSII users experience a 
significant drop in A1c level (Fredheim, Johannesen et al. 2013).  
 99.40% of insulin pump users who participated in this survey regularly counted 
their carbohydrate intake in order to calculate bolus and basal insulin doses. 
Enander, Gundevall et al. (2012) and Cukierman-Yaffe, Konvalina et al. (2011) 
reported that majority of CSII users are conscious of their diet and keep a record 
of their carbohydrate intake (Enander, Gundevall et al. 2012). 
3.6. Conclusion 
 For this survey, managing diabetes with a pump is apparently associated with 
low incidence of cardiovascular and other complications. This may represent the 
advantages of CSII but may also reflect the age, condition and enthusiasm of 
responders, as well as to the biases relating to language, the means of access to 
the survey and other factors discussed above. 
 CSII therapy using an external insulin pump enables the T1D responders to 
enjoy a more flexible lifestyle with everyday activities and to reduce the A1c 
level. 
 CSII is known to reduce hypoglycaemic and DKA events, improves glycemic 
and metabolic control and this study supports that finding. 
 As a result of better control, CSII should decrease out-patient consultations and 
hospital admissions and does not appear to be associated with significant 
adverse outcomes compared to MDI. This is reflected in this survey. 
 Moreover, CSII therapy is shown here to reduce the insulin requirement 
significantly which brings in other health advantages such as lowered BMI and 
lipids, as well as less likelihood of iatrogenic obesity.  
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 This study in line with many previous studies showed that CSII therapy provides 
multi facet benefits and minimal problems for users. Most recently 39 different 
efforts were made to study the potential disadvantages of CSII usage (for 
example site infections, pump malfunction, DKA and hypoglycemia). However, 
these studies failed to provide any conclusive evidence on the risks or ill effects 
of CSII therapy.  
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CHAPTER 4: The Immunological Effect of Exercise 
The immunological effect of exercise on Type 1 diabetic (MDI or CSII) and non-
diabetic volunteers. 
4.1. Introduction 
A complex interaction between innate and adaptive immune system cells and pancreatic 
β-cells is considered to be behind the development of type 1 diabetes (T1D) (Lehuen, 
Diana et al. 2010). A similar statement could be made for the effects of exercise, since 
these are inflammatory. The mechanism and processes of inflammation are the key 
players in the development of T1D (Kristiansen and Mandrup-Poulsen 2005). This 
chapter will outline some immunological parameters for T1D, such as tumor necrosis 
factor (TNF), interferon gamma (IFNγ), interleukin-6 (IL-6) and interleukin-1 beta 
(IL-1β). 
With respect to T1D, research studies have shown that tumour necrosis factor-alpha 
(TNFα), interleukin 1beta (IL-β), interleukin 6 (IL-6), and certain other chemokines, 
which are mediators of inflammation, are involved in the pathogenesis (Kristiansen and 
Mandrup-Poulsen 2005). These immunological markers can be detected in the blood at 
and before disease onset. 
Various silent immune occurrences take place prior to the appearance of the clinical 
symptoms of T1D. Lehuen, Diana et al. (2010) argued that autoantibodies are generated 
and self-reactive lymphocytes are triggered, penetrating the pancreas in order to 
obliterate the insulin-producing beta cells in the islets of Langerhans (Lehuen, Diana et 
al. 2010). This on-going and targeted destruction remains undetected for several years 
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and the first clinical symptoms may only become obvious after most of the beta-cells 
(possibly 80%) have been destroyed or have become non-functional. This will make the 
sufferer become reliant on insulin supplementation in order to survive (Lehuen, Diana et 
al. 2010).  
The natural process of cytokine interplay in the immune system is a complex 
phenomenon and crucial parts of this phenomenon are still unaccounted for; which is 
often associated with pathology. Most of the cytokine manipulations cause a dual effect, 
which is reliant on timing of medication, dose and channel of administration (see table 
4.1). 
Cytokine-induced destruction of β-cell is principally arbitrated by apoptosis in human 
islets (Eizirik and Mandrup-Poulsen 2001; Hoorens, Stange et al. 2001). Even though 
this has not yet been confirmed, the proximal mechanisms in cytokine signal 
transduction has been widely studied. Nevertheless, the precise distal intracellular 
molecular activities that are accountable for the death of β-cell are not yet very well 
understood. Therefore, it is more than probable that determining the cytokine-mediated 
changes in gene and protein expression profiles will generate useful information in 
relation to future treatment and prevention approaches for T1D (Rewers and Gottlieb 
2009).  
When β-cells and islets are exposed to cytokines many different alterations take place in 
the expression profiles of mRNA and proteins. These alterations are demonstrated by 
up- and down-regulation in addition to de novo synthesis of various groups of genes. 
Regulating these genes causes further loss of differentiated β-cell roles and stimulates 
both pro- and anti-apoptotic methods in the β-cell. 
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Moreover, cytokines reduce the expression of various genes concerned with the 
mitochondrial respiratory chain (Cardozo, Kruhoffer et al. 2001; Larsen, Fey et al. 
2001; Sparre, Christensen et al. 2002), which causes decreased energy production in 
reaction to cytokine disclosure. Furthermore, cytokines reduce the expression of various 
genes linked with differentiated β-cell functions and protection of β-cell mass (Cardozo, 
Heimberg et al. 2001; Cardozo, Kruhoffer et al. 2001; Larsen, Fey et al. 2001; Kutlu, 
Cardozo et al. 2003). These alterations bring about a reduction in insulin generation 
(Southern, Schulster et al. 1990; Welsh, Eizirik et al. 1991) and a reduction in the 
growth capability of the cytokine-exposed β-cells or islets (Sjoholm 1991). 
Cytokines (IL-1β and IFN-γ) also encourage production of free radicals such as 
hydrogen peroxide (H2O2) and superoxide (O2-) (Nerup, Mandrup-Poulsen et al. 1994; 
Mandrup-Poulsen 1996) that could be toxic to the β-cell. After this exposure of β-cells’ 
to cytokine several “protective” proteins like heat glutathione-S-transferase (GST), 
metallothionin, shock proteins (HSPs) and manganese superoxide (MnSOD) are up 
regulated (Rieneck, Bovin et al. 2000; Cardozo, Kruhoffer et al. 2001). 
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Table 4.1:Cytokines associated with T1D (Bergholdt, Heding et al. 2004). 
Cytokine  Function Production References 
IL-1β IL-1β Involved in the inflammatory response and contributes to inflammatory 
pain hypersensitivity;  
IL-1β induces a systemic and local response to pathogenic invasion or injury of 
tissues by inducing transcription or enhancing mRNA stability of a large range 
of pro-inflammatory genes.  
Produced by 
activated 
macrophages as a 
proprotein 
(Pociot, Mølvig et al. 1992; Krikovszky, 
Vasarhelyi et al. 2002; Schmid, Haslinger 
et al. 2012) 
TNFα  TNFα regulates a wide spectrum of biological processes including stimulating 
cell proliferation, induction of cell differentiation, apoptotic cell death, 
involvement in lipid metabolism and response to sepsis via IL1 & IL6 
production. 
Mainly secreted 
by macrophages 
and T cells 
(Pociot, Briant et al. 1993; Obayashi, 
Nakamura et al. 1999; Obayashi, 
Hasegawa et al. 2000) 
IL-6 IL-6 is a cytokine which response to muscle contraction and fatty tissue during 
exercises (IL-6 stimulates energy mobilization which leads to increased body 
temperature) and stimulates immune response. As well as an anti-inflammatory 
cytokine is mediated through its inhibitory effects on TNF-alpha and IL-1.  
Secreted by T 
cells, 
macrophages and 
produced from 
muscle 
(Jahromi, Millward et al. 2000; 
Kristiansen, Nolsoe et al. 2003; Febbraio 
and Pedersen 2005; Kristiansen and 
Mandrup-Poulsen 2005) 
IFNγ  IFNγ promotes NK cell activity. It has antiviral activity, important immuno 
regulatory functions and a potent activator of macrophages. Furthermore, it has 
anti-proliferative effects on transformed cells. 
Produced mainly 
by lymphocytes 
(NK, TH1) 
(Pociot, Mølvig et al. 1992; Awata, 
Matsumoto et al. 1994; POCIOT, 
VEIJOLA et al. 1997; Jahromi, Millward 
et al. 2000; Pravica, Asderakis et al. 2002; 
Tegoshi, Hasegawa et al. 2002) 
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In T1D, it was revealed that treating patients with etanercept (a soluble TNF-receptor) 
reduced A1c and increased the production of endogenous insulin, symptomatic of the 
safeguarding of the beta-cell function (Mastrandrea, Yu et al. 2009). This is not 
however a simple procedure; TNF  may have a dual role in T1D. For example, in 
animal models, TNF boost the diabetogenic reaction too soon or reduce the 
diabetogenic reaction too late in the T1D procedure (Lee, Xu et al. 2005). Furthermore, 
some clinical reports have revealed the development of T1D in arthritis sufferers after 
receiving etanercept treatment (Christen, Wolfe et al. 2001; Bouwens and Rooman 
2005; Tack, Kleijwegt et al. 2009), but also the resolution of T1D in patient that needed 
anti-TNF therapy to treat arthritis (Arif, Cox et al. 2010).   
Other studies have proposed that autoimmunity arises from a lack of type 1 IFN. Type 1 
IFNs can offset type 2 IFN which is presumably a key factor in autoimmune 
inflammation (Brod 1999). Nevertheless, this proposal is in fact controversial. Other 
academics propose that stimulating Toll-like receptors (TLRs) by double-stranded RNA 
or poly I: C (viral mimic) via introducing IFNγ may in fact trigger or accelerate immune 
mediated β-cell annihilation (Devendra and Eisenbarth 2004) (see figure 4.1).  
It has been observed in different studies (for more details see table 4.2) that in normal 
people (i.e. non-diabetic) regular moderate exercise causes release of some cytokines 
which enhance immune function and attenuates immune disturbances associated with 
acute exercise (e.g., a single bout of vigorous exercise) (Nieman, Nehlsen-Cannarella et 
al. 2008).  
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Acute exercise is defined as a sustained moderate for single bout (50 to 65% intensity) 
(Ploeger, Takken et al. 2009) (see section 1.7.3 for details). Acute exercise session has a 
short-term depressive effect on immune function. When a person engages in a strenuous 
exercise session, there are bodily responses that are very similar in many aspects, to 
those that are bought about from infection, sepsis, or trauma (Northoff, Berg et al. 
1998). Plasma concentrations will increase in numerous substances that are known to 
affect the functioning of leukocyte, for example inflammatory cytokines like TNF, 
macrophage inflammatory protein-1, and IL-1β; anti-inflammatory cytokines IL-6, and 
IL-1-receptor antagonist (IL-1ra). Contracting muscle fibres during exercise cause 
release of cytokine which gives rise to the level of plasma IL-6 concentration 
(Steensberg, van Hall et al. 2000; Wallberg, Mikael Mattsson et al. 2011). Nevertheless, 
IL-6 production from monocyte (Starkie, Rolland et al. 2001; Dickie, Church et al. 
2010)and production of IFNγ produced by T lymphocytes is reduced after exercise 
(Lancaster, Halson et al. 2004). Steensber, Fisher et a. (2003) showed that moderate 
increase in plasma levels of IL-6 provoke the two anti-inflammatory cytokines IL-1ra 
and IL-10 (Steensberg, Fischer et al. 2003).  
In line with the increase of the following IL-6, and IL-1ra, exercises lowers the 
percentage of type 1 T cells in this flow (Lancaster, Halson et al. 2004). Another 
significant activity of the IL-6 is that it holds back the production of TNF, which is a 
powerful activator of inflammation (Starkie, Ostrowski et al. 2003). 
Inflammation has been associated with the pathology of various chronic diseases; 
diabetes. For example, blood markers of inflammation are very much linked to 
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cardiovascular and metabolic disease in T1D middle aged people and the elderly 
(Schram, Chaturvedi et al. 2005). Thus, raised systematic levels of IL-6 during exercise 
sessions may be one of the means through which exercise protects individuals against 
developing chronic illnesses. However, it could be disputed that it is probable that the 
comparative significance of IL-6 in these circumstances is probably quite small, as 
noteworthy health benefits derived from taking frequent exercise are apparent even 
when the exercise is only light or moderate in intensity (Wallberg, Mikael Mattsson et 
al. 2011). 
Frequent moderate exercise (50-60%) has been shown to provide support for the 
immune system (Cannon, Fiatarone et al. 1994; Kenney and Ho 1995; Mackinnon 1997; 
Gleeson, Nieman et al. 2004; Nieman, Henson et al. 2005). Various studies have 
claimed that frequent moderate exercise is advantageous for cytokines and 
immunoglobulin parameters in some people (Cannon, Fiatarone et al. 1994; Kenney and 
Ho 1995; Mackinnon 1997; Furusawa, Tajima et al. 1998; Mackinnon 1999; 
MacKinnon 2000; Bauer and Weisser 2002; Gleeson, Nieman et al. 2004) (see also 
table 4.2). As moderate exercise can reinforce the immune system, extreme exercise can 
suppress the immune system (Fitzgerald 1988; Liesen and Baum 1997; Gleeson 2007) 
The inflammatory pathway to T1D is understood to have a cytokine pathway and the 
blocking agents are known. However, the effects are incompletely understood and the 
interplay is so complex that responses to experimental therapy have been paradoxical. 
Figure 4.1 explains cytokine pathway and the blocking agents in T1D (Agnès, Julien et 
al. 2010). Figure 4.1 explains that important pathways changed in expression profiling 
studies after cytokine-exposure, Toll-like receptors (TLRs) are expressed by pancreatic 
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β-cells to detect danger from microbial products and can trigger T1D, during a localized 
virus infection in the pancreas. Cytokines, such IL-1β, IFNγ and TNF-α, secreted by 
immune cells, such as macrophages, could cause direct damage (such as apoptosis) of β-
cells but could also induce self-defence mechanisms; for example, IFNγ induces 
indoleamine 2,3-dioxygenase (IDO) expression by β-cells. Programmed cell death 1 
ligand 1 (PD-L1)TNF is a “master regulator” of the inflammatory reaction in several 
organ systems (Feldmann and Maini 2003).  
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Figure 4.1: Cytokine pathway and the blocking agents in T1D (Agnès, Julien et al. 
2010).
Here where the 
blockers work 
146 
 
Table 4.2: Selected studies evaluating the acute effects of exercise bouts on inflammatory markers 
Reference No of Subjects Exercise protocol Cell Type Result Volunteers 
Bente 
(1999) 
Randomise  Acute exercise Neutrophil  Increases during and after exercise Healthy 
Lymphocyte increases during exercise and falls below pre-
exercise values 
Smith 
(2000) 
6 active men (24 
± 3 yr) 
(untrained) 
Bench press and leg 
curl eccentric actions 
4X12Rep100%1RM 
2rest 
Plasma Pre-, Post-1.5, 6, 
12 h and 1-6d after the 
session 
IL-1β was reduced at 6, 24 and 120 h after 
exercise. 
IL-6 was elevated at 12, 24, and 72 h after Ex. 
No effect on TNF-α 
Healthy 
MacIntyre
(2000) 
12 healthy 
recreationally 
active men (20-
29 yr) 
30X10Rep of eccentric 
actions of the right leg 
(quadriceps muscles) 
using the continuous 
eccentric mode on an 
exercise machine 
Plasma Pre-, Post-2, 4, 6, 
20 h and 1,2, 3, 6 and 9 d 
after the exercise session 
IL-6 increased at 6 h compared to Pre-Ex. 
By 20 h post-exercise IL-6 levels return to 
baseline values and continued the same for the 
rest of the time points, except for a higher value 
at 24 h compared to Pre-Ex 
Healthy 
Hirose 
(2004) 
10 healthy men 
untrained (20 ± 
2 yr) performed 
2 bouts of 
eccentric action 
of the elbow 
flexor using the 
same non 
dominant arm 
6X5Rep40%1RM 
2’rest for each exercise 
bout 
Plasma pre-, immediately 
post-1,3 h and 1-4 d after 
each test exercise session 
IL-1β,IL-6, and TNF-α 
After the 1st bout there was an unexpected 
decrease in plasma pro-inflammatory TNF-α (1, 
3 h and 1 d) Post-ex. 
There were no changes in the rest of the 
cytokines between bout or Pre-ex 
Healthy 
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separated by 
4wks 
Peake 
(2006) 
10 healthy 
untrained men 
(23 ± 5 
yr)completed a 
sub maximal 
followed by a 
maximal 
exercise 
protocol vs 
non-dominant 
arm randomized 
and 
counterbalanced 
Submaximal: 
10X60rep10%1RM 
elbow flexor of one arm 
Maximal: 
10X3rep100%1RM 
elbow flexor of the 
opposite arm 
Serum Pre-,Immediately 
Post-1,3 h and 1-4 d after 
each test exercise session 
IL-1ra, IL-6,TNF-α 
IL-6 was elevated 3 h Post-ex after Submaximal 
but not for Maximal protocol. 
The rest of the cytokines remain unchanged after 
the exercise protocols, with a trend for an 
increase in IL-1ra 
Healthy 
Uchida 
(2009) 
35 male 
Brazilian 
soldiers (19 ± 2 
yr)physically 
trained but not 
involved in RT 
for at least 1 yr 
A control (n = 6) plus 4 
groups follow 
1 single bench press 
exercise: 
4X20Reps 50%1RM (n 
= 8) 
5X11Reps 75%1RM (n 
= 7) 
3X10Reps 90%1RM (n 
= 7) 
3X10Reps 110%1RM 
Plasma Pre-exercise and 
24, 48 and 72 h after the 
test 
exercise session 
IL-1β and IL-6 
No changes in any cytokine compared with pre-
exercise. 
No differences in cytokine responses among the 
different intensity protocols. 
Cytokines levels were not even detectable for 
some of the participants. 
Healthy 
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(n = 7) 
2’ rest 
Same total load volume 
for all groups 
Phillips 
(2010) 
14recreationally 
active men 
(untrained for 
RT)(22 ± 2 yr) 
followed 
2different 
exercise 
protocols and a 
rest condition in 
a randomized 
order 
8 Exercises working 
major muscle groups of 
upper and lower body. 
Low intensity: 
2X12Reps 65%1RM 
High intensity: 
2X8Reps 85%1RM and 
3rd set until exhaustion 
for both protocols. 2’ 
rest 
Plasma Pre-,Immediately 
Post and6 h after each test 
exercise session 
IL-6 
Increased immediately Post-exercise compared 
to control for both exercises and went back to 
baseline levels at 6 h. 
The Low intensity protocol resulted in the 
highest total volume load and greater circulating 
IL-6 compared to the High intensity protocol at 
the Post-Ex time point. 
Healthy  
Buford 
(2009) 
24 recreationally 
active women 
(untrained for 
RT) (54 ± 4 yr) 
3 exercises: squat, leg 
press and leg extension. 
3X10Reps 80%1RM 
for each exercise 
Serum and muscle leg 
biopsies at baseline and 3 
h 
post-exercise to determine 
cytokines mRNA 
expression 
IL-1β, IL-6 and TNF-α 
No changes in serum cytokines after the exercise 
session. 
But there was mRNA up-regulation for TNF-α, 
IL-1β and IL-6 Post-exercise. 
Healthy 
Bente 
(2000) 
Resistance   TNF-α, IL-6 and IFN-γ  the expression of a broad spectrum of cytokines 
in response to exercise is possible 
Healthy  
Pietro 
Galassett 
6 male /6 
female 
30-min exercise 
challenge @ 80% 
Plasma  IL-6↑ 
 
T1D 
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(2006) VO2max 
Belotto 
MF (2010) 
Rats 3-week moderate 
exercise on a treadmill 
(60% of VO2max 
Serum TNF-α (6%) (decreased)  
IL-1β (34%) (decreased) 
IL-6 (86%) (decreased) 
 
Diabeticrats 
Jenni S 
(2010) 
7 male Moderate aerobic 
exercise 
Plasma  IL-6 (increased) T1D 
Rosa JS 
(2010) 
47 children  30 min of cycling 
exercise @ 80% of 
VO2max 
Plasma  IL-6 (increased) T1D 
Ho SS 
(2013) 
-------------- 12 weeks of 
moderate-intensity 
aerobic, resistance, 
or combination 
exercise 
 TNF-α (decreased) with aerobic exercise group 
resistance group and in the combination group 
Healthy  
Galassetti 
et al (30) 
12 children 30-min exercise 
challenge @ 80% 
VO2max 
Plasma  IL-6 (increased)  T1D 
Nikolao 
(2007) 
28 exercise group 
and 26 control 
group. 
16-week,45– 60 min 
sessions per week aerobic 
exercise walking or 
running on treadmill, 
cycling  
Plasma 
 
IL-6 
decreases resistant and inflammatory cytokines   
Healthy 
Kyle 
(2008) 
15 physically 
active PA 
15 inactive group 
PI 
12 weeks (3 days/week) 
of endurance 
 PI:  
(20 min at 70–80% heart-
Plasma 
 
TNF-α   ↑ 
IL1-β     ↑ 
CD14    ↓ 
Healthy 
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rate reserve) and 
resistance exercise 
training (eight exercises, 
two sets at 70–80% of one 
repetition maximum). 
CD16    ↓ 
 Monocytes   ↓ 
Nienam 
(2004) 
30 strengths 
trained 
male athletes 
(21 ± 1 yr) 
Already strength 
trained  
10 different exercise of 
upper and lower body, 
(lasted 2 h) 
1X10Reps 40%1RM 
+3X10Reps 
60%1RM 
2’ and 3’ rest between 
sets and exercises 
respectively 
Muscle tissue 
(vastus lateralis) and plasma 
Pre-Ex and Post-Ex. 
Muscle 
(mRNA): 
IL-1β, IL-6 and TNF-α 
Muscle mRNA was detected Pre-Ex for IL-1β, IL-
6and TNF-α and of these, IL-1β, IL-6 and TNF-α 
mRNA were increased Post-Ex. 
Plasma: 
Plasma IL-6were modestly but significantly 
increased Post-Ex. 
Healthy 
Stewart 
(2007) 
Young (25 ± 5 yr) 
and old (71 ± 4 
yr) 
men and women 
were divided in 
YPA(15) or 
YPI(14) 
and OPA(14) or 
OPI(17) 
12 wk (3 d/wk) 
The physically 
inactive trained for 12 wk 
and the physically 
active 
participants 
serve as 
Controls  
20 min warm up (walking 
or jogging) and 2 sets x 8 
exercises at 70-80%1RM 
(1
st
 set) and muscular 
failure (2nd set), 
Plasma 
baseline and after 12 wk 
training at rest 
IL-1β, IL-6 and TNF-α  
No age or physical activity differences in IL-6 or IL-
1β among groups at baseline or after training. 
TNF-α levels were higher in the young group (PA 
and PI) compared to the old group. No effects on 
TNF-α with training 
 
Healthy   
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stretching and cooling 
period 
Izquierdo 
(2009) 
12 physically 
active 
men untrained 
(33 ± 4 yr) 
7 wk 
(2 d/wk 45-60 
m/session) Non-linear 
undulating 
multi set progressive 
program  
Pre training and Post 
training test 5X10RM leg 
press. 
The Post training test 
using the same absolute 
load (kg) or another day 
using the same relative 
load (%RM) than pre-
training. 
2’ rest between sets 
Plasma 
baseline and 
after 7 wk 
training: 
Pre-ex, middle-ex, 
Post ex 0, 15 and 45 min 
IL-1β, IL-1ra and IL-6 
Post-training: there was a greater released of IL-1β 
and IL-1ra after both exercise tests (absolute and 
relative load). 
However the increases in IL-6 and 
Intensity plays a role in anti-inflammatory cytokine 
responses 
Healthy   
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4.2. Objectives of the Study 
The purpose of the present study is to examine the effects of one exercise session (acute 
exercise) and 12 sessions (chronic exercise) of combination, (resistance) and aerobic 
exercise (cycling) on selected immunological parameters such as IL-6, TNF, IFNγ and 
IL-1β on typ1 diabetic (T1D) either MDI or CSII and nod diabetic subject (ND).The 
study was approved by the Ethics Committee of De Montfort University, Leicester 
(DMU). 
4.3. Materials and Methods 
4.3.1. Study Volunteers 
Physically inactive male, aged 18–55 years, either healthy (non-diabetic ND) or 
diagnosed with T1D and using MDI or CSII were recruited for this study. All subjects 
were apparently healthy and free of disease other than diabetes.  
Study recruitment was publicised through internal and external adverts as described in 
section 2.4.1.Majority of volunteers were from DMU either staff or students.   
Exclusions criteria were playing an important role. The total number of volunteers who 
expressed an interest in this study was 49 individuals (ND= 24, MDI= 14, CSII= 11), 14 
were excluded as they did not meet the inclusion criteria. In addition, 16 participants 
were unable to attend as a result of the difficulty of making arrangements. The eventual 
sample was 19 participants. Volunteers were divided into three main groups; ND group 
(N=7), T1D using CSII group (N=5) and T1D using MDI (N=7). 
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4.3.2. Screening and preliminary testing 
All subjects were underwent a preliminary health screening and were required to obtain 
approval from their personal GP before being enrolled in the study. Subjects involved in 
this study were read and signed the exclusions and inclusion criteria forms. 
Furthermore, others forms were provided and signed by the volunteers themselves such 
as; Standard Operation Procedure (SOP), Volunteer Information Sheet (VIS), Consent 
Form, Health Screen and Record forms were provided (see section 2.4.2). 
After read and signed consent form, subjects reported to the laboratory and completed a 
health screen questionnaire, and a record sheet.  
After preliminary screening, a one-repetition maximum (1RM) was measured for 
resistance exercises (see section 2.5.6).  
4.3.3. Exercise Training 
All subjects attended the demonstration and practice sessions prior to beginning the 
exercise training program. On 1RM day, subjects were instructed in proper lifting 
technique and use of exercise equipment. The 1RMwas assessing each of the following 
resistance exercises: Squat, incline bench press, lat curl pull-down, triceps and biceps 
In the acute exercise time, all volunteer groups were asked to exercise for only one 
session (3 sets 10 rep each) at moderate intensity while the chronic stage involved 12 
sessions (48 hours between each session). As described in figure 4.2 and section 2.5, 
each session was including stretching, warm up and then resistance exercise at 50% of 
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volunteer 1RM then rest for 5min after that cycle for 20 min at moderate intensity at 50-
60% of heart-rate reserve on a recumbent ergometer bike then cool down.  
Heart rates (HR) were checked regularly at rest and after each set of resistance exercise. 
HR was also checked during all aerobic exercise to ensure that they were still exercising 
at the specified intensity level.  
 
Figure 4.2: Division of the exercise sessions throughout the study 
 
4.3.4. Blood collection 
All the blood samples were collected and analysed at DMU, School of Pharmacy, 
Leicester, UK. From each subject, 10 ml of blood was collected in EDTA tube from 
antecubital vein then centrifuged at speed of 3000rpm for 15min at 4°C. All sera were 
aliquoted and stored at -80°C until the time of analysis.  
Stretching upper and 
lower muscles  
Warm up on recumbent 
bike for 5 minutes 
Resistance  exercise [ Squat, 
Chest, Back,  Triceps and 
Bicep] at 50% of 1-RM.
(3 sets of 10 repetitions with 
40 seconds rest interval 
between each repetitions )
Rest for 5 minuets 
Aerobic  exercise on 
recumbent bike for 20 
minutes with face mask 
(ADInstruments 
Analysis system )
Warm down (stretching 
the lower and upper 
muscles 
Observation  
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During this study, three blood samples were collected from each subject at baseline 
(before any exercise), after resistance and after cardio exercise for all groups (figure 
4.3). A total of 21 blood samples were collected from MDI group, 15 from CSII group 
and another 21blood samples were collected from ND group i.e. a blood sample from 
each volunteer. 
                      Start                                              exercise                                                 End 
Rest time    warm up  Resistance Ex   5min Rest      Aerobic Ex      warm down  Recovery 
Baseline                 50-60%1RM50-60%  
of Max HR 
Blood sampling  
Figure 4.3: Exercise protocol and blood sampling scheme for acute exercise (one 
session).   
In the chronic exercise, seven blood samples were collected from each subject at 
baseline, then after 2
nd
, 4
th
, 6
th
, 8
th
, 10
th
and after 12
th
 sessions (figure 4.4). A total of 42 
samples were collected from MDI group and 35 from CSII group. Another 42blood 
samples were collected from ND group. 
A total of 171 blood samples; 63 were collected from MDI group, 45 from CSII group 
and 63 blood samples were collected from ND group. 
Exercise sessions: 
        1
st
                 2
nd
                4
th
                  6
th
                 8
th
                10
th
                12
th
 
   Start                                                                                                                                           End 
Blood sampling time  
Figure 4.4: Blood sampling scheme for chronic exercise. 
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4.3.5. Statistical Analyses 
Descriptive statistics e.g. mean, variance and standard deviation were used to express 
the data from all cytokines concentrations unless otherwise stated. Test of statistical 
significance based on two tailed t-test and p-value were conducted using 0.05 level of 
significance (i.e. α=0.05).All data were analysed using the Statistical Package for Social 
Sciences (IBM SPSS, v.19, Chicago, IL). 
4.3.6. Cytokine Measurements 
Determining the effect of acute and chronic exercise on selected inflammatory 
cytokines on T1D either MDI or CSII users and to compare these with ND was one of 
the main objectives of this study. Selected cytokines were examined; IFN-γ, TNF, IL-
6 and IL-1β. To determine the level of these cytokines, Sandwich Enzyme-linked 
Immunosorbent Assay (ELISA) was used. ELISA assay was developed using 
commercial kits (DuoSet ELISA Development Kit, R&D Systems).  
Briefly, capture, detecting and standard antibodies were diluted to the recommended 
working concentration as in section 2.10.1. The 96-well plate was coated with 100 µL 
per well with diluted capture antibody and incubated at room temperature for overnight. 
Each well was aspirate and wash by filling with wash buffer (400 µL), for a total of 
three washes. After the last wash, remaining wash buffer were removed by aspirating or 
by inverting the plate and blotting it against clean paper towels. This was followed by 
blocking the plate by adding 300 µL of reagent diluent to each well and incubated at 
room temperature for 1 hour then washed as above. Then 100 µL of sample or standards 
were added and incubated for 2 hours at room temperature then washed. 100 µL of 
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detection antibody were added and incubated for 2 hours at room temperature and 
washed.100 µL of the working dilution of streptavidin-HRP was added to each well and 
incubate for 20 minutes at room temperature and washed. Substrate Solution100 µL 
were added to each well and incubated for 20 minutes at room temperature. It was 
important to avoid placing the plate in direct light. After that 50 µL of Stop Solution 
were added to each well. Finally determine the optical density of each well. Readings 
made directly at 450 nm without correction. 
4.4. Results 
4.4.1. Acute exercise (one session) 
Pre-exercise plasma concentrations of IL-6 were lower in the CSII group compared with 
MDI and ND group. The IL-6 concentration was significantly higher in MDI group than 
in CSII and ND groups (P<0.001).In CSII and ND a statistically significant increase in 
IL-6 level was observed after resistance and cardio exercise (p = 0.025). The CSII 
volunteer group showed elevated levels of IL-6 after resistance and cardio exercise and 
at both stages this rise was statistically significant (P=0.033 and P=0.014 respectively). 
After resistance and cardio exercise MDI group showed elevated IL-6 levels but 
observed changes were not statistically significant as it failed t-test (figure 4.5). The 
statistical significance values for effect of exercise on IL-6 are detailed in table 4.3. 
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Figure 4.5: Acute plasma levels of inflammatory cytokines IL-6. 
 
Table 4.3: Description of p-value (t-test) for the effects on IL-6 of the acute exercise 
phase in MDI and pump users, comparing before and after, with respect to the resistance 
(Re) and cardiovascular (aerobic). 
Acute exercise for IL-6 
 Before vs. after 
exercise 
Before vs. after Resistance 
exercise 
After Resistance vs. after 
cardio exercise 
ND 0.34 0.71 0.42 
MDI 0.89 0.87 0.94 
CSII 0.033 0.26 0.014 
It was observed that volunteers in CSII groups have the lowest level of TNF-α. TNF-α 
was decreased in all exercise groups compared to the pre-exercise condition. In CSII 
group this reduction was statistically significant especially between pre exercise and 
after resistance (P=0.0002). But in MDI and ND groups this drop n TNF-α was not 
statistically significant (Figure 4.6).The statistical significance values for effect of 
exercise on TNF-α are shown in table 4.4. 
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Figure 4.6: Acute plasma levels of inflammatory cytokines TNF-α. CSII, Continuous 
Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, non-diabetic. T-test 
P-value was for before and after exercise, after RE and after exercise, The error bars 
show the Standard Deviation (SD). 
 
Table 4.4: Description of p-value (t-test) for the effects on TNF-α of the acute exercise 
phase in MDI and pump users, comparing before and after, with respect to the resistance 
and cardiovascular (aerobic). 
Acute exercise for TNF-α 
 Before vs. after 
exercise 
Before vs. after Resistance 
exercise 
After Resistance vs. after 
cardio exercise 
ND 0.14 0.70 0.26 
MDI 0.14 0.36 0.12 
CSII 0.09 0.0002 0.71 
Figure 4.7 is showing a significant reduction in plasma levels of IL-1β in CSII group 
with MDI and ND groups (P=0.0081, P=0.026, respectively). Moreover, there was 
significant increase in IL-1β level in CSII group (P=0.006) and (P=0.0011), (pre and 
after resistance, after resistance and at the end, respectively) after one session. In ND 
group IL-1β level was decreased after exercise (i.e. resistance and cardio). While, in the 
MDI group, IL-1β was decreased after resistance exercise and slightly raised after 
aerobic exercise, however, post exercise session the IL-1β level was still less than the 
pre-exercise levels. The statistical significance values for effect of exercise on IL-1β are 
displayed in table 4.5. 
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Figure 4.7: Acute plasma levels of inflammatory cytokines IL-1β. CSII, Continuous 
Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, non-diabetic. T-test 
P-value was for before and after exercise, after RE and after exercise, and bars showing 
SD  
 
Table 4.5: Description of p-value (t-test) for the effects on IL-1β of the acute exercise 
phase in MDI and pump users, comparing before and after, with respect to the resistance 
and cardiovascular (aerobic). 
Acute exercise for IL-1β 
 Before vs. after 
exercise 
Before vs. after Resistance 
exercise 
After Resistance vs. after 
cardio exercise 
ND 0.14 0.45 0.31 
MDI 0.56 0.30 0.22 
CSII 0.006 0.34 0.0011 
The acute plasma level of IFN-γ was significant lower in CSII group compared to MDI 
and ND groups (P=0.018, P=0.0045, respectively). In CSII and ND after resistance 
exercise IFN-γ was dropped and increased slightly after cardio exercise but was still 
lower than its initial level (figure 4.8).The statistical significance values for effect of 
exercise on IFN-γ are given in table 4.6. 
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Figure 4.8: Acute plasma levels of inflammatory cytokines IFN-γ . Ex, exercise; Re, 
resistance; CSII, Continuous Subcutaneous Insulin Infusion; MDI, multiple daily 
injections; ND, non-diabetic. with error bars showing SD  
 
Table 4.6: Description of p-value (t-test) for the effects on IFN-γ of the acute exercise 
phase in MDI and pump users, comparing before and after, with respect to the resistance 
and cardiovascular (aerobic). 
Acute exercise for IFN-γ  
 Before vs. after 
exercise 
Before vs. after Resistance 
exercise 
After Resistance vs. after 
cardio exercise 
ND 0.89 0.34 0.49 
MDI 0.87 0.44 0.35 
CSII 0.38 0.35 0.60 
4.4.2. Chronic exercise (12sessions) 
As mentioned in section 4.3.4 during this part of the study 7 blood samples were taken 
from each subject (see figure 4.4). The group of pro-inflammatory cytokines including 
IL-6, TNF-α, IFN-γ, and IL-1β have been associated with β cell destruction in vitro 
(Suk 2001). To determine the effect of exercise on these pro-inflammatory cytokines, 
plasma blood samples were collected from CSII, MDI and ND groups in different time 
points. These samples were collected before exercise and after 2
nd
, 4
th
, 6
th
, 8
th
, 10
th
 and 
12
th
 sessions.  
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Figure 4.9 demonstrates that throughout the study the level of IL-6 is lower in CSII 
group compared to MDI and ND groups and this difference was statistically significant 
(i.e. all P values less than 0.05). The level of IL-6 was high pre exercise in MDI group 
then decreased over the sessions. EURODIAB study has reported significantly higher 
levels of IL-6 in T1D sufferers on MDI therapy (Schram, Chaturvedi et al. 2005). 
Moreover, Jain, Kannan et al. (2003) also showed that in T1D hyper ketonemia elevates 
the circulating levels of plasma IL-6 (Jain, Kannan et al. 2003). Throughout this study 
IL-6 level in ND group was increased from its baseline levels (i.e. before any exercise) 
(P=0.047). In CSII, there was no significant change in IL-6 over the time. MDI and ND 
groups have almost the same level of IL-6 after sessions 4, 6 and 8 and in MDI blood 
samples taken at sessions 10 & 12 showed a drop in IL-6 level and were below the level 
observed in ND.  
 
 
Figure 4.9: Chronic plasma levels of inflammatory cytokines IL-6. Ex, exercise; CSII, 
Continuous Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, non-
diabetic. Several T-tests were conducted across periods of exercise and all p-value were 
below 0.05. Error bars show SD. 
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Throughout the study TNF-α among the group was different and this difference was 
found to be statistically with all P-values less than 0.05. There was a small though 
statistically significant increase in TNF-α level, as compared with the baseline level, in 
CSII group after sessions 6 (P=0.055), 8 (P=0.048)10 (P=0.056) and 12 (P=0.056). A 
significant increase was only seen in the last session in ND group (P=0.039) and no 
significant change in MDI group (figure 4.10).  
 
Figure 4.10: Chronic plasma levels of inflammatory cytokines TNF-α. Ex, exercise; 
CSII, Continuous Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, 
non-diabetic. P-value was for before exercise and exercise sessions. T-test P-value was 
for pre exercise and exercise sessions, error bars show SD. P- value *≤0.05. 
 
At all stages of the study statistically significant different level of IL-1β was observed 
among the groups, (i.e. all P-values were less than 0.05). The level of IL-1β was 
reduced over the sessions in CSII group. In ND group blood sample taken after session 
two showed an increase in IL-1β level as compared to baseline level but samples taken 
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after later sessions showed a small drop in IL-1β level where the difference between 
session 2 and 12 was statistically significant (P=0.033). In the MDI group, IL-1β was 
decreased after second session then sustained an increase value after session 4 (figure 
4.11). 
 
Figure 4.11: Chronic plasma levels of inflammatory cytokines IL-1β. Ex, exercise; 
CSII, Continuous Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, 
non-diabetic. P-value was for before exercise and exercise sessions. T-test P-value was 
for pre exercise and exercise sessions, Error bars show SD. P- value *≤0.05. 
The blood samples taken before exercise showed that IFN-γ level in CSII group is lower 
than the level found in other two groups i.e. MDI and ND. However, sample taken after 
session 4 and 12 showed that the level of IFN-γ in CSII rose above the levels observed 
in other two groups. In MDI group the level of IFN-γ declined through the sessions 
becoming significantly lower in the last two sessions with P=0.018and P=0.031. While 
in ND group although the level of IFN-γ dropped from its baseline level but small 
fluctuations in level of IFN-γ was observed during the study but blood sample taken 
after session 12 showed a significant drop from its baseline reading (figure 4.12). 
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Figure 4.12: Chronic plasma levels of inflammatory cytokines IFN-γ . Ex, exercise; 
CSII, Continuous Subcutaneous Insulin Infusion; MDI, multiple daily injections; ND, 
non-diabetic. P-value was for before exercise and exercise sessions. T-test P-value was 
for pre exercise and exercise sessions, Error bars show SD. P-value *≤0.05, **≤0.01. 
 
4.5. Discussion 
The subjects of this study were drawn from Non-Diabetic (ND), T1D sufferers using 
Multi Daily Injection (MDI) and T1D sufferers using insulin pump as continuous 
subcutaneous insulin infusion (CSII) groups. A venous blood sample was taken on 
arrival, during exercise (after the resistance and before cardio) and after the full 
programme of exercise (including cardio). Clear differences could be seen for the CSII 
group for many of the parameters when compared to normal and MDI groups. 
Before discussing these, it is important to show that the cardiovascular exercise was 
predominantly aerobic in nature, both for this study and for its use as a pilot for the 
future work associated with this study. For example, if the cycling amounted to very 
intense exercise, this might have increased an anaerobic component, particularly in the 
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early stages. One criticism might be levelled, for example, in the setting of the target 
heart rate. There is much in the literature about the methodology for doing this. The 
importance is that if there is an overestimate of resting heart rate, the calculated target 
heart rate would be too high for the intended moderate intensity, using the Karvonen 
formula and this might produce an unintentionally high anaerobic component into what 
should be a mainly aerobic exercise (i.e. the cardiovascular). This equation has been 
used since the 1950s but has been criticised for its failure to relate directly to VOmax and 
to be based in the original, on too few subjects (Goldberg, Elliot et al. 1988; Tabet, 
Meurin et al. 2006; Skidmore, Patterson et al. 2008; Shnayderman and Katz-Leurer 
2013). Nevertheless, this or similar equations are used and importantly, the much 
repeated advice is to take the resting heart rate in the morning before rising.  
This normal advice on timing of the resting heart rate measurement was not followed 
for this study because of the overnight variations likely to occur in blood glucose in the 
diabetic subjects as had been reported and discussed at the beginning of this study. 
Thus, in diabetes, it is a common thing to have a hyperglycemic value on waking 
(“dawn phenomenon”) and this may not affect heart rate. However, there is also a strong 
possibility of spontaneous hypoglycemic events that trigger the counterregulatory 
processes involving glucagon (Mukherjee, Carroll et al. 2011). These are mediated by 
the sympathetic nervous system and thus epinephrine (Somegyi rebound) (Mukherjee, 
Carroll et al. 2011). The symptoms of these events, apart from the direct effects of low 
blood glucose, are palpitations in the early hours via the sympathetic stimulation 
(Mukherjee, Carroll et al. 2011). Normalisation of this cardiovascular disturbance may 
take time and require intervention using either pump adjustment to reduce insulin or 
167 
 
increased glucose directly or by injected glucagon. Some T1D people have this several 
times per month as overt symptoms and others may have it but not sense it each time 
(Mukherjee, Carroll et al. 2011). Consequently, the heart rate is typically higher in the 
early morning for insulin users than late at night and actually, the heart rate for healthy 
people is little different at night than in the early morning, provided they are at rest, as 
demonstrated numerically in the classic paper by Burger on circadian heart rhythms in 
normal and diabetic people (Burger, Charlamb et al. 1999). For these reasons, our 
methodology included instruction to take the heart rate reading in bed at night and 
volunteers were given heart rate monitors for this purpose. Occasionally they reported 
that they forgot at night and had done a morning reading, but we accepted the reading 
(average of three) anyway. We also took a reading of heart rate at the beginning of the 
exercise event, but this was unrelated to the calculation and was for records, 
comparisons during the procedures and for safety. This measurement at night for the 
calculation ensured that the target heart rate for the cycling component should have 
been in the aerobic region except possibly in the very initial minute or so. 
The results of analysis of these samples could be summed up as: 
In the acute exercise phase: 
 In figure 4.5, the lowest plasma concentrations of IL-6 were found in CSII 
group. IL-6 was increased significantly in CSII and ND groups. IL-6 level was 
significantly higher in MDI group than CSII and ND groups. No significant 
differences in IL-6 level were found among MDI volunteers at the end of this 
session. 
 Figure 4.6 shows, plasma level of TNF-α were decreased in all exercise groups.  
168 
 
 Figure 4.7 is showing the plasma level of IL-1βwas significantly increased in 
CSII group. In ND group IL-1β level was decreased but not significantly. In 
MDI group, IL-1β was decreased after resistance exercise while aerobic 
exercise increased the levelIL-1β. 
 Figure 4.8 demonstrate the plasma level of IFN-γ . It was observed that IFN-γ 
levels in ND and CSII followed the same pattern. IFN-γ was decreased by 
resistance exercise in both CSII and ND groups while increased in MDI. The 
lowest level of IFN-γ was found in CSII group. However, aerobic exercise 
increased the level of IFN-γ in CSII and ND groups. ND and CSII IFN-γ levels 
were high before exercise but dropped significantly after resistance but after the 
cardio exercise showed a tendency to rise again.  
After this initial analysis subjects were invited to take part in a 6 weeks long (12 
sessions) chronic study. This study the results demonstrate that: 
 Figure 4.9 reported the plasma levels of IL-6. The CSII group has the lowest 
level of IL-6 all over the sessions (lower than normal level as in ND group). 
MDI has the highest level of IL-6 before exercise (high than normal level as in 
ND group). IL-6 level was decreased in MDI (dropped to normal) and increased 
in ND group after second session.   
 In figure 4.10 the level of TNF-α were below normal before exercise in MDI 
and CSII groups and then TNF-α level was significantly low in both CSII and 
MDI groups compare to ND group during all the exercise sessions. There was a 
significant increase on TNF-α level in CSII group after 3 sessions (6th, 8th, 
10th and 12th). While ND group increased TNF-α level after second session but 
169 
 
significantly increased only in the last session. No significant change in MDI 
group.  
 Figure 4.11 shows the level of IL-1β. The lowest level of IL-1β was found in 
CSII group all over the study. Plasma levels of IL-1β were decreased in all 
study groups compare to before exercise levels except the second session in ND 
group where an increase in IL-1β levels were observed. IL-1β was decreased 
after second session then increased in MDI group. 
 Figure 4.12 shows the lowest level of IFN-γ was reported in CSII groups. MDI 
and ND groups have almost equal of high level of IFN-γ before exercise but this 
level then decreased over the exercise sessions. The significant decreased on the 
IFN-γ level was only found in MDI group in the last two sessions. The peak of 
IFN-γ level for CSII groups was found after 4 sessions.  
The cytokine reaction to exercise is different from that provoked by severe infections 
(Febbraio and Pedersen 2002; Suzuki, Nakaji et al. 2002). For example, the fact that the 
classic pro-inflammatory  cytokine IL-1β, does not increase during exercise, suggests 
that the cytokine cascade that is provoked by exercise differs significantly from the 
cytokine cascade prompted by infections (Petersen and Pedersen 2005). Figure 4.13 
demonstrates the process of the production of pro-inflammatory cytokines in immune 
cells. This diagram shows several TLRs and endosome on membrane are activated 
which eventually lead to translocation of NF-κB and interferon regulatory factors (IRFs) 
in a MyD88 (myeloid differentiation factor 88)/TRAF TNFr-dependent manner. These 
translocations activate transcription of multiple pro-inflammatory cytokines such as 
TNF, IL-6, type-I interferon (IFN) and pro-IL-1β. TNF, IL-6 and IFN are secreted into 
extracellular space and elicit systemic inflammatory responses. The inflammasome 
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assembly digests procaspase1 and generates caspase-1, an active form of cysteine 
protease, which converts pro-IL-1β into the mature active forms IL-1β. Secreted IL-1β 
and induce systemic inflammatory response (Nakayama and Otsu 2013). In our study 
we report that the plasma level of IL-1β in the acute exercise was significantly increased 
in CSII group while a decreased in IL-1β level in ND group. In MDI group IL-1β was 
decreased after resistance only. In the chronic exercise sessions the lowest level of IL-
1β was found in CSII group. Plasma levels of IL-1β were mainly decreased in all study 
groups compare to IL-1β level before exercise levels. 
 
Figure 4.13: Production of pro-inflammatory cytokines in immune cells (see text). 
 
The immune reactive profile for exercise also differs from that of autoimmune diseases 
like T1D i.e. the immune system acts destructively and usefully for infections, 
destructively and non-usefully for autoimmune disease and constructively and usefully 
for exercise.  The high level of IL-6 in MDI was reported in the EURODIAB study as 
significantly high in T1D (Schram, Chaturvedi et al. 2005). Moreover, Jain, Kannan et 
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al. (2003) showed that hyperketonemic in T1D patents increased level of plasma IL-6 
(Jain, Kannan et al. 2003). However the level of IL-6 in CSII was the lower than MDI 
and this may explain the lack of DKA in CSII group. In this study the level of IL-6 was 
significantly increased in ND group. The increase in IL-6 after exercise is a remarkably 
consistent finding (Pedersen & Hoffman-Goetz, 2000; Pedersen et al. 2001; Febbraio & 
Pedersen, 2002). Pedersen et al. in (2001) and (2003), Febbraio & Pedersen, (2002) 
reported the increase in plasma IL-6 is clearly demonstrated by muscle contractions 
without any muscle damage (Pedersen et al. 2001, 2003; Febbraio & Pedersen, 2002). 
However, the exercise duration and intensity has an effect on the increase of IL-6. 
Moreover, it has been suggested that the increase in IL-6 after exercise is related to the 
sympatho-adrenal (realised from muscles) response to exercise (Nehlsen-Canarella et al. 
1997). In CSII, there was no significant change in IL-6 over the time. Our result in CSII 
may also result in the number of carbohydrates ingested by CSII users which was also 
reported in the Nehlsen-Canarella et al. (1997) study, when they linked the increase in 
IL-6 level during exercise with the carbohydrate ingestion before exercise session 
(Nehlsen-Canarella et al. 1997). Febbraio et al. (2002b) as well demonstrated that the 
release of IL-6 from working muscle is related to carbohydrate ingestion during 
moderate exercise (Febbraio and Pedersen 2002). 
As discussed previously, T1D is an autoimmune disease where autoreactive T cells 
damage the insulin-producing β-cells in the pancreas (Diana, Gahzarian et al. 2011). 
Recent pathological studies of T1D have associated both innate and adaptive immune 
systems’ cells with the disease (Diana, Gahzarian et al. 2011).  
A NOD mouse study shows that during the growth of T1D, numerous interactions take 
place between innate immune cells (e.g. macrophages, DC, NK, NKT etc.) and adaptive 
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lymphocytes, including anti-islet T cells, involving CD4 and CD8 markers as have been 
noted clinically (Diana, Gahzarian et al. 2011). They observed that IFN-γ is important in 
this inflammatory mechanism, while Kristiansen and Mandrup-Poulsen (2005) suggest 
that inflammatory mediators such as TNF-α, IL-1β and IL-6 play a key role in the 
inflammatory development of both T1D and T2D.  
This role of T-Cells in the development of T1D is still a debateable issue because there 
is another T-cell population which reduces pathological responses of autoimmune 
system. For example, forkhead box P3 (Foxp3) (see figure 4.14), molecules generated 
by regulatory CD4 T cells, prevent the advancement of diabetes (Tang and Bluestone 
2008). Diana, Gahzarian et al. (2011) in the NOD mouse study discussed the protective 
function of such a T-cell population (Diana, Gahzarian et al. 2011). 
Figure 4.14 is adapter from Herold, Vignali et al. (2013) and explains how regulatory T 
cells that have lost FOXP3 expression may contribute to autoimmune disease. The 
molecule forkhead box P3 (Foxp3) is expressed by regulation of CD4 T cells which 
lead to, inhibition of diabetes  development (Tang and Bluestone 2008).In healthy 
individuals, developing thymocytes that do not express highly self-reactive T cell 
receptors (TCRs) mature and leave the thymus (left-hand panel). The forkhead box P3 
(FOXP3) gene is methylated in these cells. By contrast, highly autoreactive T cells are 
deleted during development as a part of negative selection. Regulatory T (TReg) cells 
also develop in the thymus and, compared with conventional mature T cells, express 
TCRs that show increased affinity for self-antigens. Owing to the demethylation of the 
FOXP3 locus and expression of FOXP3 protein, TReg cells have anti-inflammatory 
functions. However, in patients with type 1 diabetes (T1D) and other autoimmune 
diseases, TReg cells may not maintain complete demethylation of FOXP3 owing to 
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defects in interleukin-2 signalling or other mechanisms (right-hand panel). These 'ex-
TReg' cells remain autoreactive and, in the absence of FOXP3 expression, can produce 
potentially pathogenic pro-inflammatory cytokines. It has been suggested that such cells 
will participate in pathological immune responses to self antigens. In addition, failure to 
eliminate highly autoreactive T cells during thymic development may lead to the escape 
of potentially pathologic T cells into the periphery. 
 
Figure 4.14: How Regulatory T cells, that have lost forkhead box P3 (FOXP3) 
expression, may contribute to autoimmune disease. Adapted from (Herold, Vignali et al. 
2013). 
 
Studies have shown that IL-6 mediate local inflammation and tissue destruction, and 
curbs the resistance of T cells against apoptosis, encourages activation of T helper cells 
and regulates the balance between regulatory T cells and Th17 cells (Neurath and 
Finotto 2011). IL-6 strategies are considered to be an innovative and effective line of 
action against the inflammatory diseases such as diabetes. Evidence gathered from 
several studies based on experimental models suggests that autoimmune and chronic 
inflammatory disease could be treated by blocking the IL-6 signalling (Neurath and 
Finotto 2011). As IL-6 has an ability to inhibit low-grade TNF-α production, IL-6 may 
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inhibit TNF-α induced insulin resistance (Nehlsen-Canarella et al. 1997). This statement 
supports our result in figure 4.5 (IL-6) and figure 4.6 (TNF-α), where our results show 
the increase in IL-6 and at same time the decrease in TNF-α level in all study groups to 
almost the same level. The increase in IL-6 level may have an important role in 
mediating the beneficial health effects of exercise in inactivity and obesity-related 
disorders such as diabetes (Nehlsen-Canarella et al. 1997) (Nieman, Nehlsen-Cannarella 
et al. 2008). 
In one study neutralising antibodies were administered regularly to blockade IL-6 and 
as a result suppression of T1D was noticed. Rabinovitch (1998) discussed the role 
played by IL-6 in experimental T1D development. It was suggested that IL-6, like other 
cytokines e.g. TNF and Th1 is an important player in the development of the disease.  
The present study suggests that in T1D who are using CSII, the IL-6 levels increased in 
acute (figure 4.5) and chronic exercise (figure 4.9), which demonstrates a positive effect 
of exercise. As Wallenius et al. (2002) have confirmed the advantage of high level on 
IL-6 in reduction of body weight in mice when treated with IL-6 (Wallenius, Wallenius 
et al. 2002). Moreover, Pedersen, Steensberg et al. (2004) concluded the biological roles 
of IL-6 as: (i) induction of lipolysis; (ii) suppress TNF-α production; (iii) stimulation of 
cortisol production (Pedersen, Steensberg et al. 2004).These results are supported by 
Langberg, Olesen et al. (2002) who argued that during exercise connective tissues cause 
a surge in the level plasma IL-6. While Fischer (2006) noticed that during exercise 
skeletal muscles produce IL-6 and IL-6 flows from muscle to plasma (Fischer 2006)  
Furthermore, at the end of the cycling session an elevated level of IL-6 was observed 
which falls back during the recovery period following the exertion (Steensberg, van 
Hall et al. 2000; Starkie, Rolland et al. 2001; Steensberg, Febbraio et al. 2001). 
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However, in the present study, MDI users demonstrated a decline in IL-6 during chronic 
sessions, which may be caused by lack of insulin in the system. This conclusion is 
supported by Noneless, Galassetti, Iwanaga et al. (2006) who witnessed effects of 
exercise and prior hyperglycemia on IL-6 levels in serum and suggested that the level of 
IL-6 in serum primarily depends on prior glucose levels and physical activity. On the 
other hand in CSII group below normal levels of IL-6 was observed before exercise but 
after resistance and cardio exercise sessions a significant increase in the IL-6 level was 
observed (see Figure 4.5).  
As mentioned above in the present study it was observed that levels of IL-6 elevated 
after exercise while the levels of TNF-α declined. Keller, Keller et al. (2004) observed 
in knockout mice that decline in TNF-α level may not be associated with IL-6 and 
caused by some IL-6 independent mechanisms. It has also been reported that IL-6 
triggers the production of anti-inflammatory cytokines (Petersen and Pedersen 2005) 
and inhibits TNF-α production in humans (Plomgaard, Bouzakri et al. 2005) and it is 
probable that muscle-derived IL-6 provides protection against TNF-induced insulin 
resistance (Petersen and Pedersen 2005). 
In healthy humans as well as occasionally in T1D, high levels of TNF-α modifies 
insulin signal transduction and causes insulin resistance in the skeletal muscle 
(Plomgaard, Bouzakri et al. 2005). Therefore, reduced level of TNF-α, as seen after 
exercise in this study, reduces the insulin resistance in the skeletal muscle. It has been 
revealed that TNF-α did not have an effect on muscle fatty acid oxidation but amplified 
fatty acid incorporation into diacylglycerol, which may be involved in the creation of 
TNF-induced insulin resistance in skeletal muscle (Bruce and Dyck 2004). A rise in 
TNF-α lead to a rise in insulin resistance in other words actions of insulin are 
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susceptible to TNF-α arbitrated inhibition when insulin concentrations are low (which 
was revealed in the current study) and are the least susceptible when insulin 
concentrations are high (Zhang, Wheatley et al. 2003). This study confirms the fact that 
diabetes sufferers have an increased level of TNF-α in their skeletal muscle and in their 
plasma as compared with non-diabetics (see figure 4.10).  
It is clear from the above discussion that exercise causes a surge in IL-6 and a decline in 
levels of TNF-α in T1D sufferer. Taking into consideration the diverse biological 
profiles of TNF-α and IL-6 and the fact TNF-α can trigger IL-6 release, one theory 
posits that metabolic syndrome is caused by adipose tissue-derived TNF-α, and that 
elevated systemic levels of IL-6 depends on levels of TNF-α (Petersen and Pedersen 
2005). Figure 4.15 demonstrates that contracting muscle fibres produce and release IL-
6, which induces several metabolic effects. IL-6 induces lipolysis and fat oxidation and 
is involved in glucose homeostasis during exercise. In addition, IL-6 has strong anti-
inflammatory effects and may inhibit TNF-induced insulin resistance. sTNF-R, soluble 
TNF receptor (Petersen and Pedersen 2005). 
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Figure 4.15: Contracting muscle fibres and production of IL-6 (Petersen and Pedersen 
2005). 
 
In a study, it has been shown that, in rodents, macrophages generate pro-inflammatory 
cytokines IL-1β and TNF-α and may play a pathogenic role on β-cells (Arnush, Scarim 
et al. 1998; Dahlen, Dawe et al. 1998). When compared with other control strains, for 
example non-obese resistant (NOR) mice, macrophages from NOD mice generate 
higher levels of the inflammatory IL-1β, and TNF-α cytokines (Uno, Imagawa et al. 
2007). 
Analysis of blood samples after acute exercise session a rise in IL-1β was observed in 
CSII group in the present study, which is in line with the findings of Gleeson (2007) 
who observed an increase in IL-1β during and after acute exercise in the CSII. But in 
MDI this increase was only witnessed after a cardio i.e. cycling session. This increase in 
MDi may be caused by high level of insulin in the body. 
However, in case of chronic exercise it was observed that in all three groups (i.e. ND, 
MDI and CSII) the levels of IL-1β dropped (see Figure 4.11). Furthermore, the drop in 
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IL1-β levels was more significant in CSII as compared to MDI. This further supported 
the hypothesis that exercise has a positive impact on diabetes sufferers and CSII 
provides a better mean to manage the blood glucose levels. As reported previously IL-
1β is inhibit β cell function as an pro-inflammatory  cytokine acting in T1D during the 
autoimmune process (Maedler, Sergeev et al. 2002). In this study the low level in IL-1β 
reported in CSII group (figure 4.7 and 4.11) may result in the benefit of CSII therapy, as 
the low level of IL-1β and TNF-α reported for CSII group (figure 4.6 and 4.10) can 
indicate the progressing of autoimmune against β cells destruction (Dogan, Akarsu et al. 
2006). This means the low level of IL-1β lead to or may be used as an indicator of 
continuing autoimmune aggression against β cells before the development of extensive 
β-cell. Baumann, Salem et al. (2012) supported this statements, the secretion high level 
of both pro-inflammatory cytokines such as; IL-1β (as in figure 4.7 and 4.11), TNFα (as 
in figure 4.6 and 4.10), and INFγ (as in figure 4.8 and 4.12) in this study, is a fatal 
destruction process of β-cells (Baumann, Salem et al. 2012). 
TNF-α and IL-1β cytokines are usually depicted as pro-inflammatory  cytokines and 
these cytokines arouse the generation of IL-6, and it is clear from the above discussion 
that higher levels of IL-6 are helpful to manage T1D.  
When there are low concentrations of IL-1β the cytokine enhances insulin secretion, 
increases β-cell replication and lowers apoptosis. The precise opposite of this occurs 
after prolonged exposure to higher levels of IL-1β in T1D (Donath, Böni-Schnetzler et 
al. 2010). It is therefore justifiable to propose that under physiologic circumstances, IL-
1β that is excreted locally by islet cells, comprising β-cells, plays an key role in the 
daily maintenance of β-cell mass and function, whilst the long-term and pathologically 
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heightened levels of islet IL-1β related to inflammation of the islet, causes a decrease in 
β-cell function and mass in diabetes (Donath, Böni-Schnetzler et al. 2010). 
Type 1 T cells mainly generate IFN-γ and TNF-α, and their actions trigger macrophages 
and killer mechanisms, such as T-cytotoxic cells, therefore pushing the immune system 
towards cell-mediated immune reactions, which mainly offer protection against 
intracellular pathogens like viruses (Lancaster, Halson et al. 2004). In autoimmune 
diabetes NOD mice they found that IFN-γ and TNF-α as an effectors molecules leading 
to β cell death (Suk, Kim et al. 2001) 
In this study IFN-γ levels showed conflicting patterns. But overall it was observable that 
the IL-6 and IFN-γ levels increased after 4 exercise sessions in CSII groups. In chapter 
5, the limitations of this pilot study will be discussed in terms of the selection of the 
participants. However, these matters have some bearing here too. Inevitably in a study 
of this kind, it is impossible to match people in many of the respects that may be 
deemed desirable simply to recruit enough that satisfy some other major criteria. In this 
chapter, recruits may differ in the oxidative stress, degree of inflammatory change and 
the lifestyle influences that may or may not have been declared. 
During and after the exercise IFN-γ production by T lymphocytes is restricted 
(Lancaster, Halson et al. 2004). Even following relatively short periods (1–3 wk) of 
intensified training, marked reductions in the circulating number of T cells producing 
IFN-γ have been observed (Lancaster, Halson et al. 2004). In anti-IFN-γ antibody-
treated mice, IFN-γ blood levels were dramatically decreased TNFα and IL-6 levels 
remained unaffected by anti-IFN-γ treatment (Matthys, Mitera et al. 1995). 
Furthermore, IFN-γ can activate macrophages and motivate enhanced pro-inflammatory 
cytokine production, such as IL-1β and TNF-α (Lehuen, Diana et al. 2010). Moreover in 
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our study the benefit of the suppression of TNF-α by IL-6 is reported as the low level of 
TNF-α can play a role in T1D, as the blocking of TNF-α early during pathogenesis may 
prevented diabetes completely (Christen, Wolfe et al. 2001). 
Preventing diabetes in NOD mice provoked by complete Freund adjuvant injection is 
reliant on the presence of NK cells that generate IFN-γ (Lee, Kwon et al. 2012).  
In summary this study examined the effects of exercise on cytokines like IL-6, TNF-α, 
IL-1β and IFN-γ in ND, MDI and CSII groups. As discussed above it was noticed that 
exercise leads to an increase in IL-6 and IFN-γ, while causing a reduction in TNF-α and 
IL-1β levels. The above mentioned literature supported the findings of this study and 
the hypothesis of the study that exercise (acute and chronic) in diabetics helps to 
manage the disease and CSII has a positive impact on the T1D. 
4.6. Conclusion 
 This study has shown that there is a difference between normal healthy 
volunteer cytokines and those in diabetes. Diabetic levels are known to be higher 
than ND and it is reasonable to assume that the MDI levels are suppressed 
compared with the untreated level over the exercise programme. However, the 
effect of a more continuous infusion appears to be a greater suppression than 
normal. 
 The greater suppression of cytokines in CSII does not appear to be linked with 
increased risk and in fact seems associated with healthy outcomes (chapter 5). 
 These levels can be seen to respond to acute and more chronic forms of exercise 
in this study. This supports the suggestion that muscle-derived IL-6 plays a key 
role in exercise-induced leukocyte trafficking. This is important because it has 
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been demonstrated by different studies that the physiological concentrations of 
IL-6 provoke an anti-inflammatory, not inflammatory reaction in humans and 
that IL-6 is independent of TNF-α. The low production of pro-inflammatory 
cytokine TNF-α concentration may be explained by the inhibiting role of high 
levels of IL-6 via independent mechanisms during exercise.  
 The data produced in the study reveals that a regular exercise regime can lead to 
a rise in IL-6 and a decline in TNF-α. Furthermore, the reduced levels of TNF-α 
is associated with the reduced level of IL-1β, while both possess pro-
inflammation properties. On the other hand IFN-γ and IL-6 performs anti-
inflammatory role in the immune system. 
 Diabetes being an inflammation-driven disease can benefit from anti-
inflammatory properties of high levels of IL-6 and IFN-γ and reduced levels of 
TNF-α and IL-1β. The study demonstrate anti-inflammatory effects of taking 
regular exercise which could provide protection against chronic systemic low-
grade inflammation involved in the maintenance, the vulnerability to infection 
and the progression of the disease. 
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CHAPTER 5: Effect of exercise on Lipids Profiles and glycemic control 
Effect of exercise on lipids profiles and glycemic control for type1 diabetic (MDI and 
CSII) and non-diabetic (ND) 
5.1. Introduction 
Diabetes Mellitus is linked with heightened cardiovascular disease (CVD) mortality that 
is present within all age groups. However, in young people with Type 1 Diabetes (T1D) 
CVD is considered to be a major risk and is linked with high mortality (McVeigh, 
Gibson et al. 2013). Patients who have T1D also usually have lipid disorders (Verges 
2009; Vergès 2011) and thus it is essential to investigate lipid abnormalities in people 
with T1D to reduce CVD with this group of people. Hyperglycemia and dyslipidaemia 
are very prevalent metabolic abnormalities in adults who have T1D and this increases 
their risk of developing CVD (Maahs, Ogden et al. 2010). T1D patients who have 
reduced or suboptimal glycemic control will eventually present with heightened LDL 
levels in comparison to non–diabetic people and T1D patients with optimum glycemic 
control (Guy, Ogden et al. 2009). The hemoglobin A1C (A1c) is significantly linked 
with alterations in fasting lipids in adults who have T1D but not taking dyslipidaemia 
medications (Maahs, Ogden et al. 2010). The important lipid measurements include; 
low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (TC) 
and triglyceride (TG).  
Heightened lipid availability decreases insulin-stimulated glucose disposal in the 
skeletal muscle, which is usually characterised by fatty acid–mediated inhibition of 
insulin signalling (Szendroedi, Frossard et al. 2012). Reduced insulin sensitivity is 
linked with amore atherogenic lipid profile in people who have T1D either as adults or 
183 
 
in their youth (Maahs, Nadeau et al. 2011). TG levels are correlated with vascular 
disease in T1D (Mäkinen, Soininen et al. 2013). 
The Diabetes Control and Complications Trial (DCCT) showed that intensive (rather 
than conventional) insulin therapy is linked with a considerable reduction in LDL, total 
TC and TG in adults who have T1D (Maahs, Ogden et al. 2010). The improvement of 
glycemia is suggested as an initial treatment for dyslipidaemia when caring for patients 
with T1D. Nevertheless, lipid-lowering medicine can also be administered if lipid goals 
are not obtained (Buse, Ginsberg et al. 2007; Brunzell, Davidson et al. 2008). 
5.2. Effect of Exercise on Lipids and glycemia control 
When overweight healthy people took part in 16 weeks of aerobic and resistance 
training, they presented with elevated lipid profiles (Tibana, Navalta et al. 2013). It is a 
well-established fact that the long-term benefits of frequent aerobic physical activity 
laid out for the general population can be applied to T1D patients (De Feo, Di Loreto et 
al. 2006). Yet T1D patients struggle to manage and control blood glucose levels during 
exercise and this hinders their pursuit for regular exercise (Kilbride, Charlton et al. 
2011). Exercise is linked with an heightened risk of hypoglycemic or hyperglycaemic 
events (Kapitza, Hövelmann et al. 2010). Small-scale studies have revealed that in 
patients with T1D, resistance training (weight lifting) decreases A1c (Yardley, Kenny et 
al. 2013). Furthermore, Shriver (2011) after his study reported a statistically significant 
impact of exercise (aerobic, resistance and combined training) on the management of 
glucose (A1c). While in T1D sufferers, in contrast to MDI therapy, constant 
subcutaneous insulin infusion (CSII) is found to be helpful to reduce the occurrence of 
hypoglycemia during frequent moderate-to-heavy intensity aerobic training and was not 
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linked with a heightened risk of post-exercise late-onset hypoglycaemia (Yardley, Iscoe 
et al. 2013). 
It has been suggested that the roles of intensive insulin as a treatment of T1D is not only 
to improve A1c and the prevention of premature cardiovascular events (Nathan, Cleary 
et al. 2005) but are also linked with lipid profiles (Feitosa, Feitosa-Filho et al. 2013). 
The improvements of glycemic control without weight gain has been associated with 
lipids control and this include triglyceride, total cholesterol and LDL (Purnell, 
Hokanson et al. 1998). CSII is a way of attaining stringent glycaemic control and yet 
minimising the associated problem of hypoglycemia and possibly of weight gain 
(Hindmarsh, Peters et al. 2013). T1D patients may have lipids disorders such as high 
LDL and low HDL (Guy, Ogden et al. 2009) and may influence lipid transfers 
(Bagdade, Ritter et al. 1991; Bagdade and Dunn 1992). However, in T1D (as distinct 
from the better known resistance in T2D) the high triglycerides level is linked with 
insulin resistance (Coen, Dubé et al. 2010).The increased in inflammatory markers such 
as IL-6 in T1D (as shown in chapter 4) is associated with changes in the lipid profile 
(Snell-Bergeon, West et al. 2010).However, the relation between intensive insulin 
treatment and the status of lipid metabolism in T1D need more investigations (Feitosa, 
Feitosa-Filho et al. 2013) and the benefits of exercise in T1D is not clear yet (Chimen, 
Kennedy et al. 2012). Moreover, the evidence for T1D in relation to the advantage of 
exercise on glycaemic control are less clear (Chimen, Kennedy et al. 2012). 
5.3. Insulin pump compared to MDI 
In comparison to conventional insulin therapies, CSII (or insulin pump) can enhance 
glycaemic management and promote dietary flexibility in patients with T1D as shown 
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in chapter 3. There is strong evidence to show that intensive insulin treatments that 
generate stringent glycaemic control decrease or delay the inception of the long term 
difficulties associated with diabetes. In adult diabetes the lipids concentration are linked 
with risk of CVD (Weis, Turner et al. 2001). T1D adult associated with high risk of 
atherosclerotic disease compared to healthy (Krolewski, Kosinski et al. 1987).Guy, 
Ogden et al. (2009) found that the lipids level are affected by glycemic control in youth 
T1D with duration of ~4 years (Guy, Ogden et al. 2009). The same study reported the 
optimal A1c in T1D youth result in optimal lipid profiles (TC and LDL) compare to 
non-diabetic youth while the other group of T1D youth with suboptimal A1c have 
higher standard lipid levels and prevalence of lipid abnormalities (total cholesterol, LDL 
cholesterol, and non-HDL cholesterol) than non-diabetic youth. Similarly, Petitti, 
Imperatore et al. (2007) reported that the TC, LDL and triglyceride are increased with 
increasing A1c in T1D (Petitti, Imperatore et al. 2007).  
In T1D adult with poor glycemic control the lipid levels are increased (Guy, Ogden et 
al. 2009). It has been suggested that the enzyme induction in adipose tissue by insulin, 
in intensive therapy is typically associated with a marked fall of triglyceride-rich 
particles (James and Pometta 1990). This statement may explain the low TG and LDL 
and high HDL in well-controlled T1D. However, the relation between T1D and lipids 
may be affected by ethnic group (Dias, Brown et al. 2013). 
A major study comparing CSII and MDI in T1D with lipid parameters was in 2009. 
This confirmed that CSII therapy for T1D improved the lipid profile compared to MDI 
(Derosa, Maffioli et al. 2009). The same study reported that the LDL, HDL, TG and TC 
were improved after 6 month of CSII therapy compared to MDI. Moreover, even short 
term (2 weeks) of CSII therapy in T2D improved the lipids such as TG, LDL, HDL, TC 
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and non-esterified fatty acid (NEFA) (Li, Xu et al. 2004). However, most past  studies 
analysed the different T1Dinsulin route therapies (CSII and MDI)were focused on 
glycemia control rather than on lipids profiles (Derosa, Maffioli et al. 2009). Moreover, 
recently Peters et al. (2013) claimed that there is not much evidence to suggest if insulin 
pump users utilised increased dietary flexibility, and if dietary quality is impacted upon 
or affects outcomes (Peters, Mount et al. 2013). 
The target goals of T1D therapy either CSII or MDI are to achieve normal or near 
normal glycemia, prevent late vascular complications, reduce hypoglycemia events, 
improve quality of life, and limited weight gain. As discussed in chapter 3 insulin pump 
therapy may or can dramatically aid in achieving all of these goals. 
5.4. Study Objectives 
The purpose of this study was to examine the effects of six weeks of combination 
exercise (resistance and aerobic), twice a week, on lipid profiles and glycaemic control 
in T1D using MDI, T1D using CSII and non-diabetic (ND).The ethical approval for this 
study was gained from De Montfort University (DMU) Ethics Committee, School of 
Health and Life Science, Leicester, UK.   
5.5. Subjects and Methods 
5.5.1. Volunteers 
As mentioned above three groups of volunteers were involved in this study i.e. T1D 
using CSII, T1D using MDI and non-diabetic ND. The volunteers were 18-55 years old 
and not physically active or engaged in any regular exercise or training programmes. 
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5.5.2. Study Recruitment 
Study recruitment was publicised through internal and external adverts as described in 
section 2.4.1.Initially 49 individuals (ND= 24, MDI= 14, CSII= 11) expressed an 
interest to participate in this study. However, 14 were excluded because they failed to 
meet the inclusion criteria, while, 16 participants were unable to attend because of their 
personal commitments and difficulty in making necessary arrangements to participate. 
The eventual sample was 19 participants (ND= 7, MDI= 7 and CSII=5) who completed 
the exercise programme. 
5.5.3. Six Weeks Exercise 
The participants were required to participate in moderate exercise programme involved 
two visits per week for six weeks (48 hours between, as improved insulin sensitivity is 
said to be lost after 48 hours (Shriver 2011). Each visit lasted for more than 90 minutes, 
again based on trials by others (CDC 2011; Shriver 2011) and as described in figure 5.1, 
to include stretching upper and lower muscles, a warm up on the bike for 5 min, the 
resistance exercise, the aerobic exercise, then warm down and rest (full description in 
sections 2.5.7-2.5.10). 
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Figure 5.1: Division of the exercise sessions throughout the study 
 
5.5.4. Parameters measured 
Lipids profile including; TG, HDL, LDL and TC were measured; before starting the 
exercise programme and used as the individual base line, after 6 sessions and after 12 
sessions of exercise according to UK guidelines and NICE, 2010 (issue date: May 2008 
and reissued March 2010) (Cooper, Nherera et al. 2008) (see table 5.1). Body fat % and 
BMI was calculated before and after study. Rated Perceived Exertion (RPE) was 
recorded three times in each session; after 1
st
, 2
nd
 and 3
rd
 sets of resistance exercise and 
during cardio exercise the RPE was recorded twice; at 10 and 20 minutes. The 
respiratory exchange ratio (RER) was measured 3 times during cardio exercise; at zero 
point (after the rest of 5 min after RE), at 10 and 20 min of cardio exercise. T1D 
volunteers either CSII or MDI groups calculated their carbohydrates daily. T1D people 
Stretching upper and 
lower muscles  
Warm up on recumbent 
bike for 5 minutes 
Resistance  exercise [ Squat, 
Chest, Back,  Triceps and 
Bicep]
At 50% of 1-RM.
(3 sets of 10 repetitions with 
40 seconds rest interval 
between each repetitions )
Rest for 5 minuets 
Aerobic  exercise on 
recumbent bike for 20 
minutes with face mask 
(ADInstruments 
Analysis system )
Warm down (stretching 
the lower and upper 
muscles 
Observation  
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respond variously to insulin therefore the carbohydrate to insulin ratio was calculated 
before and after the study for T1D groups. 
A1c was measured before first session and after 12 sessions. BG was measured three 
times during the sessions; before exercise, after resistance and after cardio exercise. 
Daily insulin (Units/day) used by volunteers during the study were recorded. 
Table 5.1: Lipids level according to UK guidelines and NICE, 2010. 
Lipid (mmol/l) Normal  Abnormal  Very abnormal 
Total Cholesterol (Tc) Less than 4.0 4.1-6.0 Greater than 6 
LDL-Cholesterol Less than2.0 2.6-3.9 4.0-4.8 
HDL-Cholesterol >1.4 1.0-1.5 Less than 1.0 
Triglyceride (TG)  less than 1.69 1.7-2.25 2.26-5.65 
5.5.5. Statistical Analysis 
Descriptive statistics like mean, variance and standard deviation were used to express 
the data. Test of statistical significance based on two tailed t-test and p-value were 
conducted using 0.05 level of significance (i.e. α=0.05).All data were analysed using the 
Statistical Package for Social Sciences (IBM SPSS, v.19, Chicago, IL). The 
carbohydrate to insulin ratio example was calculated as 1 in 10 for example: 
When T1D intake 10g of carbohydrate they need 1 unit of fast acting insulin to cover 
this amount of carbohydrate. 
5.6. Results 
5.6.1. Characteristics 
A total of 19 males who met the selection criteria participated. The samples consisted of 
7 diabetic type 1 (MDI), 7diabetic type 1 insulin pump users (CSII) and 7 non-diabetic 
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(ND). Study characteristics including age, BMI, DM duration and pump duration, BG 
tests per a day and types of insulin are described in table 5.2.  
Table 5.2: Practical study subjects’ characteristics; DM, Diabetes mellitus; BG, blood 
glucose; BMI, body mass index and body fat%. Data are means ± SD 
Variables MDI CSII ND 
Age, y 36 12.5 30.88.7 31.45.3 
DM duration, years 13.6 14.69.8 
Pump duration, years 
4.11.7 
----------- 
Types of insulin  Novorapid / Glargine (45%) 
Novorapid / Lantus (28%) 
Novorapid / Levemir (13.5%) 
Novomix (13.5%) 
Apidra (15%) 
Novorapid (60%) 
Humalog (15%) 
 
----------- 
BG test frequency 
(daily) 
0.8 7.81.9 ----------- 
BMI 
Before study 
After study 
 
29.36.9 
29.16.9 
 
25.12.5 
24.82.2 
 
26.23.3 
26.23.3 
Body fat % 
Before study 
After study 
 
31.310.9 
29.211.4 
 
26.93.4 
25.083.3 
 
237.4 
20.77 
5.6.2. Exercise intensity 
The target intensity of resistance exercise (RE) was moderate (11-14) according to the 
Rated Perceived Exertion (RPE) scale (6-20) (which describes how hard the exercise 
feels to the participant) (see table 2.3) and estimated maximum heart rate (HRmax) was 
used for cardio (bike) exercise, as in the full explanation provided in section 2.5.5. 
Table 5.3 shows the RPE during resistance exercise and table 5.4 is the RPE during 
cardio exercise. The RPE was measured following the completion of each set of RE 
exercise. The session RPE is a reliable method to measure various intensities of RE 
exercise (Scherr, Wolfarth et al. 2013). 
In order to indicate which fuel (carbohydrate or fat) is being metabolised to supply the 
body with energy during the 20 minutes of cardio, the respiratory exchange ratio (RER) 
was used. Williamson, Fuld et al. (2012) confirmed the validity of RER in aerobic 
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exercise (Williamson, Fuld et al. 2012).This is the ratio between the amount of 
consumed O2 and produced CO2 in one breath and it was measured 3 times; at zero 
(after the rest of 5 min after RE), at 10 min of cardio and at the end of cardio (see table 
5.5). Without any activities and with a light diet RER is about 0.8. However, during 
intense exercise the RER value can exceed 1, as a result of greater production of CO2 by 
the working muscles and more of the inhaled O2 gets used rather than being expelled. 
As Rubini, Paoli et al. (2012) reported a positive significant correlation between O2 
uptake and CO2output during exercise (Rubini, Paoli et al. 2012). 
The interaction between exercise and meal intake can be determined by RER (Kang, 
Raines et al. 2013). In this study when RER=0.70 it indicates that fat is the largest fuel 
source, RER=0.85 suggests a mix of fat and carbohydrates, and a value of RER=1.00 or 
above is indicative of carbohydrate being the main fuel source. However, in this study 
the diets of individuals were not controlled. It was difficult to do so with T1D for either 
MDI or CSII as they must calculate their carbohydrates in order to adjust their insulin 
basal and bolus rate. 
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Table 5.3: Rated Perceived Exertion (RPE) for all study groups during resistance exercise (RE). Data are means ± SD 
RPE for RE 
MDI group sessions 
1 2 3 4 5 6 7 8 9 10 11 12 
1
st
  set 130.6 121 12.71.1 12.71.1 12.11.1 12.70.5 12.90.4 131 12.30.5 12.41.1 120.6 11.70.8 
2
nd
  set 13.60.8 130.8 13.71.0 130.0 130.6 13.41.0 13.41.0 13.10.7 13.30.8 13.11.2 12.41.0 12.11.1 
3
rd
 set 14.62.1 141.6 141.2 13.90.7 13.71.3 141.4 14.11.5 13.60.8 14.31 13.61.3 13.11.6 12.61.5 
                             CSII group sessions 
1
st
  set 12.81.3 12.20.4 120.7 12.41.5 120.7 11.80.4 11.20.8 11.20.8 120 11.50.6 11.80.4 11.20.4 
2
nd
  set 14.21.3 12.60.9 13.20.8 13.21.8 12.40.9 12.60.9 121.2 11.61.1 12.20.5 120.8 120.7 11.60.9 
3
rd
 set 15.61.3 141.0 14.20.8 141.2 13.41.3 13.41.1 131.4 12.81.5 131.4 12.81.5 12.21.1 11.81.3 
                           ND group sessions 
1
st
  set 11.71 11.70.8 120.8 120.8 11.60.5 11.50.5 11.21.3 11.61 121.5 11.82 11.41 10.91.3 
2
nd
  set 13.31 13.41.1 13.30.8 13.41 12.61 12.71.3 12.10.7 12.71.1 12.41.1 12.71.7 12.10.7 11.91.2 
3
rd
 set 14.42.2 14.12.6 13.82.4 13.72.3 12.82.1 12.12.5 12.32.4 12.32.7 12.52.5 12.42.3 11.71.8 11.72.0 
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Table 5.4: Rated Perceived Exertion (RPE) for all study groups during cardio exercise. Data are means ± SD 
Cardio   
exercise 
RPE 
MDI group sessions 
1 2 3 4 5 6 7 8 9 10 11 12 
After 10 
min 
13.61.8 14.00.6 12.71.1 12.91.1 13.00.8 13.71.3 12.31.0 12.10.7 12.71.1 12.71.0 11.90.7 11.71.0 
After  20 
min 
13.01.5 13.10.9 12.71.0 12.90.9 13.10.7 13.30.8 12.71.1 12.30.8 13.31.4 12.91.1 12.01.0 11.71.0 
                     CSII group sessions 
After 10 
min 
12.20.8 12.60.5 12.41.5 13.01.6 12.21.1 12.20.8 11.60.5 11.81.0 12.31.3 12.31.3 12.01.9 11.81.1 
After  20 
min 
12.81.3 13.01.0 12.81.8 13.01.6 12.61.5 12.41.1 12.01.2 12.01.2 12.31.3 12.31.3 12.01.9 11.81.1 
                      ND group sessions 
After 10 
min 
12.32.2 13.31.7 12.80.9 12.41.3 12.31.8 12.72.1 11.91.0 12.11.1 11.91.6 12.01.9 11.41.0 11.01.3 
After  20 
min 
13.72.0 14.11.9 14.01.4 13.32.3 12.71.8 13.02.4 12.31.0 12.31.1 12.12.1 12.41.8 11.71.5 11.32.2 
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Table 5.5: Respiratory exchange ratio (RER) during cardio exercise. Mean test duration was 1200 seconds Data are means ± SD 
RER 
MDI group sessions 
1 2 3 4 5 6 7 8 9 10 11 12 
Zero point  10.2 10.2 10.1 10.2 10.1 10.2 10.1 0.90.1 10.2 10.2 1.10.1 10.2 
At 10 min  1.10.2 1.10.2 1.10.2 10.2 1.10.2 1.10.2 1.20.3 1.10.2 1.20.2 1.10.2 1.10.1 10.2 
At 20 min  1.10.2 1.10.2 10.2 1.10.2 1.10.2 1.10.2 1.10.1 1.10.2 1.20.2 1.10.2 1.20.1 10.2 
                       CSII group sessions 
Zero point  10.3 10.3 0.90.3 0.90.3 10.2 10.1 10.2 10.2 10.1 10.1 10.2 10.1 
At 10 min  1.10.2 10.2 10.2 10.2 1.10.2 1.10.2 10.2 10.2 10.2 10.2 10.2 10.2 
At 20 min  1.10.2 10.2 10.2 10.2 1.10.2 1.10.2 1.10.2 1.10.1 1.10.2 10.2 10.2 1.10.2 
                      ND group sessions 
Zero point  10.2 0.80.1 0.90.1 0.90.1 0.90.1 0.90.1 0.90.2 0.90.2 0.90.1 0.90.1 0.90.1 0.90.1 
At 10 min  10.2 0.90.1 0.90.1 0.90.1 10.1 0.90.1 0.90.2 0.90.1 0.90.1 0.90.1 0.90.1 0.90 
At 20 min  10.2 0.90.1 0.90.1 0.90.1 1.02 0.90.1 0.90.2 0.90.2 0.90.1 0.90.1 0.90.1 0.90 
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5.6.3. Effect of exercise on Lipids 
Lipids profiles were measured three times during this study and table 5.6is described the 
result for all lipids (LDL, HDL, TC, TG) and table 5.7 shows the lipid profiles P value 
for all study groups. 
Table 5.6: Lipids profiles as mean  SE 
Lipids (mmol/L) MDI CSII ND 
LDL level  
Before exercise 
After 6 sessions  
After 12 sessions  
1.730.8 
1.870.9 
1.590.7 
2.000.6 
1.970.7 
1.500.5 
1.950.6 
1.950.6 
1.850.7 
HDL level  
Before exercise 
After 6 sessions  
After 12 sessions  
1.370.7 
1.500.7 
1.640.6 
1.520.3 
1.550.3 
1.680.2 
1.300.6 
1.590.7 
1.620.5 
TC level 
Before exercise 
After 6 sessions  
After 12 sessions  
4.020.7 
3.840.7 
3.720.6 
4.030.8 
3.930.7 
3.600.6 
3.920.6 
3.651.0 
3.500.7 
TG level 
Before exercise 
After 6 sessions  
After 12 sessions  
1.470.9 
1.530.9 
1.370.6 
1.120.4 
0.900.3 
0.790.2 
1.340.6 
1.310.2 
1.170.2 
TC/HDL 
Before exercise 
After 6 sessions  
After 12 sessions  
 
2.93 
2.56 
2.27 
 
2.65 
2.54 
2.14 
 
3.02 
2.30 
2.16 
HDL/LDL 
Before exercise 
After 6 sessions  
After 12 sessions  
 
0.79 
0.80 
1.03 
 
0.76 
0.79 
1.12 
 
0.67 
0.82 
0.88 
TG/HDL 
Before exercise 
After 6 sessions  
After 12 sessions  
 
1.07 
1.02 
0.84 
 
0.74 
0.58 
0.47 
 
1.03 
0.82 
0.72 
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Table 5.7: Lipids profiles between study groups (P-values) 
  CSII vs MDI CSII vs ND MDI vs ND 
L
D
L
 Before Exercise 0.322 0.946 0.213 
After 6 sessions 0.796 0.881 0.704 
After 12 sessions 0.835 0.389 0.637 
H
D
L
 Before Exercise 0.944 0.806 0.670 
After 6 sessions 0.565 0.495 0.738 
After 12 sessions 0.971 0.479 0.445 
T
C
 Before Exercise 0.699 0.751 0.876 
After 6 sessions 0.957 0.928 0.855 
After 12 sessions 0.373 0.867 0.164 
T
G
 Before Exercise 0.495 0.534 0.850 
After 6 sessions 0.095 0.044 0.934 
After 12 sessions 0.074 0.016 0.335 
T
C
/H
D
L
 
Before Exercise 0.696 0.720 0.812 
After 6 sessions 0.942 0.794 0.761 
After 12 sessions 0.599 0.728 0.114 
H
D
L
/L
D
L
 Before Exercise 0.440 0.954 0.383 
After 6 sessions 0.507 0.810 0.331 
After 12 sessions 0.613 0.940 0.441 
T
G
/H
D
L
 Before Exercise 0.644 0.386 0.961 
After 6 sessions 0.433 0.658 0.835 
After 12 sessions 0.100 0.264 0.252 
 
5.6.3.1. Low-density lipoprotein cholesterol (LDL) 
LDL was decreased from 2mmol/L before exercise to 1.5mmol/L after 12 sessions of 
exercise in CSII group (Figure 5.2). However, although the trend was probably a 
decrease, the LDL in MDI and ND groups showed some fluctuation and a smaller 
overall decline. 
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Figure 5.2: LDL, Low-density lipoprotein cholesterol for the subjects before, during 
(after 6 sessions) and after 12 sessions of exercise. Data are means ± SEM and 
discussed in the text. The changes were insignificant statistically. 
 
5.6.3.2. High-density lipoprotein cholesterol (HDL) 
All study groups showed increase in HDL. Sample taken after six sessions showed a 
nominal rise in CSII group. However, after 12 sessions all three groups showed a 
significant rise in HDL (Figure 5.3). 
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Figure 5.3: HDL, High-density lipoprotein cholesterol for the subjects before, during 
(after 6 sessions) and after 12 sessions of exercise. Data are means ± SEM and 
discussed in the text. The changes were insignificant statistically. 
 
 
5.6.3.3. Total Cholesterol (TC) 
The total cholesterol (TC) for ND and CSII groups was significantly decreased after 12 
sessions of exercise compared to before exercise (P<0.01 and P=0.026 respectively). 
MDI showed a decrease in the level of TC but this was not significant after 12 sessions 
(Figure 5.4). 
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Figure 5.4: Total Cholesterol for the subjects before, during (after 6 sessions) and after 
12 sessions of training. Data are means ± SEM; P-value was for before exercise and 
after 12 sessions of exercise. *≤0.05, **≤0.01. and is discussed in the text.  
 
5.6.3.4. Triglyceride (TG) 
In CSII group a statistically significant decline in triglyceride was observed (P=0.03) 
with values falling from 1.10mmol/L to 0.78mmol/L (Figure 5.5).  
 
Figure 5.5: Triglyceride for the subjects before, during (after 6 sessions) and after 12 
sessions of training. Data are means ± SEM; P-value was for before and after exercise. * 
p-value (≤0.05) i.e. statistically significant was for before exercise and after 12 sessions 
of exercise and discussed in the text. The other changes were insignificant statistically. 
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5.6.4. Cholesterol ratio 
Further analyses were conducted to determine the cholesterol ratio including (TC/HDL, 
HDL/LDL and TG/HDL) and table 5.8 showing the normality of these ratios. 
Table 5.8: Cholesterol ratio levels 
 Preferable Ideally 
TC/HDL Under 5.0 Under 3.5 
HDL/LDL Over 0.3 Over 0.4 
TG/HDL Under 4 Under 2 
5.6.4.1. TC/HDL 
The total cholesterol/HDL ratio is a useful indicator of cardiovascular disease. All 
the study groups here had ideal TC/HDL ratios. Moreover the TC/HDL was 
decreased after 12 sessions of moderate exercise of cardio and resistance for each 
group. The lowest TC/HDL ratio was found in CSII group, followed by the ND 
group. The MDI group had the highest TC/HDL ratio; however it is below 3 
mmol/L (figure 5.6).  
 
Figure 5.6: Average total cholesterol to HDL ratio (TC/HDL). 
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5.6.4.2. HDL/LDL 
The HDL-cholesterol to LDL-cholesterol ratio (HDL/LDL) was well within the ideal 
range in all study groups, However, the HDL/LDL ratio was improved over the study 
(see figure 5.7) for each group. The Pump group and the ND group showed a slightly 
better response to exercise in this small study. 
 
Figure 5.7: Average HDL-cholesterol to LDL-cholesterol ratio (HDL/LDL). 
 
5.6.4.3. TG/HDL 
In the CSII group the triglyceride to HDL ratio (TG/HDL) was well within the 
medically accepted range. The MDI group had a higher ratio compared to ND and CSII 
groups and the CSII group had a lower profile than the ND throughout the timescale. 
However, after 12 sessions of moderate exercise all study groups (i.e. CSII, MDI, ND) 
showed improvement in their TG/HDL ratio, as depicted in figure 5.8  
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Figure 5.8: Average triglyceride to HDL- cholesterol ratio (TG/HDL). Please see the 
text for description and discussion. 
5.6.5. Effect of exercise on insulin doses 
The total amounts of insulin (basal and bolus) used as a mean for each diabetic group 
during the study are described in table 5.9. The bolus (unit/day) was approximately 
similar in both CSII and MDI in an exercise day and non-exercise day. The total amount 
of insulin units used was decreased in both groups for an exercise day. There is no 
significant difference between CSII and MDI it terms of carbohydrate to insulin ratio 
(table 5.9). However, the MDI cohort had a higher carbohydrate to insulin ratio 
compared to CSII. There were no events of hypoglycemia, hyperglycemia or DKA 
recorded during the exercise sessions for all study groups. 
Table 5.9: Daily insulin used by volunteers during the study Mean SD 
 
Exercise day 
Unit/day 
 
Non exercise 
day 
Unit/day 
 
Total insulin Carbohydrate to 
insulin ratio 
e.g. (10g of 
carbs/insulin units) 
Exercise 
day 
Unit/day 
 
Non 
exercise 
day 
Unit/day 
 
Basal Bolus Basal Bolus Before 
study  
After 
study  
CSII 
20.4 
 
9.5 
39.8   
18.2 
25.0   
11.5 
45.3   
12.3 
60.2         
26.9 
70.7         
20.1 
1.400.5 1.400.5 
MDI 
37.00    
12.1
2 
42.50      
24.7
5 
40.67      
9.02 
48.0      
25.4
6 
79.50      
35.13 
88.67      
36.69 
1.500.70 1.500.70 
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5.6.6. Blood glucose level 
The blood glucose (BG) was decreased at the end of each session for all groups as described for each group were described separately; 
figure 5.9 for ND, figure 5.10 for CSII and figure 5.11 for MDI).  
 
Figure 5.9: BG level for ND group before, after resistance and after cardio exercise. Data are means ± SEM; P-value was for before 
exercise vs after exercise and after resistance vs after exercise
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Figure 5.10: BG level for CSII group before, after resistance and after cardio exercise. Data are means ± SEM; P-value was for before 
exercise vs after exercise and after resistance vs after exercise. 
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Figure 5.11: BG level for MDI group before, after resistance and after cardio exercise. Data are means ± SEM; Data are means ± SEM; P-
value was for before exercise vs after exercise and after resistance vs after exercise.
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The A1c level was significantly decreased when compared before and after the 
completed exercise programme (types of exercise and the intensity) in both CSII and 
MDI groups (P=0.005 and P<0.001 respectively) (see figure 5.12). 
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Figure 5.12:A1c for MDI and CSII group before and after 12 sessions of training. Data 
are means ± SEM; P-value was for before and after exercise. **≤0.01, ***≤0.001. 
 
5.7. Discussion 
This study examined the effects of 12 sessions (6 weeks) of moderate intensity of 
aerobic (bike) and resistance exercise. This was a pilot study, in which the methodology 
and aims were devised in order to investigate not only the role and effects of exercise, 
but the responses of participants with alternative forms of insulin delivery. In much in 
vitro work, matching of conditions is relatively simple and even in vivo work with 
animal subjects the variables can be minimised in well recognised ways. T1D people, 
however, will differ in age, body weight, fat distribution as well as duration of disease, 
experience since diagnosis and the possibility of silent complications. There will be 
differences in their ability to control their blood glucose profile for a variety of reasons, 
*** 
** 
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including idiopathic, calorie utility-related, dietary and compliance. Whether pump 
users or not, their insulin dosage profile will be a variable in a study such as the one 
here, as will their eating habits (even if not their calorie totals) because serious 
interference with food intake and insulin habit would be clearly likely to have breached 
health and safety and ethics. Nevertheless, as demonstrated by good A1c readings, all 
the subjects who were diabetic in this study were well motivated in the maintenance of 
good BG control and of compliance with keeping to a similar diet the day before and 
during each study event. 
 
The percentage of male T1D volunteers within the age limit and criteria set in this study 
will be much less than 0.5% of the male population with pump users forming less than a 
tenth of these and it turns out that pump users are not particularly forthcoming. 
Therefore finding even 5 matched pump-user volunteers within a small geographical 
location was a challenge. Help with recruitment might have been better if we had 
secured NHS ethical approval and been able to enlist from hospital patient lists, but 
experience of the research group had shown that this was a long laborious process that 
was not acceptable due to the timescale of the project. In fact, all participants in the 
group had to be entirely voluntary anyway (for example, a hospital patient could never 
be unwillingly seconded) and so inevitably the study groups, diabetic and healthy 
counterparts, were self-selecting, having answered adverts. Healthy people will not have 
seen the advertisements in the same places as diabetic subjects and pump users will 
have seen adverts in web forums, for example, not used by anyone but a pump user. 
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The overall effect was that standardising the group had to be accepted as a possible 
limitation on the validity of the study. Future studies will address this to some extent by 
looking to obtain NHS approval, for example, in order to increase the numbers. 
Nevertheless, our inclusion and exclusion criteria found subjects who were not very 
dissimilar to one another except for one overweight (not obese) T1D MDI user. It is 
obvious from the literature that similar studies have also found recruitment hard and 
many have similarly small numbers e.g. Jenn, S. (2010), Peake (2006), Hirose (2004) 
and Pietro Glassett (2006). 
The metabolic effects were intended originally to have included an aerobic 
(cardiovascular) component and a resistance part that would be mainly anaerobic. For 
the reasons explained in chapter 1, the 50-60% intensity is likely to have constituted 
anaerobic exercise in the untrained, especially diabetic volunteers. However, the degree 
to which this was the case is an issue when comparing the untrained diabetic with the 
untrained healthy volunteers and so the resistance exercise has been termed as that and 
not specifically as anaerobic in this study. 
Given these limitations, the main findings of this investigation are as follow:  
 In table 5.2, BMI was not changed in MDI and ND groups whereas in CSII this 
was slightly decreased after 12 sessions. Nevertheless, the body fat percentages 
were slightly decreased as in MDI from 31.3 to 29.2, CSII from 26.9 to 25.08 
and ND 23 to 20.7. 
 The body fat percentage changed slightly in all study groups (table 5.2). MDI 
group had the highest body fat percentage (31.3%) then CSII (27%) and ND 
(23%). 
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 The exercise intensity (RPE) during resistance exercise (RE) for all groups was 
moderate to high (13-15.6) for the first two sessions which may explain the lack 
of weight lifting experiences and confidence. However, after couple of sessions 
the RE intensity back to the target (10.2-12.6); in MDI group the highest RPE 
number was given is 12.6 while CSII 11.8 and ND 11.7 (see table 5.3). 
Moreover, the RPE during cardio exercise was changed in all the groups; MDI 
from 13 to 11, CSII from 12.8 to 11.8 and ND from 13.7 to 11.3 (see table 5.4). 
 The ratio between the amount of consumed O2 and produced CO2 (Respiratory 
exchange ratio-RER) was measured to indicate which fuel (carbohydrate or fat) 
was being metabolised to supply the body with energy during the 20 minutes of 
cardio. As in table 5.4 the RER was used between 1.0 and 1.1. at the beginning 
of the study and this high level could explain that the volunteers were 
uncomfortable with the face mask. Williamson, Fuld et al. (2012) confirmed the 
validity of RER in aerobic exercise (Williamson, Fuld et al. 2012). Without any 
activities and with a light diet RER is about 0.8. However, during intense 
exercise RER value can exceed 1, as a result of greater production of CO2 by the 
working muscles and inhaled more of the O2 gets used rather than being 
expelled as shown in table 5.4. As Rubini, Paoli et al. (2012) reported a positive 
significant correlation between O2 uptake and carbon CO2 during exercise 
(Rubini, Paoli et al. 2012). 
 The lipid LDL was ≤2 mmol/L in CSII group before exercise sessions then 
reduced after 12 sessions to 1.5 mmol/L. However, MDI group has the lowest 
LDL level with 1.73 mmol/L then decreased to 1.59 mmol/L after 12 sessions. 
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ND group started with LDL level of 1.59 mmol/L then slightly decreased to 1.58 
mmol/L after 12 sessions (see figure 5.2).  
 The CSII group started this study with desirable cholesterol HDL 1.52 mmol/L 
then slightly increased 1.68 mmol/L. The MDI group started with HDL level 
1.37 mmol/L then improved (1.64 mmol/L) after 12 sessions. However, the ND 
group started this study with borderline high of HDL 1.30 mmol/L then after 12 
sessions of exercise become desirable (1.62 mmol/L) (see figure 5.3). 
 All study groups started with desirable TC level (<4.03 mmol/L) then after 12 
sessions decreased (<3.72 mmol/L). However, CSII group managed to reduce 
TC significantly after 12 sessions (from 4.03 mmol/L to 3.60 mmol/L) (see 
figure 5.4). 
 All study groups started this study with desirable TG level <1.47 mmol/L. The 
CSII group has the lowest level of TG (1.12 mmol/L) before exercise, then 
significantly reduced after 12 sessions (0.80 mmol/L) (see figure 5.5). 
 Cholesterol ratio for TC/HDL and HDL/LDL in all study groups was ideal 
(under 3.5 mmol/L and over 0.4 mmol/L respectively). The TG/HDL ratio for 
CSII and ND groups was well within the ideal range.  
 The MDI group used more insulin unites a day (basal and bolus) compared to 
CSII group. The total amount of insulin unites used daily was decreased in 
exercise day in MDI (from 88 units to 80 units) and CSII (from 70 units to 60 
units) groups (table 5.9). 
  Carbohydrate to insulin ratio were not changed before study and after for both 
CSII and MDI (table 5.9).  
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 In this study no hypoglycemia or significant hyperglycemia were recorded 
during any exercise sessions for any of the study groups. 
 The BG level was decreased after each session for all study groups. The BG 
level was mainly increased after resistance exercise each session for ND group 
and then decreased after cardio exercise (figure 5.9). In CSII (figure 5.10) and 
MDI (figure 5.11) groups the BG level was decreased after resistance and cardio 
exercises as they started with high BG level (8 mmol/L). 
 The A1c level was significantly decreased after 12 sessions in MDI and CSII 
groups.  
This study showed that CSII, MDI and ND groups have several benefits of this exercise 
programme.  
The exercise intensity was investigated in this study by the reliability of the session 
rating of perceived exertion (RPE) scale (6-12). Moderate intensity was associated to be 
from 11-14 of RPE scale and consisted of 3 sets of 10 repetitions at 55-65% 1RM. This 
result is supported by the ACSM guidelines and the reliable method to measure various 
intensities of RE exercise (Scherr, Wolfarth et al. 2013). 
The BMI was not significantly improved in all study groups. This result in line with 
Harris, Kumraoto et al (2009) in a meta-analysis concluded that the BMI was not 
improved with 6 months of  physical activity in schools (healthy children) (Harris, 
Kuramoto et al. 2009). Other study determining the effect of aerobic (40 min walk or 
run) versus resistance training on T1D for 12 weeks 3 times, BMI were not changed 
with either aerobic alone or resistance alone exercise (Ramalho, de Lourdes Lima et al. 
2006). However, in healthy people a moderate to high intensity aerobic exercise (60 
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min/day, 2 to 3 times/week) for 16 weeks resulted in a significantly decreased BMI 
(Yoshida, Ishikawa et al. 2010).  
A combination exercise programme of aerobic and resistance at moderate intensity for 
30 min, 5days/week for 12 weeks for overweight and obese adults was reported to 
produce a significant improvement of BMI, compared to aerobic alone which had no 
effects on BMI (Ho, Dhaliwal et al. 2012). However, a study by Church et al. (2010) for 
9 months of combination exercise observed a significant decrease in BMI compared to 
RE alone (Church, Blair et al. 2010). The use of insulin is the only therapy for T1D and 
this often results in weight gain (Hindmarsh, Peters et al. 2013). BMI is an indirect 
measure of body fat percentage body and lipid concentrations (Lamb, Ogden et al. 
2011). The mechanisms involved for the accumulation of fat with exogenous insulin are 
unclear and further investigations are warranted (Ho, Dhaliwal et al. 2012).  
Similarly, combination exercise for 12 weeks decreased but not significant the 
percentage of body fat as shown in Ho, Dhailwal et al (2012) study and many other 
studies like Healthy Lifestyle in Europe by Nutrition in Adolescences (HELENA) 
(Martinez-Gomez, Ruiz et al. 2010).The body fat percentage seems to reflect serum 
lipid concentrations in obese healthy (Choi, Pai et al. 2002). Lipids profile such as 
triglycerides is the main component of body fat in health people (Arrese and Soulages 
2010). Prabhakaran, Dowling et al. (1999) reporeted the effect of resistance exercise 
alon for 14 weeks on body fat percentege as well as lipid profile in healthy 
(Prabhakaran, Dowling et al. 1999). However, Laaksonen, Atalay et al. (2000) reported 
the improvement of lipids profile after 12- to 16-week (30-60 min, 3-5 times a week) 
aerobic exercise in young T1D but not the body fat percentage (Laaksonen, Atalay et al. 
2000). 
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The lipids profiles LDL and HDL are improved in this study in all study groups. Ho, 
Dhaliwal et al (2012) had also shown same result in their study after 12 weeks of 
training. The decrease of LDL and the increase of HDL in our study is associated with 
loss of BMI as reported in Guo study (Guo, Kawano et al. 2011). 
Improved glycemia control in T1D patients also improves plasma lipid profile (Feitosa, 
Feitosa-Filho et al. 2013). It has been suggested that the high dosage of insulin in T1D 
and poor glycemic control may lead to lower LDL; this may explain the low level of 
LDL in MDI group in this study (Feitosa, Feitosa-Filho et al. 2013). A1c in adult T1D 
has been significantly associated in change in lipids including LDL, HDL,TG and TC 
when dyslipidaemia disappeared medications (Maahs, Ogden et al. 2010).This study 
was comparing T1D with dyslipidaemia medication and without; the high A1c is 
associated with poor lipids control (TC, LDL, TG and non-HDL). In the present study, 
we also found the TC and TG were significantly low after 12 sessions (six weeks) of 
combined exercise in CSII groups. Triglycerides, TC, LDL and HDL were improved 
significantly in T1D after using CSII therapy (Weng, Li et al. ; Derosa, Maffioli et al. 
2009).  
Pro-inflammatory cytokines may play a role in lipid profiles. It has been shown that 
IFN-γ was positively associated with TC and LDL cholesterol in patients (Hocaoglu, 
Kural et al. 2012). IL-6 is involve in hepatic triglyceride secretion as well as lipoprotein 
lipase activity (Fernández-Real, Broch et al. 2000). TC and HDL was increased when 
TNF-α was blocked (Pollono, Lopez-Olivo et al. 2010). 
To predict heart disease risk TC/HDL and HDL/LDL ratios are used (Lemieux, 
Lamarche et al. 2001). In this study the TC/HDL ratio was already ideal in all the 
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participant groups. Results of this study demonstrate that the TC/HDL ratio was 
improved in all study groups over the 12 exercise sessions as in figure 5.6. This 
included the ND group and the reason is probably that the latter were not taking 
medication, whereas the diabetic participants often were. Consequently there were no 
very dramatic changes, but the so-called healthy group clearly also benefited in terms of 
slight but beneficial lipid ratio changes. 
Lowering the TG/HDL ratio in our study (figure 5.8) is supported by Nicholls (2011) 
study which explained the beneficial impact on progression of coronary atherosclerosis 
in diabetic patients (Nicholls, Tuzcu et al. 2011). Moreover the TG/HDL ratio predicts 
all-cause mortality in women with suspected myocardial ischemia (Bittner, Johnson et 
al. 2009). Plasma concentration of TG/HDL ratio might be a useful surrogate estimate 
of insulin action (Salazar, Carbajal et al. 2012). Moreover, circulating cholesterol and 
triglyceride levels are associated with vascular injury in T1D (Mäkinen, Soininen et al. 
2013). Lipoproteins are responsible for transporting lipids, and alterations in their 
subclass distributions may partly explain the increased mortality in individuals with 
T1D (Mäkinen, Soininen et al. 2013). 
Cholesterol metabolism seems to play a role in vascular health beyond serum lipids in 
T1D (Koponen, Hallikainen et al. 2011). This could related to the insulin role as a 
central player in the regulation of lipid metabolism (Vergès 2009). 
Abnormalities in lipid levels are observed in T1D patients with poorly controlled 
glycemia, (i.e. increased triglycerides and LDL cholesterol), or in micro- or macro 
albuminuria (i.e. with a background of increased triglycerides and LDL cholesterol, but 
decreased HDL cholesterol). However, T1D with good glycemia control show normal 
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or slightly decreased triglyceride and LDL-cholesterol levels and, sometimes, increased 
HDL-cholesterol levels. However, even with good glycaemic control in T1D, 
qualitative abnormalities of lipoproteins can sometimes be observed and abnormalities 
are not fully explained by hyperglycemic tendency. Peripheral hyperinsulinemia, 
associated with subcutaneous insulin administration (to deal with high blood glucose) 
has been implicated. The precise consequences and pathways of such qualitative lipid 
changes on the development of cardiovascular disease in T1D patients are, as yet, still 
unknown (Vergès 2009). 
In this study, T1D patients (MDI or CSII) tended to decrease their total insulin doses in 
an exercise day, so this differed from our survey.  De Mol, De Vries (2011) reported the 
decrease in insulin doses by 14.2% when T1D patients did aerobic exercise (de Mol, de 
Vries et al. 2011). In the meta-analysis by Kennedy, Nirantharakumar et al. (2013) the 
reduction of insulin doses around the time of exercise time was associated with 
decreased hypoglycemia after exercise (Kennedy, Nirantharakumar et al. 2013). 
Moreover in Hall, McDonald et at (2013) assessed the role of combination exercise 
(resistance and aerobic) for 3-6 weeks on insulin sensitivity in T1D,and their results 
suggested that this mixture of exercise may improve glucose tolerance, with each 
exercise type leading to differential improvements (ie decreased requirement) for 
exogenous insulin (Hall, McDonald et al. 2013).  
In one study, the reduction of basal insulin during exercise created a trend towards 
hyperglycemia in T1D with CSII therapy (Younk, Mikeladze et al. 2011). Yardley, 
Kenny et al. (2012)  reported that the combination of  resistance and aerobic exercise 
with T1D patient reduced the severity of post-exercise hypoglycemia and improved the 
glycemic stability throughout exercise for individuals with T1D when they performed 
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resistance exercise before aerobic exercise (Yardley, Kenny et al. 2012). Moreover, 
Yardley, Iscoe et al. (2013) concluded that the regular moderate-to-heavy exercise in 
T1D using CSII was more likely to limit post exercise hyperglycemia compared to MDI 
users and did not increase the risk of post-exercise late-onset hypoglycemia (Yardley, 
Iscoe et al. 2013). Hyperglycemia in T1D is most likely during high intensity exercise 
because of counterregulatory effects (Yardley, Kenny et al. 2012) whereas 
hypoglycemia can happen at rest after moderate intensity (McCrimmon 2011). 
Moreover, recently Davey, Howe et al. (2013) reported the moderate intensity increased 
the risk of hypoglycemia during exercise and several hours after (Davey, Howe et al. 
2013). Several factors have been associated with exercise-related hypoglycemia such as 
start exercise session with BG level below 5 mmol/L, insufficient carbohydrate intake 
increased duration of moderate-intensity exercise (McCrimmon 2011). 
In this study the BG level was commonly reduced after cardio exercise sessions but not 
at hypoglycemia level which is similar to Yardley, Iscoe et al. (2013) finding with MDI 
and CSII groups when they had similar reductions in glucose levels during moderate 
intensity exercise (Yardley, Iscoe et al. 2013). Moreover, Guelfi, Jones et al. (2005) 
concluded that the decline in BG levels is more with moderate-intensity exercise 
compared with intermittent high-intensity exercise in T1D (Guelfi, Jones et al. 2005). 
As shown in this study the aerobic exercise is a more likely cause of a decrease in BG 
level than resistance exercise and Yardley, Kenny et al. (2012) found similarly 
(Yardley, Kenny et al. 2012). Moreover, they recommend performing aerobic exercise 
after resistance exercise. This regimen will cause less of a decline in blood glucose 
during exercise in individuals with T1D than when exercise is performed in the opposite 
order. 
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This study concludes that A1c was significantly decreased in MDI and CSII groups 
after 12 sessions of resistance and aerobic exercise (figure 5.12). However, not all 
others have observed the same. In one study of T1D, exercise was largely unsuccessful 
in showing a benefit on A1c (Chimen, Kennedy et al. 2012) and we postulate that this 
could result from hyperglycemia immediately after exercise using inappropriate 
protocols such as the predominance of resistance exercise.   
Salem, AboElAsrar et al. (2010) reported that exercise improves glycemic control 
among T1D (Salem, AboElAsrar et al. 2010) in children with T1D. Regular physical 
activity has been recommended to control glycemia without increasing the risk for 
severe hypoglycemia (Herbst, Bachran et al. 2006). Physical activity has provided clear 
evidence of improved glycaemic control in T2D patients (Chimen, Kennedy et al. 
2012). In T1D the improvement of A1c leads to improve lipids profile (Maahs, Ogden 
et al. 2010) as shown in LDL for CSII group (figure 5.2), HDL in CSII and MDI groups 
(figure 5.3), TC for CSII and ND groups (figure 5.4) and triglyceride in CSII group 
(figure 5.5) and cholesterol ratios (figure 5.6-5.8) 
5.8. Conclusion 
 Physical activity at moderate intensity that includes a combination of aerobic 
and resistance training has provided clear evidence of improving glycaemic 
control. Others have found that reductions in A1c demonstrated the advantages 
of resistance exercise but not aerobic exercise in T1D (Yardley, Iscoe et al. 
2013). 
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 We found that performing resistance exercise before aerobic exercise is more 
beneficial because this may lead to less hypoglycemia during exercise in 
individuals with T1D.  
 For one individual who responded with hyperglycaemic levels post exercise, this 
improved over the six weeks. 
 The reduction in basal insulin rate before exercise was safe and effective in 
reducing hypoglycemia because doing so may attenuate the decline in glucose 
levels during subsequent aerobic exercise.  
 Aerobic exercise after resistance exercise seems to lead to lower reliance on 
glucose supplementation during exercise. In the ND group, this order of exercise 
was shown to increase the use of lipids as a fuel source during exercise.  
 The lipid profiles were improved for volunteers, including LDL, HDL, TC and 
TG plus the various ratios, but not the BMI or body fat. 
 Regular moderate physical activity should be recommended in patients with 
T1D. Resistance exercise should be programmed in before cardiovascular 
exercise. 
  
219 
 
Chapter 6: Epilogue 
 
6.1. General Discussion 
The overall objective of this thesis was to further the understanding of the effect of 
exercise on T1D patients who received insulin either via MDI or via CSII. This study 
was conducted by employing three groups of volunteers i.e. T1D using CSII, T1D using 
MDI and ND. 
Key observations from these studies are discussed in the following sections. 
I. The most important parameter evaluated in T1D patients using CSII was the 
A1c. It was observed that after using CSII the A1c level dropped as compared to 
before. Moreover, pump users concluded that they calculated their carbohydrates 
and following a diet, consumed more frequent meals, exercised frequently. 
Exercise was mainly aerobic (walking) at moderate to high intensity for 3 times 
weekly. Insulin pump users were asked if they regularly counted carbohydrates 
intakes and 99.4% participants answered that they did. CSII users had desirable 
lipid levels; ie total cholesterol, LDL cholesterol and HDL cholesterol (75%, 
68% and 65% respectively). They reported that the exercise decreased the BG 
level compared to before exercise. However, they very rarely had hypoglycemia 
events during exercise sessions and stated that hypoglycemia was not of 
particular concern to them as a barrier to exercise. The last point evaluated was 
part of their opinion of quality of life and treatments with a pump. Pump users 
reported that their daily life was much better than those on MDI therapies as 
CSII have more freedom from worry about daily injecting before meals and 
better control over their BG readings. Currently CSII is the closest choice 
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available to the physiologic method of insulin delivery, offering the possibility 
of more flexibility and more precise insulin delivery than MDI.  
II. One of the most important goals of this thesis was to determine the effects of 
combined exercise training; resistance exercise (resistance training ie weight 
lifting) and aerobic training (cycling exercises) on the immunological changes 
(IL-6, IL-1β, TNFα and INFγ) in patients with T1D using MDI or CSII and non-
diabetic. 
The effect of exercise on (IL-6, IL-1β, TNFα and INFγ) was divided into acute 
and chronic effects as described in chapter 4. The results of the immunological 
changes indicate the importance of the immune response and its occurrence of 
IL-6, IL-1β, TNFα and INFγ in T1D. Both studies show the strong association of 
these cytokines (IL-6, IL-1β, TNFα and INFγ) with T1D as autoimmune 
diabetes. This link between these cytokines as secreted by T-cells and 
macrophages, with the pathogenesis of T1D has been a focus in some recent 
studies. However, the relationship of combined exercise (resistance and aerobic) 
and plasma cytokines (IL-6, IL-1β, TNFα and INFγ) with T1D either MDI or 
CSII and non-diabetic has been explored for the first time in the current study.  
III. The other important goals of this study were to determine the effects of this 
exercise training on; BMI, body fat %, RPE, RER, lipid ratios, total amount of 
insulin (basal and bolus), BG and A1c changes in patients with T1D using MDI 
or CSII and non-diabetic. 
The BMI and body fat were not significantly affected by the 12 sessions 
(6weeks) of moderate intensity of aerobic and resistance exercise in both study 
groups. The Rated Perceived Exertion (RPE) decreased during cardio and 
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resistance through the exercise sessions in all groups. However, Respiratory 
exchange ratio (RER) was unchanged during cardio exercise in all groups. The 
LDL and HDL were not affected by this exercise programme while TC was 
significantly affected in the ND and CSII groups (increased and decreased 
respectively). The TG was decreased significantly only in the CSII group. The 
total amount of insulin was decreased on exercise days but not significantly in 
MDI and CSII. The BG level was mainly increased after resistance only in ND 
group and then back to normal or lower after cardio exercise. Cardio exercise 
was decreased the BG level in both MDI and CSII. The A1c was advantageously 
and significantly affected by the 12 sessions of resistance and cardio exercises. 
6.2. Recommendations 
The studies in this thesis highlight several directions for future research: 
1. The need to develop use of autoimmune markers (especially TNFα) for proper 
diagnosis in the screening of diabetes mellitus and to describe patients who will 
benefit from early insulin therapy and who may eventually benefit from specific 
immunotherapy.  
2. The need to determine if cytokine markers can be used as indicators for T1D 
progression and can be used to monitor the efficacy of therapy and in TID 
patients and in those who are at risk of developing T1D. 
3. The biology of cytokines needs to be investigated to improve our understanding 
in regulating autoimmune diabetes in humans and possibility of potential 
therapies involving cytokines, such as specific blockers. 
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4. The need to advise T1D patients to change to insulin pump therapy, as our 
results indicates that this is a major improvement over MDI, using lipid, glucose 
and immune markers as the criteria for assessment.  
5. Exercise should be one of the major tools of diabetes therapy since its 
effectiveness, as shown here, can be proved by objective metrics.  
6. This research using moderate intensity exercise (resistance and aerobic) has 
shown beneficial results following a single session in term of immunological  
and following six weeks of both exercise types in people with T1D.  
7. Where a combination is used, there is greater advantage if the resistance exercise 
comes first. 
8. Recommendations are needed to improve the education program for those 
treating T1D, especially by extending the use of insulin pumps, whether for 
children or adult. The restriction in the UK to their use mainly in children and in 
difficult to treat adults, as imposed by NICE is short-sighted. This research 
result can be used to guide this process because it is clear that exercise works 
synergistically with pump use to great advantage in T1D.  
6.4. Limitations 
There are some limitations with respect to this work that need to be considered: 
In this study there were limitations that were noted.  
 The main limitation was sample size. The target number of volunteer was to 
recruit 60 subjects: 20 T1D on MDI therapy, 20 non-diabetic and 20 T1D on 
insulin pump therapy. However, fewer were recruited in all groups and because 
pumpers were rarer, fewer still of these were found. The subjects who were 
recruited underwent tests to make sure that they were matched, safe and suitable 
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on the basis, for example, of background health and body measurements. Several 
were rejected in this process. Greater volunteer numbers and even sized groups 
would have improved the confidence in the comparison of the study groups (ND, 
MDI and CSII). On reflection, NHS ethical approval would have increased the 
pool of possible recruits and although NHS ethical approval can take more than a 
year, it would have been worth doing. 
 The tissue storage regulations limited this study in practical terms to frozen (-
80C) plasma and serum only and not for the blood cells. For this reason that we 
were not able to do the cellular assays like Peripheral Blood Mononuclear Cells 
(PBMCs). This, in addition to cytokine measurements, would have provided a 
more informative profiling of the cellular immune system such as monocytes and 
lymphocytes (T cells, B cells, and natural killer (NK) cells) to describe the 
diabetic status.  
 This study is the first to apply the immunological and metabolic parameter 
measurements to assess the response of pump users in comparison to MDI, to this 
combination of exercise. Thus there is no precedent available to compare and 
contrast the findings of this study and this did limit the discussion.  
 As mentioned previously a survey was conducted using a questionnaire with 
structured questions. It is a general practice to conduct a pilot study before the 
launch of the original survey but in this study this was not done here. During the 
development of the questionnaire advice was taken from health professionals and 
researchers especially statisticians with specialist knowledge of questionnaire 
design to make the questions simple and understandable.  It is a common practice 
to use triangulation i.e. multitude of methods are used to verify the results of the 
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study. Unfortunately, in this study the only scope for the triangulation was to 
compare the survey with the experiences of the exercise volunteers and with other 
studies in the literature. Every care was taken during the data analysis to use 
variety of statistical techniques to analyse the data and check the validity, 
consistency and significance of data. It is probably important to note that this 
study itself was a pilot for others planned, but the questionnaire results might well 
have been improved if a very small trial group had been recruited. An example is 
that the shortcomings of the lipid readings section might have been improved. 
6.5. Future work 
This study has raised number of additional questions and areas for future research.  
The observations on the effect of acute and 12 sessions of aerobic and resistance 
exercise on ND and T1D using CSII or MDI as insulin therapy indicate that the 
advantages of these exercise for T1D patients. It would therefore be interesting to 
investigate: 
 insulin sensitivity in both groups.  
 use of Peripheral Blood Mononuclear Cells (PBMCs), the immune system 
technical for blood cells which a critical component, such as monocytes and 
lymphocytes, with the lymphocyte population consisting of T cells, B cells, and 
natural killer (NK) cells. 
 the comparison of T2D using insulin with T1D for the same exercise 
programme and cytokines. Since pumps are being developed for T2D users, a 
further comparison might be incorporated. 
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 a focus on subjects from a single ethnic group of sufficiently large sample size 
such as Saudi Arabia or south Asia, since the diabetes problem may be different 
in ways this study could determine.  
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Appendix A 
List of insulins in the market 
The table highlights the various insulin types, their manufacturers, the insulin source and how it's available. It also highlights insulin ranges 
that have been discontinued. 
Insulin type Name of insulin Manufacturer Source Vial, cartridge or 
prefilled pen 
Rapid-acting 
analogue 
Humalog Lilly analogue vial & cartridge 
Humalog Lilly analogue prefilled pen 
Novorapid Novo Nordisk analogue vial 
Novorapid Penfill Novo Nordisk analogue cartridge 
Novorapid Novolet Novo Nordisk analogue prefilled pen 
          
Long-acting 
analogue 
Lantus Aventis analogue vial, cartridge & prefilled 
pen 
Levemir Novo Nordisk analogue cartridge 
    
Short-acting Human Actrapid Novo Nordisk human vial 
Actrapid Pen* Novo Nordisk human prefilled pen 
Actrapid Penfill* Novo Nordisk human cartridge 
Human Velosulin* Novo Nordisk human vial 
Pork Actrapid* Novo Nordisk pork vial 
Humaject S* Lilly human prefilled pen 
Humulin S Lilly human vial & cartridge 
Hypurin Bovine Neutral CP Pharmaceuticals beef vial & cartridge 
Hypurin Porcine Neutral CP Pharmaceuticals pork vial & cartridge 
Insuman Rapid Aventis Pharma human vial & cartridge 
Insuman Rapid Opti Set Aventis Pharma human prefilled pen 
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Medium &  
long-acting 
Humulin I Lilly human prefilled pen 
Humulin I Lilly human vial & cartridge 
Humulin Lente Lilly human vial 
Humulin ZN Lilly human vial 
Human Insulatard Novo Nordisk human vial 
Insulatard Penfill Novo Nordisk human cartridge 
Human Insulatard Pen* Novo Nordisk human prefilled pen 
Human Monotard* Novo Nordisk human vial 
Pork Insulatard* Novo Nordisk pork vial 
Human Ultratard* Novo Nordisk human vial 
Hypurin Bovine Isophane CP Pharmaceuticals beef vial & cartridge 
Hypurin Bovine Lente CP Pharmaceuticals beef vial 
Hypurin Bovine Protamine Zinc CP Pharmaceuticals beef vial 
Hypurin Porcine Isophane CP Pharmaceuticals pork vial & cartridge 
Insuman Basal Aventis Pharma human vial & cartridge 
Insuman Basal OptiSet Aventis Pharma human prefilled pen 
          
Analogue 
mixtures 
Humalog Mix25 Lilly analogue cartridge 
Humalog Mix25 Lilly analogue prefilled pen 
Humalog Mix50 Lilly analogue prefilled pen 
NovoMix 30 Novo Nordisk analogue prefilled pen & cartridge 
          
Mixtures Humaject M3 Lilly human prefilled pen 
Humulin M2 Lilly human cartridge 
Humulin M3 Lilly human vial & cartridge 
Humulin M5 Lilly human vial 
Human Mixtard 30** Novo Nordisk human vial 
Human Mixtard 50 Novo Nordisk human vial 
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Human Mixtard 10 Pen Novo Nordisk human prefilled pen 
Human Mixtard 20 Pen Novo Nordisk human prefilled pen 
Human Mixtard 30 Pen** Novo Nordisk human prefilled pen 
Human Mixtard 40 Pen Novo Nordisk human prefilled pen 
Human Mixtard 50 Pen Novo Nordisk human prefilled pen 
Mixtard 10 Penfill Novo Nordisk human cartridge 
Mixtard 20 Penfill Novo Nordisk human cartridge 
Mixtard 30 Penfill** Novo Nordisk human cartridge 
Mixtard 40 Penfill Novo Nordisk human cartridge 
Mixtard 50 Penfill Novo Nordisk human cartridge 
Pork Mixtard 30* Novo Nordisk pork vial 
Hypurin Porcine Isophane 30/70 
mix 
CP Pharmaceuticals pork vial & cartridge 
Insuman Comb 15 Aventis Pharma human vial & cartridge 
Insuman Comb 15 OptiSet Aventis Pharma human prefilled pen 
Insuman Comb 25 Aventis Pharma human vial & cartridge 
Insuman Comb 25 OptiSet Aventis Pharma human prefilled pen 
Insuman Comb 50 Aventis Pharma human vial & cartridge 
Insuman Comb 50 OptiSet Aventis Pharma human prefilled pen 
* Denotes that the insulin range is discontinued.  ** Mixtard 30 withdrawn on December 31, 2010. (Adapted from diabetes.co.uk) 
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Appendix B 
Comparisons of Current Insulin Pumps 
Links 
800#'s 
Animas 
(877) 
937-7867 
Accu-Chek 
(800) 
280-7801 
Medtronic 
(800) 
933-3322 
Insulet 
(781) 
457-5000 
Sooil US 
(866) 
747-6645 
Tandem Diabetes 
(877) 801-6901 
Model Ping 
 
Spirit® 
 
Paradigm Revel 
 
OmniPod 
 
DiabecareIIS 
 
t:slim 
 
Dim. [mm] 51 x 77 x 18 80 x 47 x 24 523: 50.8x76.2x20.3 
723: 50.8x91.4x20.3 
pod: 41x61x18 
pda: 66x110x26 
46 x 77 x 19 79.5 x 50.8 x 15.2 
Volume 5.525 ci 
90.54 cc 
    Pod: 2.7 ci 
PDA: 11.5 ci 
4.3 ci 
67 cc 
3.746 ci or 
61.38cc 
Weight 3.9 2.8, 4.8 523: 3.53 oz OP: 1.2 oz 1.9 oz 3.95oz. with full 
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[oz] with battfull cartridge 
inf set 
723: 3.81 oz (full res.) 
PDM: 4.0 oz 
(w/ batteries) 
reservoir 
Reservoir 
Size 
200u plastic 315u 523: 176 u 
723: 300 u 
200u 300u plastic 300u 
Connection Luer lock Luer lock Proprietary Built-in Proprietary Luer Lock 
Screen 
Size 
          60.198 
Colors blue, silver, black, pink, green Blue, with 30 pump 
skins in colors and 
styles 
blue, clear, pink, 
purple, smoke 
or customize 
white Black, Gray, Pink, Green, 
White 
Standard Black. 
Case available in 5 
colors: aztec 
black, midway 
silver, alpine 
white, pacific 
purple, roselle 
pink Black screen 
with blue, orange, 
red, grey text 
251 
 
Basal 
Increment 
0.025u 0.1u from 0.1 to 25.0 
u/hr 
0.025 u 0.05 u u/hr, up to 30 
u/hr 
0.1 u/hr or 0.01 u/hr 0.001 at 
programmed rates 
≥ 0.1 units/hr 
Total 
Basals 
12/day 24/day 48/day 48/day 24/day 16/day 
Basal 
Profiles 
4 5 3 7 1 6 
Basal 
Interval 
30 min 60 min 30 min 3 min 60 min 1 minute 
increments 
Basal 
Delivery 
varies, 0.2 u/hr every 3 mins every 3 mins varies, 0.6 u/hr = 
every 10 mins 
  every 4 mins Every 5 mins 
Temp 
Basal 
-90% to +200% in increments 
of 10% for 0.5 to 24 hours (30 
min increments) 
in 10% increments 
from 0% to 200%, and 
15 min to 24 hr 
+/- 0.1 u increment 
as single basal rate 
for 0.5 to 24 hrs or 
as % of current basal 
% or u/hr (1-12 hrs, 
in 30 min 
increments) 
10% increments from 0% to 
200% and up to 12 hours 
6 temporary basal 
rates. Duration 15 
minutes to 72 
hours. Increments 
of 1 minute. From 
0% to 250% of 
current basal (in 
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increments of 1%). 
Bolus 
Increments 
0.05 visual or audio, 0.1, 1.0, 
5.0 audio 
0.1, 0.2, 0.5, 1.0, 2.0 .025, 0.1 visual, 0.5 
or 1.0 visual or 
audio, remote extra 
0.05, 0.1, 0.5, 1.0u 0.1, .05, 1.0u 0.05 - 25 units 
Carb and 
Correction 
Factors 
yes, carb and BG values can 
be entered into the pump or 
meter-remote 
yes, manual carb, BG 
from Accu-Chek BG 
monitor 
yes, manual carb, 
BG direct from BD 
meter or manual 
entry 
yes Yes, manual carb Yes, manual carb 
Bolus Type units or carbs: standard, 
extended, combination 
quick, scroll, extended, 
multiwave 
units or carbs: 
standard, extended, 
combination 
Meal, correction, 
meal & correction; 
normal, extended, 
combination 
Normal, extended, 
combination 
units or carbs, 
normal, quick, 
extended 
1 u Bolus 
Duration 
1 or 3 sec 5 sec 30 sec 40 sec 12 sec ~ 30 sec 
Battery AA lithium or alkaline x 1 AA x 1 Alkaline or 
Rechargeable 
AAA for pump, A23 
for remote 
AAA x 2 (PDA) 1/2 AA 3.6v lithium Integrated 
rechargeble 
lithium polymer 
battery 
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Battery 
Life 
4-6 with lithium, 2-4 with 
alkaline 
4 week 3 weeks 4 weeks 8-10 weeks 7 days with a full 
charge 
Motor DC DC DC stepper DC Micro-Delivery 
Technology 
Memory non-volatile: 500 boluses, 270 
basals, 120 daily totals, 60 
alarms, 60 primes, 900 BG 
levels 
non-volatile: 90 days 
(4,500 events); history 
recall of last 30 
boluses, alerts, daily 
insulin totals, and 
temporary basal rate 
increases 
4000 events, volatile 
(basal & history loss 
can occur): 24 
boluses, 7 day totals 
90 days of data (up 
to 5400 records) 
Last 500 boluses, primes and 
daily totals. Last 100 alarms 
(all time and date stamped) 
Up to 90 days 
(11,000 events) 
Software 
Download 
ezManager Max, downloads in 
3 minutes with dongle and 
software that is available at 
Animas 
Pocket Compass with 
Bolus Calculator , 
insulin pump 
configuration software, 
IR Communication 
Port 
Medtronic 
CareLink® Therapy 
Management System 
and ParadigmPAL™ 
3.0 Software at 
Medtronic 
Omnipod Extension 
for the CoPilot 
Health Management 
System 
none t:connect Diabetes 
Management 
Application; Mac 
and PC 
compatible, Micro 
USB download of 
t:slim Pump and 
supported BG 
meters 
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Water? 12 ft for 24 hrs IPX 8, 60 minutes at 
2.5 meters 
splash resistant watertight Watertight IPX7 Rating. 
Watertight - tested 
at 3 feet for 30 
minutes. 
Extra 
Features 
Meter-remote offers wireless 
bolus calculation and delivery 
within 10 ft. ezCarb software 
stores up to 500 food items 
from Calorie King database on 
the meter-remote. Calculator 
features for carbohydrates, 
blood glucose corrections and 
insulin; reminders for time of 
day and when to perform 
blood glucose checks. Pump 
and meter-remote are available 
in Spanish. PC and Mac 
downloads are available with 
ezManager Max software 
choice of standard, 
advanced or custom 
selectable user menus, 
icon- and menu-driven 
programming, backlit 
display, reversible 
display screen, 12 
languages, audible or 
vibrating bolus 
confirmation and alerts. 
  
Enhanced CGM 
Feature, Predictive 
Alerts, Low and 
High Alerts, Rate of 
Change Alerts, 
REAL-Time Trend 
Graphs 
backlight, reminders 
& alerts, child lock, 
integrated Freestyle 
meter, 1000 
common foods in 
PDA, Tubeless 
Carb Counting Program, 
Auto Dose capability, Bolus 
frequency restrictions, preset 
meal and default bolus. 
PIN# programming and 
access to functions including 
daily maximums and mode 
settings for healthcare 
professions / caregivers. 
Backlight, icon menu. Auto 
display of remaining insulin 
and remaining battery life. 
Lock-out feature with PIN 
unlock. Twelve languages 
Only touch screen 
insulin pump in 
the US 
Guarantee 4 years 4 years 4 years 4 years 4 years 4 years 
Adapted from: diabetesnet.com 
  
255 
 
Appendix C 
It is a pleasure to accept your revised manuscript entitled "Insulin pump users would not rule out using an 
implantable artificial pancreas: experiences of diabetes self-management by insulin pump users and their 
attitudes toward a non-electronic implantable closed loop insulin pump (INSmart)" in its current form for 
publication in Practical Diabetes. 
Thank you for your contribution. 
Sincerely, 
Dr. Rustam Rea 
Co-Editor, Practical Diabetes 
rustam.rea@nhs.net 
 
Insulin pump users would not rule out using an implantable artificial pancreas: experiences of diabetes self-
management by insulin pump users and their attitudes toward a non-electronic implantable closed loop insulin 
pump (INSmart) 
M. J. Taylora, R. Gregoryb, H. Mitchellc, M. Alblihedd, A. Alsabihe, P. Tomlinsa, T.S. Sahotaa  
ABSTRACT 
Aim: To establish the limitations of open loop continuous subcutaneous insulin infusion (CSII) as perceived by 
current users of the technology, and to ascertain their interest in and requirements for a non-electronic implantable 
closed loop insulin pump, INSmart, currently under development for the treatment of type 1 diabetes. INSmart has 
been surgically implanted in the peritoneum in animal models and continuously restored normoglycemia. 
Methods: A bottom-up survey design was used to determine both positive and negative experiences of patients 
currently using CSII to define the performance characteristics they would require from a non-electronic, implantable 
closed loop insulin pump. 
Results: 360 insulin pump users completed the survey. All respondents had type 1 diabetes, were predominately from 
English-speaking countries and had been diagnosed before age 34 years. Most had well controlled blood glucose (BG) 
according to their self-reported HbA1c results. They reported a reduction in this value after transferring to CSII from 
multi-dose injections. However, 70% of pump users had more than three hypoglycaemic episodes per week. 80% 
reported self-measured BG values above 10 mmol/L three or more times per month. 94% respondents considered a 
(non-electronic implantable) closed loop insulin pump would make their BG management easier and improve their 
quality of life.  
Conclusions: The majority of respondents felt there were still many disadvantages to current external insulin pumps 
such as their constant visible presence, rotation of insertion sites and skin inflammation. These shortfalls could be 
overcome by a device, such as INSmart that provides a relatively instant feedback mechanism for controlling insulin 
release due to its proposed location in the peritoneal cavity. Running Head: Attitudes Toward a Non-electronic 
Implantable Closed Loop Insulin Pump (INSmart) 
a
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LE1 9BH, United Kingdom. 
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Department of 
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Introduction 
Successful glycaemia management in diabetes requires 
mean blood glucose (BG) concentrations that result in 
glycated haemoglobin (HbA1c) values close to the 
normal range, while avoiding hypoglycaemia. 
Although of proven efficacy, it is difficult to achieve 
this chronically using multi-dose insulin injections or 
open-loop continuous subcutaneous insulin infusion 
(CSII), as evaluated in the Diabetes Control and 
Complications Trial (DCCT) [1,2] for patients with 
type 1 diabetes. 
The attraction of a closed loop insulin delivery system 
which can maintain normoglycaemia is obvious to 
both patients and health care services that have to deal 
with the costs of poor diabetes control around the 
world. [3]. In order to produce an effective closed loop 
system, insulin needs to be released and metabolised 
over an appropriate time scale to minimise fluctuations 
in BG levels. Several methods for accomplishing 
closed loop control have been developed in both 
human and animal models [4-6] but the “perfect” 
artificial pancreas remains elusive [7,8], because of 
limitations in one or more of the contributory 
components of a closed loop system, namely delivery 
devices and sensors. 
External insulin pumps or CSII are driven by 
mechanical force and provide a continuous infusion of 
a short-acting insulin delivered from a soft cannula 
under the skin. The major drawbacks to this therapy 
however, are primarily the slow absorption of insulin 
into the plasma, the need to re-site subcutaneous 
cannulas every 48 hours in order to minimise the risk 
of tube blockages and skin infection at the insertion 
sites. These contribute to delays and failures in 
response and have contributed to the difficulty in 
converting a CSII system to a closed loop system. 
Similarly, subcutaneous glucose sensors which have 
become part of some integrated CSII systems rely on 
the difference between subcutaneous glucose and BG 
being proportional to the rate of change taking place in 
BG [9], this time lag limits the sensitivity of 
continuous glucose monitors to detect hypoglycaemia; 
algorithms can be produced to mitigate this where 
there are sufficient data from sequential readings to 
give the BG/time gradient. 
Intraperitoneal insulin infusion offers a more 
physiological route for insulin delivery devices, 
producing greater porto-systemic and hepatic insulin 
gradients, and controls hepatic glucose metabolism 
more efficiently. Recent research [10, 11] in our 
laboratory has focused on producing an implantable 
insulin delivery device (INSmart) which would deliver 
insulin to the peritoneum in an automated fashion 
linked to changing glucose levels (Fig. 1a & b). 
INSmart delivers insulin via a glucose-sensitive gel 
which acts as both a sensor and controller of the 
amount of insulin released (Fig. 1c). The glucose-
sensitive gel comprises polymerised derivatives of 
dextran and a glucose-sensitive lectin, concanavalin A. 
The highly viscous gel that forms due to the 
equilibrium binding between the dextran and the lectin 
binding sites impedes insulin release. These changes in 
the presence of glucose as the binding sites are 
disrupted resulting in a reduction in the viscosity of the 
gel that facilitates insulin release. This process is both 
reversible and repeatable, being sensitive to the 
changes in glucose levels that occur in the peritoneal 
cavity. The gel layer is therefore both the sensor and 
the delivery port in this design and contains no 
electronics or moving parts. The benefits of an 
INSmart device for the treatment of diabetes are that it 
could provide automated control preventing 
hypoglycaemia and also the long term harm from 
hyperglycaemia. However the associated risks from an 
implantable device could arise from surgery, leakage 
of the insulin reservoir and infection. 
A prototype design was used to demonstrate the 
feasibility of this novel approach by restoring 
normoglycaemia in diabetic rats [12] and pigs [13] for 
up to 5 weeks but would require some redesign to 
provide it with biocompatibility, reliability and 
security to be optimal for clinical use. In designing a 
clinically-testable prototype it is important to take 
account of the views of prospective users of such a 
device. To gain insight from the potential users' 
perspective about the characteristics that they would 
expect of such a device it was decided to conduct a 
survey of current users of CSII.   
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2. Method 
We surveyed CSII users to determine their current 
approach to glucose management, their appreciation of 
its importance and to understand the practical 
difficulties of achieving desired control with their 
current pump therapy. Questions were multiple choice 
or open ended and addressed BG management, basal 
and bolus delivery, diet, hypo- and hyperglycaemia as 
well as short and long term insulin pump management. 
We also wanted to know what they thought about the 
concept of a surgically implantable pump such as 
INSmart, if it could bring the advantage of closed loop 
functionality. A closed loop INSmart device or 
‘artificial pancreas’ could present an alternative to 
pancreatic or islet transplants, and to electronic-sensor 
controlled pumps, assuming biocompatibility, 
predictability and security can be assured. 
Survey Design, distribution and response collection  
An international survey of patients with diabetes 
currently using CSII was carried out. This was aimed 
at gauging their opinions of whether a closed loop 
implantable insulin pump was an attractive 
proposition, the premise being that since this group of 
patients already managed their diabetes in a partly 
automated way, they might offer unique insights about 
the concept.   
The questionnaires were produced in English and 
distributed to insulin pump users through various 
channels. Advertisements were placed in various local 
and national media (such as newspapers) within the 
UK, and in publications from various diabetes charities 
such as Diabetes UK. An interactive web-based 
version of the survey (Survey Monkey®) was also 
available via a dedicated website for participants who 
wanted to submit responses via the internet. The UK 
Diabetes Network and 'Pumpers' also distributed 
copies to members on their databases. Finally we used 
social networking sites such Twitter® and Facebook® 
to publicise the survey. 
Participants answered 56 questions which were either 
multiple choice or open ended, relating to their 
background, the insulin pump brand being used, the 
type of insulin used in the pump, basal and bolus 
doses, infusion set, insertion sites, the current quality 
of glycaemic control as evidenced by self-reported 
Hb1Ac concentration and the frequency and severity 
of hypo- and hyperglycaemic events, and self-reported 
diabetes complications. Specifically they were asked 
about the practical difficulties they experienced with 
CSII in achieving their glucose targets. Finally they 
were asked to respond to a description of the 
implantable closed loop insulin pump, INSmart. 
Analysis of responses 
The responses from Survey Monkey® were 
downloaded in Microsoft Excel® and then coded 
before inputting into SPSS®. All postal responses 
were entered manually using the same coding directly 
into SPSS®. 
 3. Results  
Pump users current approach to glucose management 
360 completed surveys were received and analysed. 
30.4% of responses were from the United Kingdom, 
which is predominantly where the survey was widely 
distributed and advertised. Many responses were also 
collected from the US (39.9%), Canada (2.8%) and 
0.35% of the total responses each from Australia, 
France, India, Israel and Switzerland, however 25% of 
respondents did not disclose which country they lived 
in. About 88% of the survey respondents were below 
the age of 34 at diagnosis of diabetes. 36.4% were 
between the age of 0-11 years, 27.5% between the ages 
12-21, and 24.4% between 22-34 years of age and are 
thus likely to have type 1 diabetes [14]. All responses 
collected from respondents under the age of 17 were 
completed by their parents. 
Fig. 2a shows the most commonly used pump was the 
Medtronic Paradigm® device (57.6%) and 
Novorapid® (insulin Aspart) and Humalog® (insulin 
lispro) were the insulins most commonly infused (Fig. 
2b). Respondents were asked whether the pump they 
used was chosen by them, or had been given to them 
by their medical advisors. As 44% had been given the 
pump by their medical advisors this suggests that the 
choice was made by diabetes physicians and/or 
Diabetes Specialist Nurses rather than patient choice. 
When insulin pump users were asked about the amount 
of insulin they infused over a 24 hour period 50.6% 
used 20-40 Units, 24.4% used 40-60 Units and 12.7% 
have used more than 60 Units. Most (57.3%) reported 
infusing a basal rate of 0.5-1 Units/hr, with 20.3% 
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using 1-2 Units/hr and 18.4% using 0.5 Units/hr. Only 
3.2% of respondents infused a basal rate of more than 
2 Units/hr.  
Most respondents (52.2%) used the standard or 'spike' 
bolus to cover meals.  
The majority of respondents (65.7%) had a HbA1c 
value between 42-64 mmol/mol (6.0-8.0%), a broadly 
acceptable range [1,15]. 13.9% had HbA1c values 
between 32–42 mmol/mol (5.1%-6.0%), indicative of 
overly tight control, associated with a significant risk 
of hypoglycaemia. 2.8% had HbA1c values above 
76mmol/mol (9.1%) and 0.3% had values above 
86mmol/mol (10%) which indicates very poor glucose 
control. 77.8% people could recall their HbA1c result 
before starting CSII; 57.3% reported that it had 
improved subsequently. 
About 70% of the respondents reported having a 
hypoglycaemic episode at least once a week. In most 
cases (39.9%) respondents were able to sense that they 
were hypoglycaemic and 51.6% of these respondents 
confirmed that this occurred at BG below 4 mmol/L. 
79.4% respondents reported BG values above 10 
mmol/L more than three times in the month preceding 
the survey, and most (68.7%) claimed that they would 
respond by taking a correction bolus straightaway. 
However, 9.8% reacted to elevated BG by waiting 60-
90 minutes before re-testing their BG and 10.1% by 
drinking water. Some respondents would change their 
infusion set, in case it had become blocked.  
Pump users' reactions to a description of an 
implantable closed loop pump (INSmart) 
Fig. 3 summarises the responses from an open question 
asking the respondents what they thought about closed 
loop insulin delivery from a device like INSmart, 
which removes the necessity to adjust insulin in 
response to changes in BG but possibly not to 
eliminate entirely the need for routine BG tests. Over 
90% of respondents were in favour of closed loop 
insulin delivery and gave reasons for these views. 
31.5% of respondents thought that having a closed 
loop system would provide them with better BG 
control than their current insulin pump treatment, in 
particular 10% of the respondents thought that a closed 
loop system would offer the best possible chance of 
achieving glycaemic control in the non-diabetic range. 
The majority of respondents felt there were still many 
disadvantages to current external insulin pumps such 
as their constant visible presence, rotation of insertion 
sites, cannula site irritation/infection and skin 
inflammation. The concept of a so-called artificial 
pancreas is widely acknowledged by interested parties 
as the “holy grail” in insulin delivery and BG 
management and although only 10% of respondents 
actually selected this answer, many of the other 
responses encompassed elements of the concept. Other 
common responses included: ‘it would fit into their 
lifestyle more easily’ suggesting that they would be 
able to forget about the constant vigilance required 
from BG testing and insulin administration. ‘It would 
be accurate, safe and sensitive’ which highlights that 
most people with diabetes still have issues relating to 
BG control as well as safety. 
Only 4% of respondents did not think that closed loop 
delivery would be an attractive proposition. The main 
concern from these responses related to a possible 
failure of the device indicating that they would not feel 
safe or comfortable allowing a device to deliver their 
insulin automatically. Other responses included 
concerns that the device would not allow the user to 
make their own adjustments and that they would 
constantly worry that the device would fail. A more 
obvious reason for not finding this type of device 
attractive for respondents was they would find the 
insertion surgery invasive and undesirable. These 
responses suggest insulin pump users tend to be well 
adapted to the demands of running a pump safely and 
effectively and it is not surprising that they would 
identify not only the advantages, but also the potential 
disadvantages and hazards of an implantable closed 
loop system. 
Table 1 shows the positive responses to a question 
where respondents were asked if what their opinions 
would be regarding a closed loop insulin pump that 
needed to be implanted under the skin. It can be seen 
that the main concerns to an implantable closed loop 
delivery device relate to the surgery and the refilling of 
the insulin in such a device. The main negative 
responses to an implantable insulin pump related to 
concerns about the surgery itself and possible resulting 
infection, as well as device safety, the concept of an 
implanted device and the impact on others including 
children.  
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Fig. 4 shows the general preference for refilling an 
implantable insulin pump, such as INSmart, was 
weekly (40.5%). This was a deliberately open ended 
question and the reason most respondents opted for 
this preference was that they felt this would allow 
them to remember to refill the reservoir on a set time 
every week.  
4. Discussion  
The bottom-up survey was designed to gain an 
understanding of insulin pump therapy together with 
users’ experiences of their condition and treating it 
with infused insulin. This was aimed at gauging their 
opinions of whether a closed loop implantable insulin 
pump was an attractive proposition, the premise being 
that since they already manage their diabetes in a 
partly automated way, they might be particularly 
perceptive about the prospect in ways not obvious to 
others. 
Many of the background responses implied that pump 
users were all type 1 and that they had been diagnosed 
early in life. The majority of the respondents were 
from the UK and North America. The lack of 
responses from France may have been as a result of the 
survey being written in English as Sulmot et al. [16] 
have reported that insulin pump use in the country, 
especially for children and adolescents with type 1 
diabetes, increased 10 fold between 2001 and 2007. A 
higher proportion of patients with type 1 diabetes in 
the US use pumps compared with UK residents and 
these are funded by the medical insurance companies. 
In the UK, the criteria for pump use are somewhat 
different and depend more on the local Commissioners 
implementing NICE guidelines [17] for pump use. 
Clear choices emerged for the pump brand and the 
insulin type. Bartalo et al. [18] has shown that there are 
no pharmacokinetic or pharmacodynamic differences 
in the absorption profiles of insulin lispro and aspart 
and conclude that the use of short acting insulin in 
CSII therapy provides a small but statistically 
significant improvement in glycaemic control 
compared with regular insulin. Glycemic control was 
also dependent on the infusion line and has been 
shown to deteriorate after 48 hours of use leading to an 
incremental loss of glycemic control [19]. 
In this survey, quantities of insulin used per day and 
the dose rate used were variable but within expected 
ranges. In general terms, pump users are reported to 
need about 80% of the dose given to type 1 people by 
injection, and this relates to the efficiency of 
converting long acting insulins to diffusible insulin 
that can reach the plasma. Basal insulin needs were 
found to be below 1Units/hr for most of the 
respondents. Insulin requirements are believed to 
increase during the night and early morning (dawn 
phenomenon) due to a decrease in insulin sensitivity 
caused by cortisol and growth hormone secretion. 
Basal insulin requirement begins peaking in juveniles 
(<20 years) before midnight and maintains a relative 
high throughout the night [20], drops in the morning 
and increases again from noon to midnight. Basal 
needs for adults (> 20 years) show a more abrupt peak 
in the morning followed by a drop off until noon and 
gradually increasing in the evening. Basal rates thus 
require fine tuning by those on insulin pump therapy.  
The bolus pattern, although subject to variation 
depending on the circumstance, tended towards the 
standard spike bolus for the respondents in this survey. 
A spike bolus delivers the incremented dose of insulin 
in a short time similar to a subcutaneous injection and 
as most insulin pump users were well versed in 
judging their insulin input in response to their meals, 
this method gave adequate blood glucose control. An 
extended square wave bolus used by 5.1% of 
respondents, delivers a larger dose of insulin spread 
over a longer period of time such as an hour or two and 
useful when eating foods high in protein. The delay in 
the delivery of carbohydrates from the digestive 
system when eating and digesting protein can approach 
the insulin duration-of-action, so in these cases the 
blood glucose level is better controlled by a slow 
extended release of insulin that matches the profile of 
carbohydrates entering the bloodstream. 24.4% of 
respondents used a combination bolus (standard + 
extended), as often one method of bolusing does not fit 
the elevated blood glucose levels from the different 
types of carbohydrates present in their meal. This 
provides a large initial dose of insulin, and extends the 
tail of the insulin action. It is appropriate for high 
carbohydrate and high fat meals such as pizza and 
chocolate cake. 
A super bolus (1.6% respondents) considers the basal 
rate delivery of insulin following the bolus as part of 
the bolus and can be borrowed ahead and given 
together with the bolus. This type of bolus is often 
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used to prevent hypoglycaemia. Cukierman-Yaffe et 
al. [21] has reported that there is a significant 
relationship between glycaemia indices and the use of 
a bolus calculator (a feature is several insulin pumps). 
Diabetes patients that used the bolus calculator in 50% 
of their boluses had a lower HbA1c and mean BG 
value suggesting better glucose control. 
Most responders had very well controlled glucose as 
described by their HbA1c and reported an 
improvement after transferring from MDI. However, 
70% had more than three hypos per week. Frequent 
troublesome hypoglycaemia with MDI is an indication 
for CSII and we did not ask whether this frequency had 
reduced since starting CSII. However, 90% of pump 
users said they could detect an oncoming hypo and 
that, for them, it became a problem only if the BG 
dropped below 4 mmol/L. 
Continuous glucose monitoring (CGM) using a 
Guardian sensor® has been shown to improve HbA1c 
values over a 12 week period and lower the incidence 
of hypoglycaemia compared with self-monitoring of 
BG in CSII users [22, 23]. There was, however, a high 
incidence of drop outs for CGM due to patient 
discomfort. These findings are similar to those 
reported by a Juvenile Diabetes Research Foundation 
trial [24] which also found a significant improvement 
in HbA1c of young diabetes patients who used a 
sensor, although they did not find an alteration in the 
incidence of hypoglycaemic events.  
By contrast, 80% of respondents had BGs above 10 
mmol/L three or more times per month and their 
remedy was either to give an additional bolus (70%) or 
watch and wait (10%) or drink water (10%). While 10 
mmol/L is the upper limit of normal BG levels, this 
may in practice indicate that levels are much higher. 
Together this information about glucose control 
reveals that although convenient, pump therapy might 
be less effective than reported, although not 
necessarily less effective than MDI therapy. It may be 
that an anonymised survey elicits information that 
differs from other sources for a variety of reasons that 
relate to surveys in general as well as to diabetes. It 
also implies that despite being on a reliably constant 
basal dose of insulin and with boosts conveniently 
selected for delivery to a tailored pattern coupled with 
features such as electronic memory and safety lockout 
features, respondents were commonly above the target 
BG range. An increase in BG with CSII may result 
from an occlusion of the infusion line or cannula, 
although more commonly problems arise from human 
error, for example inaccurate carbohydrate estimation, 
inaccurate insulin carbohydrate ratios, insulin 
sensitivity factors as well as lifestyle factors such as 
exercise and stress. Whether the post prandial BG peak 
would be detected would depend on the user testing at 
the relevant times. 
The positive attitude towards an artificial pancreas 
such as INSmart focused on the control of BG and user 
independence as well as improved quality of life. 
Negative responses were perceptions about relying on 
an automated system that could possibly fail or not be 
reliable. The concept of an implantable device rather 
than an external (and therefore easily-removable) 
pump was clearly worrying to some. There were 
comments about the need for comfort, the safety of 
implantation and maintenance including refill which 
would all need to be demonstrated for an INSmart type 
device to secure approval from the Medical Devices 
Directive in the UK [25] (FDA in the US).  
The behaviour, attitude and use of existing external 
pump users from the open ended questions from this 
survey provided some useful feedback toward a 
redesign of the existing device which has now 
successfully been implanted into diabetic pigs. It is 
apparent that current external pumps have 
shortcomings which an implantable INSmart device 
could overcome: 
•Automated delivery of insulin to real time changing 
glucose levels by the fast uptake of glucose in the 
peritoneum 
•No changing of infusion lines, rotation of sites and 
not visible  
•No moving parts or electronic power requirements  
•No need to regularly check BG levels 
•No need to bolus for mealtimes 
However, an implantable INSmart device would still 
need to overcome risks such as leakage of insulin or 
smart gel, infection and surgery. 
5. Conclusion 
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The general consensus from the survey was that most 
respondents felt that an implantable artificial pancreas 
would be a close match to a functioning healthy 
pancreas and therefore appealing. The vast majority of 
respondents felt that there are many disadvantages to 
using current external insulin pumps such as its 
constant visible presence, rotation of insertion sites and 
skin inflammation, the need for frequent BG testing 
and adjustment of insulin flow in the absence of 
feedback from a sub-cutaneous implanted sensor. 
These shortfalls could be overcome by a device, such 
as INSmart that provides a relatively instant feedback 
mechanism for controlling insulin release due to its 
location in the peritoneal cavity. Its performance 
would be a much closer match to a fully functioning 
healthy pancreas and therefore very appealing to the 
pump users surveyed. The key requirements of an 
INSmart like device identified by the survey are that it 
needs to be comfortable to ‘wear’, safe and reliable 
and easily refilled on a weekly basis.  
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Figure 3Perceptions of the acceptability of the implantable artificial pancreas 
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 Insulin pump users thoughts about the concept of a closed loop 
insulin pump implanted under the skin 
 
% 
Positive responses 
Would make feel like a happy, relaxed normal person 1.8 
To control my blood sugar better 14.5 
Children would prefer this 0.9 
Only if it was comfortable, effective and made me feel better 13.1 
It has some advantages over current pump 3.2 
Having it implanted would not bother me as long as it was provided to 
others 
3.2 
If it sensed BG better and was available free 1.8 
It would be better because I wouldn’t need to be remove for exercising 
and swimming  
3.2 
Only if it is not dangerous (infection, re-fill, size, painful, rejected)  21.3 
It may improve my quality of life (less stress, noticeable) 12.2 
Negatives responses 
Only if it was small in size 4.5 
It would depends surgery to implant it 4.5 
Only if there is no catheter and no scar tissue 4.1 
It scares me 2.3 
Only if it was easier to manage 2.3 
I would be willing to try 1.4 
I couldn’t trust it 2.2 
I need more information 5.4 
 Table 1: Insulin pump users thoughts about the concept of a closed loop insulin pump 
implanted under the skin (numbers in column denote the percentage of respondents) 
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 Your answers will be treated as strictly confidential  
 Please tick (✓) appropriate box.  
Section A: About you 
Q1. Are you? 
1-  Female 
2-  Male 
Q2. How would you best describe your occupation? 
1-  Professional  
2-  Skilled 
3-  Semi- skilled 
4- Manual labour 
5-  Student 
6-  Retired 
7-  Others 
Q3. How old are you? 
1-  Between 1-10 years 
2-  Between 11-20 years 
3-  Between 21-30 years 
4-  Between 31-40 years 
5-  Between 41-50 years 
6-  Between 51-60 years 
7-  Between 61-80 years 
8-  Over 80 years 
Q4. How old were you when your diabetes was first diagnosed? 
1-  Between 1-10 years 
2-  Between 11-20 years 
3-  Between 21-30 years 
4-  Between 31-40 years 
5-  Between 41-50 years 
6-  Between 51-60 years 
7-  Between 61-80 years 
8-  Over 80 years 
 
Q5. What is your highest level of education?  
1-  PhD 
2-  Master degree 
3- Bachelor 
4-  You are still in full time education under bachelor 
5-  You have not had any formal education 
6-  Other, please specify …………………………….. 
Q6. What is your ethnic group? (Please tick one box from section A to E) 
a. WHITE 
1.  British 
 2.  Irish 
3.  Any other White background (Please write in……………………) 
b. MIXED 
         4.  White and Black Caribbean 
5.   White and Black African 
6.   White and Asian 
7.   Any other mixed background (Please write in…………………) 
c. ASIAN OR ASIAN BRITISH 
8.  Indian 
9.  Pakistani 
10.  Bangladeshi 
11.  Any other Asian background (Please write here ……………..) 
d. BLACK OR BLACK BRITISH 
12.  Caribbean 
13.  African 
14.  Any other Black background (Please write in………………….) 
e. CHINESE OR OTHER ETHNIC GROUP 
15.  Chinese 
16.  Any other ethnic group (Please write in………………………….) 
Q7. Which country do you live in?  
1.The UK 2.US 3.Australia 4.Canada 5.Israel 
6.India 7.Switzerland 8.France 9.Saudi 10.Other 
Q8.If you are from the UK, what is your approximate income before tax (UK£)?    
1- Unemployed 
2- 0-10,000 
3- 10,000-20,000 
4- 20,000 – 30,000 
5-  30.000- 40.000 
6- 40,000- 50.000 
7-  50.000-100.000 
8- Over  100,000 
Section B: about your diabetes 
Q9. How was your diabetes diagnosed?  
1-  By your GP 
2-  By hospital clinic  
3-  By friend/ family  
4-  By ambulance/ A&E (Accident and Emergency) 
5-  By your self 
6-  By medical cheek-up (work, insurance) 
7-  Others please state…………………………………… 
Q10. What type of diabetes do you have? 
1-  Type 1 
2-  Type 2 
3-  I don’t know 
4-  Other Please state 
 Q11. Is there a history of diabetes in your family? 
1. No 
2.  If Yes Please state who……………….. 
Q12. Please state your weight, height  
1. Height………… 
2. Weight……….. 
Q13. What was your HbA1c when you were diagnosed with diabetes? (if known) 
1- Below 5 % (31) 
2- Between 5.1 and 6 % (31 and 42 ) 
3- Between 6.1 and 7 % (43 and 53 ) 
4- Between 7.1 and 8 % (54 and 64 ) 
5- Between 8.1 and 9 % (65 and 75 ) 
6- Between 9.1 and 10 % (76 and 86) 
7- Over 10.1 %(86) please state…………………………………. 
Q14. What was your average HbA1c before using insulin pump therapy? 
1- Below 5 % (31) 
2- Between 5.1 and 6 % (31 and 42 ) 
3- Between 6.1 and 7 % (43 and 53 ) 
4- Between 7.1 and 8 % (54 and 64 ) 
5- Between 8.1 and 9 % (65 and 75 ) 
6- Between 9.1 and 10 % (76 and 86) 
7- Over 10.1 %(86) please state…………………………………. 
8- Don’t know 
Q15. What is your average HbA1c now that you are using insulin pump therapy? 
1- Below 5 % (31) 
2- Between 5.1 and 6 % (31 and 42 ) 
3- Between 6.1 and 7 % (43 and 53 ) 
4- Between 7.1 and 8 % (54 and 64 ) 
5- Between 8.1 and 9 % (65 and 75 ) 
6- Between 9.1 and 10 % (76 and 86) 
7- Over 10.1 %(86) please state…………………………………. 
8- Don’t know 
Q16. What do you think your HbA1c should be? 
1- Below 5 % (31) 
2- Between 5.1 and 6 % (31 and 42 ) 
3- Between 6.1 and 7 % (43 and 53 ) 
4- Between 7.1 and 8 % (54 and 64 ) 
5- Between 8.1 and 9 % (65 and 75 ) 
6- Between 9.1 and 10 % (76 and 86) 
7- Over 10.1 %(86) please state…………………………………. 
8- Don’t know 
Q17.In the last 12 months, have you had any of the following tests?  
 Yes No Don’t know 
1. Your blood pressure taken by a doctor or nurse.    
2. A cholesterol test by a doctor or nurse.    
3. An eye test where a photograph of the back of your eyes was taken.    
 4. Your bare feet were examined.    
5. You have had your weight checked by a doctor or nurse.    
Q18. For each question please tick yes or no. 
 Yes No 
1. Has your eyesight suffered as a consequence of your diabetes?   
2. Do you have diabetic kidney disease?   
3. Do you require dialysis?   
4. Have you had a kidney transplant?   
5. Is your usual blood pressure normal?   
6. Do you take any medication to control your blood pressure?   
7. Are you on lipid lowering medication (for high cholesterol or triglycerides)?   
8. Have you ever had a heart attack?   
9. Do you ever have chest pain due to angina?   
10. Have you ever had heart bypass surgery (coronary artery bypass)?   
11. Have you ever had a balloon angioplasty or a coronary stent placed?   
12. Have you ever had, or suspected that you had a stroke?   
Q19. Please tell us what you cholesterol levels are, if know? 
1. Total cholesterol level ……………………………………. 
2. High-density lipoprotein (HDL)………………………….. 
3. Low-density lipoprotein (LDL)……………………………   
Q20. Do you take medication to lower your cholesterol such as statins?  
1- Yes 
2- No  
Your insulin Pump 
Q21. What kind of insulin pump do you use? 
1- Medtronic Paradigm 
2- Roche 
3- Animas 
4- Smiths Medical – Cozmo  
5- Accu-Chek Spirit  
6- Other, please state 
Q22. How many years have you been using a pump? 
1- Less than 1 year 
2- Between 1 and 3 years 
3- Between 3 and 5 years 
4- More than 5 years 
Q23. What kind of insulin do you infuse into your pump? 
1- Human insulin - Actrapid® 
2- Insulin lispro - Humalog® 
3- Insulin glulisine - Apidra® 
4- Insulin Aspart - Novorapid® or Novolog 
5-  Humulin S® 
6-  Humulin I® 
7-  Insulatard® (Isophane) 
8-  Mixtard® 
9-  Humulin M3® 
10-  Levemir® (detemir) 
11-  Lantus® (Glargine) 
 12- Other, please state…………………... 
Q24. Typically, what are your basal rates throughout a non-exercise day? 
1-  Less than 0.5Unit/hr 
2-  Between 0.5Unit/hr and 1Unit/hr 
3-  Between 1Unit/hr and 2Unit/hr 
4-  More than 2Unit/hr 
Q25. How do you bolus for meals on a non-exercise day? 
1-  Standard bolus (Spike) 
2-  Extended bolus (Square wave) 
3-  Combination bolus (Spike and Square wave) 
4-  Super bolus (Increased spike) 
5-  Other, please specify………………………… 
Q26. What was the total amount of insulin you typically use on a non-exercise day? 
1- Less than 20Units 
2- Between 21Units and 30Units 
3- Between 31Units and 40 Units 
4- Between 41Units and 50 Units 
5- Between 51Units and 60 Units 
6- More than 61 Units, please state…………………………… 
Q27. How many times you test your blood glucose on a non exercise day? 
1- 1-3 times 
2- 4-6 times 
3- More than 6 times 
Q28. Typically, what are your basal rates throughout an exercise day? 
1-  Less than 0.5Unit/hr 
2-  Between 0.5Unit/hr and 1Unit/hr 
3-  Between 1Unit/hr and 2Unit/hr 
4-  More than 2Unit/hr 
Q29. How do you bolus for meals on an exercise day? 
1-  Standard bolus (Spike) 
2-  Extended bolus (Square wave) 
3-  Combination bolus (Spike and Square wave) 
4-  Super bolus (Increased spike) 
5-  Other, please specify…………………….. 
Q30. What was the total amount of insulin you typically use on an exercise day? 
1- Less than 20Units 
2- Between 21Units and 30Units 
3- Between 31Units and 40 Units 
4- Between 41Units and 50 Units 
5- Between 51Units and 60 Units 
6- More than 61 Units, please state…………………………… 
Q31. Do you use pre-exercise bolus? 
1. No  
2. Yes, please state how much…………… 
Q32. What is acceptable blood glucose (BG) before exercise? 
1-  Below 4 mmol/l (72 mg/dl) 
2-  Between 4-7 mmol/l (72-126 mg/dl) 
3-  Above 7 mmol/l (126 mg/dl) 
Q33. How does exercise change your blood glucose? 
 1-  Increase your blood glucose 
2-  Decrease your blood glucose 
3-  No change 
Q34 .How many times do you test your blood glucose on an exercise day? 
1- 1-3 times 
2- 4-6 times 
3- More than 6 times 
Q35. If your blood glucose was less than 4mmol/L (72 mg/dl) pre-exercises, what would 
you do? 
1. Miss out your pre-exercise bolus 
2. Reduce your pre-exercise bolus 
3. Leave the exercises today 
4. Postpone exercise for another day 
5. Take some carbohydrate then exercise 
6. Nothing 
7. Other, please state…………………………………………… 
Q36. If you experienced a hypoglycemia (low blood glucose) after exercise what action 
would you take? 
1- Reduce the insulin rate 
2-Increase the insulin rate 
3- Wait to re-check the blood glucose 
4-Drink water or any drink with low calories 
5-Seek medical help 
6-Other (please specify)………………………….. 
 
Section C: Your attitude to exercise 
Q37.How important is participating in sport and exercise to you? 
1-Important 
2- No view   
3- Not important at all 
Q38 .Have you always led an active exercise lifestyle? 
1- Yes 
2- No 
3- Please explain how ……………………….. 
Q39. Typically what is your blood sugar value pre-exercise? 
1- Below 5 mmol/l (90 mg/dl) 
2- Between 5.1 and 6 mmol/l(91-108 mg/dl) 
3- Between 6.1 and 7 mmol/l (109-126 mg/dl) 
4- Between 7.1 and 8 mmol/l (127-144 mg/dl) 
5- Between 8.1 and 9 mmol/l(144-162 mg/dl) 
6- Between 9.1 and 10 mmol/l (163-180 mg/dl) 
7- Over 10.1 mmol/l, (181 mg/dl) please state…………………………………. 
 
 
 
 
 Q40.  Please tick (✓) appropriate box 
 Yes, please state No, please state 
1. Is your pump switched on during exercise?   
2. Do you have any pump problems during exercise?   
Q41. If you don’t switch your pump on during exercise, do any of the following apply? 
1- You are not sure about the pump sensitivity during exercise 
2- You are worried about discomfort 
3- You worry that your  blood glucose goes up to abnormal level (hyperglycemia) 
4- You worry that your blood glucose goes down (hypoglycemia) 
5- Interferes with exercise program 
6- Advised by medical professional to switch pump off during exercise 
7- Other……………………. 
Q42.How much exercise did you participate in before you started your pump therapy?  
1- None 
2- Less than 1 hour a week 
3- between 1-3 hours a week 
4- More than 5 hours a week 
5-  Other…………………………. 
Q43.Has this changed since you have been on your pump? 
1- No  
2- Yes, please state…………………………….. 
Q44.What would you say the level of intensity is when you exercise? 
1. Light(Easy, does not induce sweating unless it's a hot, humid day, no noticeable 
change in breathing patterns.) 
2. Moderate(Somewhat hard, sweat after about 10 minutes of exercise. Breathing 
becomes deeper and more frequent.) 
3. Heavy(Hard, sweat after 3-5 minutes. Breathing is deep and rapid.) 
Q45.Typically, what type of exercise do you do?  
1- Aerobic exercise (e.g. walking, cycling, jogging and swimming)  
2- Anaerobic exercise (e.g. resistance training and weight lifting) 
3- A mixture of aerobic and anaerobic 
4- Other………………….. 
Q46. Please select all that apply. 
1. Walking  
2. Cycling   
3. Free Weights  
4. Swimming  
5. Sit ups/ Push ups  
6. Yoga  
7. Team Sports Basketball/Football  
8. Running  
9. Boxing/ Kick Boxing  
10.  Combination, e.g: combined walking and weight lifting  
11.  Cross-training (combining of exercises to work various parts of the body)  
12.  Other. Please state……………  
 Q47. Are there any barriers preventing you from taking part in more sport?  
1 Health reasons    2  
3 Lack of motivation    4  
5 Embarrassment about how I look .eg overweight or fitness lack 6  
7 Lack of time    8  
9 It does not interest me    10  
11 It is too expensive 12  
13 Lack of transport 14  
15 Fear of Injury 16  
17 Don't know 18  
19 Other, Please state……………………………. 
Q48. Typically, how many days in the week do you undertake physical activity? 
1. Every day 
2. 1-2 days 
3.  3-5 days 
4.  None 
Q49. In a typical exercise session how long do you spend participating in sport or 
exercise?   
1. Less than 30 minutes. 
2.  From 30 to 1 hour. 
3. From 1 to 2 hours. 
4. From 2 to 3 hours. 
5. From 3 to 4 hours. 
6. More than 4 hours. 
7. None  
Q50. How many times do you exercise per day? 
1. Once 
2. Twice 
3. 3 times. 
4. More than 3 times. 
Q51. Being physically active is good for the following, for each factor please place a tick 
in the box that you most agree with most? 
 Agree No view Disagree 
1. General Health    
2. HBA1c    
3. Blood glucose    
4. Hypoglycemia    
5. Hyperglycemia    
6. Diet    
7. Any additional comments…………………………………………………. 
Q52. Where do you typically exercise?   
1.  At school/ college/ work/ university 
2.  In a sports team (e.g. football, netball) 
3.  In a class or club (e.g. aerobics, dance, etc) 
4.  Gym  
 5.  On your way home or school. 
6.  Don’t know 
7.  Elsewhere, please state……………………………… 
 Q53. Are you a member of any sport centre or physical activity group? 
1. Yes 
2. No 
Q54. How often do you climb the stairs at home? (Average over the last 3 months): 
please tick one 
1- None  
2- 1 to 5 times a day 
3- 6 to 10 times a day 
4- 11 to 15 times a day 
5- 16 to 20 times a day 
6- More than 20 times a day 
Q55. Typically when do you do your exercises? Tick all that apply 
1. Morning 
2. Afternoon 
3. Evening 
4. After meal 
5. Before meal 
Q56. How often do you suffer with hypoglycaemia during a week?  
1- None 
2- Once 
3- 2 or 3 times 
4- More than3 times 
Q57. Has exercise increased or decreased the number of hypoglycaemia you have? 
1- Increase 
2- Decrease 
3-  No effect 
Q58. Do you experience hypoglycaemia while exercising? 
1- Always  
2- Frequently 
3- Rarely 
4- Never 
Q59. How many times per week is your measured fasting blood glucose 10 mmol/L (180 
mg/dl) or above? 
1.  Once  
2. Twice 
3.  More than twice times 
4.  Never 
Q60. What do you do if your blood sugar is over 10mmol/L (180mg/dl)? 
1. Reduce the insulin rate 
2. Increase the insulin rate 
3. Wait to reduce the blood glucose 
4. Drink water or any drink with low calories 
5. Seek medical help 
Q61. Have you ever experienced diabetic ketoacidosis as a consequence of exercise?  
1- Yes  
2-  No  
 Section D: Your diet  
Q62. Q.  How many calories do you think you eat and drink in a typical day? 
1. 1500 or less 
2.  Over 1500 up to 2000 
3.  Over 2000 up to 2500 
4.  Over 2500 up to 3000 
5.  Over 3000 up to 3500 
6. 3500 or more 
7. I don’t know 
Q63. Do you count carbohydrates regularly in order to help you to control your 
diabetes? 
1. Yes 
2. No 
Q64. Do you eat special diabetic food/ drink? (e.g. Low calorie, soft drink, diabetic 
chocolate etc…) 
1. Yes 
2. No 
Q65. Which of these are important to you? 
1-  Reducing fat 
1.  Staying motivated 
2.  Eating better 
3.  Finding someone to exercise with 
4.  Discovering a physical activity that you like 
5.  To reduce your HbA1c value 
6. Others, please state…………………. 
Q66. Do you see a dietician? 
1- Frequently 
2- Regularly 
3-  Never 
 Q67.Which of the following factors influenced your decision to participate in sport? 
Please tick all that apply  
 Because friends/ family do it    To improve your health    
 Because doctor advised you To relieve stress and relax   
 To keep well with your diabetes You are overweight 
 To improve your physical appearance, self-motivation  Because of HbA1c is high  
 Because you are unfit   Don't Know    
Dietician DSN (Diabetic Specialist Nurse) 
 Other (please specify)…………………………………………………………… 
Q68. Do you follow a medically approved dietary programme? 
1. No  
2. Yes (please specify)………………………………… 
Q69. How would you describe your diet approach to you?   
1.Your eating habits are healthy  
2.You are too busy to find healthy foods or meals 
3. You don't know enough about good nutrition or how to eat healthily 
4. Sometimes, you try to eat healthy food  
 5. You can’t resist junk food 
6. Your eating habits are poor 
Q70.What other factors affect your eating habits?  
1. Your parents and/or family don’t eat healthily. 
2. Your school / work don’t offer healthy choices at lunch or mealtimes  
3. You and your friends are always going out to eat and socializing over food and you end up eating 
lots of junk food.  
4.You really don’t feel like it’s worth it or have the motivation to try to change your habits. 
5. You eat healthy diet 
6. Others  
Q71. Do you drink alcohol? 
1- Yes 
2- No 
1-  Yes, but not on the exercise day 
Q72. Do you smoke on an exercise day? 
1-Do not smoke 
2- Yes, please state how many……………………. 
Q73. How often are you ever too unwell or stressed to exercise?  
1. Frequently 
2. Sometimes  
3. Rarely 
4. Other (please specify) 
Q74 .Have you experienced any of the following symptoms after exercise? 
1. Bleeding 
2. Chafing 
3. Flushing Hives 
4. Hypothermia 
5. Muscle cramps 
6. Red face 
7. Shortness of breath 
8. Urinary (pain,colour or blood) 
9. None 
 
Q75. Please write any comments you would like to add 
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Standard Operation Procedure (SOP) 
Title of Project: The effects of aerobic and resistance exercise on diabetes 
Name of Principal Investigators: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd Alblihed  
 
Preliminary procedures 
Before enrolling in the study the volunteer will be asked to attend a screening visit where we will: 
 discuss and complete confidential questionnaires regarding his health, family 
history and physical activity level. 
 measure his blood pressure. 
 measure his height and weight  
 provide an opportunity for him to ask questions 
 familiarise him with equipment to be used in the study and teach him how  to use 
the recumbent ergometer bike and how to lift the weights safely in the multigym 
machine. 
 This session will also be used to determine the intensity of exercise (moderate 
intensity) on the recumbent ergometer bike and how much weight he should lift 
in the resistance exercise session later.  
These preliminary procedures will enable us to determine whether the volunteer suitable to 
safely participate in the study or not. 
Main experimental trials  
The main experimental trials will involve 2 x 2 hour exercise sessions a week for a 6- week 
period,( exercise session includes rest + final observation of volunteer for hypos etc…). 
Blood glucose levels will be monitored before, during and after each session, using a standard 
finger prick test. Cholesterol, High density lipoprotein and Triglyceride will be monitored 
before, during and after exercise programme and after the second session in each week of 6 
weeks of exercise programme using a finger prick test. There may be occasions when the 
volunteer may not be allowed to participate if that or another health issue is deemed to 
threaten wellbeing. 
 Each exercise session will consist of a combined  exercise protocol of 30 min of resistance 
exercise (3 sets of 8 -10 repetitions at 50 – 60% of one-repetition maximum strength 1-RM ) 
using upper and lower muscle groups followed by 30 min moderate cycling at 50 – 60% of  
predetermined maximum heart  rate (HRmax)  or ratings of perceived exertion (RPE). 
The exercise session will include the following 6 phases: 
1. Warm-up: start with cycling for 5 - 10min on the recumbent ergometer bike at low to 
moderate intensity (30 to 40% of HRmax). Warm-up is an essential part of the exercise 
session and designed to prepare the body for exercise, increase body temperature and to 
reduce the potential post-exercise injury or pain (muscle stiffness). 
2. Stretching: stretch lower and upper muscle groups for 5 min  
loosens upper arm and 
chest muscles 
Stretching shoulder, middle 
back, arms, hands, fingers, 
wrist 
 
 
 
Stretching the back and 
shoulder muscles 
Stretching the chest, top of 
shoulder and lower arm 
muscles 
 
Stretching the 
shoulders and neck 
Stretches triceps, top of 
shoulders, waist 
 
 
 
 
 
Stretching the quadriceps 
 
 
Hip flexor stretches 
 
 
 
 
Chest stretch for pectoral muscle 
Stretches inner thigh, groin 
 
 
 
 
Stretches side of shoulder and back of upper 
arm 
  
3. Resistance exercise:  this phase will include 30 min of five different exercises working 
upper and lower muscle groups (3 sets of 8 -10 repetitions at 50 – 60% of one-repetition 
maximum strength 1-RM )  and using the Multigym machine 
Working muscle groups as follows: (3 sets of 8 -10 repetitions each exercise) 
a. Squat b. Incline bench 
press 
c. lat curl pull 
down 
d. Triceps e. Biceps  
 
4. Cycling 
The volunteer will do moderate cycling at 50 – 60% of  predetermined maximum heart rate 
(HRmax)  or ratings of perceived exertion (RPE) for  30 min. The volunteer and the bike will 
be attached to monitoring equipment that can produce instant graphical representation of 
performance linked to work done and produce different metabolic parameters such as Oxygen 
consumption (VO2), Carbon Dioxide Production (VCO2), Respiratory Exchange Ratio 
(RER), Heart rate (HR) etc. The volunteer attachment will be via a breathing mask and by 
ECG stick-on electrodes. 
 
 5. Cool-down: cycling for 5 - 10min on the recumbent ergometer bike at low to moderate 
intensity (30 to 40% of HRmax). The purpose of the cool-down phase is reducing the risk 
of injury and brings the body physiological responses back to normal such as heart rate 
and blood pressure. 
6. Stretching: stretch lower and upper muscle groups for 5 min. 
 
 
 
 
     
I ………………………………(NAME AND ADDRESS OF PARTICIPANT)    would like 
to participate in a focus group/interview in the DMU research study ‘Investigating views on 
acceptable methods for controlling blood sugar’. 
 
 
 
 
___________________________     ___________________ 
Signed by Participant       date 
 
Name …………………………………..Address…………………………………………….. 
 
Postcode……………………………….. Telephone number …………………………………. 
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   Volunteer Information Sheet (VIS) General practitioner  
Title of Project: The effects of aerobic and resistance exercise on diabetes 
Name of Principal Investigators: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd Alblihed  
         Date 26/10/2011 
Dear general practitioner  
We would like to give you some information and details about the research study. This 
information is just to understand why the research is being done and what it would involve 
for the volunteer. Please take time to read the following information carefully. Talk to the 
volunteer about the study if you wish.  
Ask us if there is anything that is not clear or if you would like more information.  
What is the purpose of the study? 
As part of the growing research work into diabetes, School of Pharmacy, De Montfort 
University (DMU) are working to investigate  the effects of  combined exercise programme 
(aerobic and resistance)  on blood glucose, metabolic and immunological parameters that 
could help people with the management of their diabetes. 
This research involves a combination of two types of exercises and this is where we need the 
volunteer help. We would like to invite the volunteer to take part in this study which will help 
us to understand the role of exercise and how it can help people with diabetes to maintain a 
healthy body weight and to possibly better manage their blood glucose level. 
We will keep volunteer information strictly confidential and nobody other than the research 
team will have access to the volunteer personal information.  
Before any research goes ahead it has to be checked by De Montfort University Research 
Ethics Committee. They make sure that the research is fair.  
Why the volunteer have been invited? 
 The volunteer have been invited to take part in this study because he is male and have either 
Type 1 or Type 2 diabetes, and his age between 18 - 55. 
Does he have to take part? 
It is up to him to decide. We will answer any questions he has about the study and go through 
this information sheet. We will then ask him to sign a consent form to show he has agreed to 
take part. The volunteer is free to withdraw at any time, without giving a reason. This would 
not affect the standard of care he is receiving from his doctor or hospital. 
What will happen to the volunteer if he takes part? 
Preliminary procedures 
Before enrolling in the study the volunteer will be asked to attend a screening visit where we will: 
 discuss and complete confidential questionnaires regarding his health, family history and 
physical activity level. 
 measure his blood pressure. 
 measure his height and weight  
 provide an opportunity for him to ask questions 
 familiarise the volunteer with equipment to be used in the study and  teach him how to 
use the recumbent ergometer bike and how to lift the weights safely in the multigym 
machine. 
 This session will also be used to determine the intensity of exercise on the recumbent 
ergometer bike and how much weight the volunteer should lift in the resistance exercise 
session later  
These preliminary procedures will enable us to determine whether the volunteer is suitable to 
safely participate in the study. 
Main experimental trials  
The main experimental trials will involve 2 x 2 hour exercise sessions a week for a 6- week 
period. (Exercise session includes rest + final observation of volunteer for hypos etc…). 
 Blood glucose levels will be monitored before, during and after each session, using a 
standard finger prick test. Cholesterol, high density lipoprotein and triglyceride will be 
monitored before, during and after exercise programme and after the second session in each 
week of 6 weeks of exercise programme using a finger prick test. There may be occasions 
 when the volunteer may not be allowed to participate if that or another health issue is deemed 
to threaten wellbeing. 
Each exercise session will consist of a combined  exercise protocol of 30 min of resistance 
exercise (3 sets of 8 -10 repetitions at 50 – 60% of one-repetition maximum strength 1-RM ) 
using upper and lower muscle groups followed by 30 min moderate cycling at 50 – 60% of  
predetermined maximum heart  rate (HRmax)  or ratings of perceived exertion (RPE). 
The exercise session will include the following 6 phases: 
1. Warm-up: start with cycling for 5 - 10min on the recumbent ergometer bike at low to 
moderate intensity (30 to 40% of HRmax). Warm up is an essential part of the exercise 
session and designed to prepare the body for exercise, increase body temperature and to 
reduce the potential post-exercise injury or pain (muscle stiffness). 
2. Stretching: stretch lower and upper muscle groups for 5 min as shown in standard 
operating procedure. 
3. Resistance exercise: this phase will include 30 min of five different exercises working 
upper and lower muscle groups (3 sets of 8 -10 repetitions at 50 – 60% of one-repetition 
maximum strength 1-RM )  and using the multigym machine  
4. Working muscle groups as shown in standard operating procedure. 
5. Cycling 
The volunteer will do moderate cycling at 50 – 60% of  predetermined maximum heart  
rate (HRmax)  or ratings of perceived exertion (RPE) for 30 min. The volunteer and the 
bike will be attached to monitoring equipment that can produce instant graphical 
representation of performance linked to work done and produce different metabolic 
parameters such as Oxygen consumption (VO2), Carbon Dioxide Production (VCO2), 
Respiratory Exchange Ratio (RER), Heart rate (HR) etc…. The volunteer attachment will 
be via a breathing mask and by ECG stick-on electrodes. 
6. Cool-down:   cycling for 5 - 10min on the recumbent ergometer bike at low to moderate 
intensity (30 to 40% of HRmax). The purpose of the cool-down phase is reducing the risk 
of injury and brings the body physiological responses back to normal such as heart rate 
and blood pressure. 
7. Stretching: stretch lower and upper muscle groups for 5 min. 
Expenses and payments  
We would like to pay expenses to the volunteer and to offer an incentive of £50 each on 
completion of 50% and £120 on completion of 95% of the dates agreed to. 
 What are the possible benefits of taking part? 
There may be no benefits to the volunteer but as a result of being involved in this study he 
will receive health and fitness information about himself including fitness tests and body 
measurement. The findings of this study will be published in scientific Journals so that 
understanding about how exercise can help people with diabetes to improve their health and 
control their weight and blood glucose levels. This information may contribute towards 
improved exercise guidelines for the diabetic patients. 
We will provide the volunteer with feedback about the main study findings and also about his 
own results and would be delighted to explain our findings and discuss possible implications 
with him. 
What if there is a problem?  
The chance of something going wrong is small. All of the procedures involved in this study 
are low risk and our screening tests are designed to ensure that the volunteer will only 
participate if it is safe for him to do so. However, if he has any concerns at any time about 
any aspect of the way he has been approached or treated during the course of this study, he 
should ask to speak to the researchers who will do their best to answer his questions (contact 
details below), and the normal De Montfort University complaints mechanisms will be 
available to him. 
Will the volunteer taking part in the study be kept confidential? 
All information that is collected about the volunteer during the course of the research will be 
kept strictly confidential. Any information about him, which leaves the University, will have 
his name and address removed so that he cannot be recognised from it. 
What will happen if the volunteer don’t want to carry on with the study? 
While we do not expect the programme to cause the volunteer to become upset if this does 
happen then he will have the option to pause or stop his participation immediately, he may 
continue only if he wanted to. If he withdraw from the study, we will destroy all his 
identifiable data, but may use the data collected up to his withdrawal.  
Who has reviewed the study? 
This study has been reviewed and approved by the Faculty of Health and Life Sciences Ethics 
Committee at De Montfort University. Approval does not guarantee that he will not come to 
any harm if he takes part. However, approval means that the committee is satisfied that the 
 volunteer rights will be respected, that any risks have been reduced to a minimum and 
balanced against possible benefits and that he has been given sufficient information on which 
to make an informed decision. 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have any doubts 
or questions, please ask for further explanations by contacting Ahmed Alsabih on 
p09053155@myemail.dmu.ac.uk or Mohamd Alblihed on p06004947@myemail.dmu.ac.uk 
or Prof.Taylor on 01162506317 or mjt@dmu.ac.uk . 
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Leicester School of Pharmacy 
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Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
Consent Form 
Title of Project: The effects of aerobic and resistance exercise on diabetes 
Name of Principal Investigator: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd Alblihed  
Please initial at the end of each point 
1. I confirm that I have read and understand the Participant Information Sheet dated. 
(05/10/2011) (Version 2) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. I understand that 
agreeing to take part means that I am willing to undertake some exercise and giving samples 
in the above study. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my legal rights being affected. 
3. I understand that any information I provide is confidential, and that no information that 
could lead to the identification of any individual will be disclosed in any reports on the 
project, or to any other party. No identifiable personal data will be published. The identifiable 
data will not be shared with any other organisation.   
4. I understand that confidentiality can be guaranteed for information which I might disclose 
in any session or visit I attend. I understand that this information will be used only for the 
purpose(s) set out in this statement and my consent is conditional on the University 
complying with its duties and obligations under the Data Protection Act 1998.  
5. I agree to take part in the above study. 
 
Participant Name…………………….. Signature…………………….Date…………………. 
Person Taking consent………………...Signature……………………Date………………….. 
When completed, copy for patient; copy for researcher site file. 
 
 Appendix I 
Leicester School of Pharmacy 
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Volunteers Health Screen for Study Volunteers 
Name: ……………………………… Volunteer Identification Number……………………. 
It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continuing well-being and (ii) to avoid the possibility of individual health issues confounding 
study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
At present, do you have any health problem for which you are: 
(a) on diabetes medication, prescribed or otherwise         yes [    ]           no [ ]   
(b) other medication                                                         yes [    ]           no [ ] 
(b)  attending your general practitioner                       yes [    ]           no [ ] 
(c) on a hospital waiting list                                  yes [     ]          no [ ] 
In the past two years, have you had any illness which required you to: 
(a) consult your GP yes [ ] no [ ] 
(b) was this related to diabetes    yes [ ] no [ ] 
(b) attend a hospital outpatient department  yes [ ] no [ ] 
(c) be admitted to hospital     yes [ ] no [ ] 
 
Have you ever had any of the following: 
(a) Convulsions/epilepsy     yes [ ] no [ ] 
(b) Asthma      yes [ ] no [ ] 
(c) Eczema      yes [ ] no [ ] 
(d) Heart problems     yes [ ] no [ ] 
(e) A blood disorder     yes [ ] no [ ] 
(f) Head injury      yes [ ] no [ ] 
(g) Digestive problems     yes [ ] no [ ] 
(h) Hearing problems     yes [ ] no [ ] 
 (i) Problems with bones or joints   yes [ ] no [ ] 
(j) Disturbance of balance/co-ordination   yes [ ] no [ ] 
(k) Numbness in hands or feet    yes [ ] no [ ] 
(l) Disturbance of vision     yes [ ] no [ ] 
(m) Thyroid problems     yes [ ] no [ ] 
(n) Kidney or liver problems    yes [ ] no [ ] 
(o) Chest pain                               yes [ ] no [ ] 
(p) Any other health problems    yes [ ] no [ ] 
 
 
 
Do you currently smoke     yes [ ] no [ ] 
 Have you ever smoked                yes [ ] no [ ] 
  
 If so, for how long did you smoke and when did you stop? …………………… 
 
How many units of alcohol do you typically drink in a week? …………………. 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm whether 
problem was short-lived, insignificant or well controlled.) (Use a separate sheet if 
necessary) 
………………………………………………………………………………………………… 
…………………….……………………………………………………………………………
………………………………….…………………………………………….…………………
………………………………………….………………………………………………………. 
 
Name and address of your GP 
………………………………………………………………………………… 
 
Letter received from GP                                      
 Appendix J 
 
 
 
Private and confidential  
De Montfort University Diabetes and Exercise Group 2012 
Volunteer Record Sheet 
 
Volunteer Identification Number: 
 
TITLE…….… FIRST NAME………………………..… SURNAME…………………………….… 
DATE OF BIRTH…………………………………..…. AGE………………MALE / FEMALE … 
CORRESPONDENCE ADDRESS…………………………………………………………….... 
………………………………………………………… POSTCODE: …………………….………. 
HOME TELEPHONE: ……………………………….. MOBILE: ………………………….……….. 
WORK TELEPHONE ……………………………… 
EMAIL ADDRESS: …………………………………………………………………………………. 
Please tick    I am happy for De Montfort University Diabetes and Exercise Group to contact me by 
email  
(We may will be sending key information via emails, so please include an up to date email 
address that you will check on a regular basis)  
PERSON TO CONTACT IN CASE OF EMERGNCY………………….……………………… 
RELATION TO YOU…………….……………………………………………………..………. 
HOME TELEPHONE: ……………………………….. MOBILE: ………………………….…. 
EMAIL ADDRESS: …………………………………………………………………………….. 
Type of diabetes?               Healthy        Type 1                   Type 2                    Other 
Number of years with DM duration………………..… 
Do you have any other medical conditions?   Yes/ No 
If yes, please state: ……………………………………………………….…… 
Do you have any specific dietary requirements?      Yes/ No 
If yes, please state: …………………………………………………………………. 
Name of your GP…………………………………….  Tel…………………………… 
Address …………………………………………………………….Post Code…………………. 
Do you have any existing medical conditions    Yes / No 
If yes, please state.………………..…………………………………………………………………..…  
Any infectious diseases                                       Yes / No 
 If yes, please state ……………………………………………………………………….……….. 
Have you been in hospitalised the past year        Yes / No  
If yes, why …………………………………………………………………………………………… 
History of acute diabetic complications  
 
    
 Number of Hypoglycemia (low blood sugar) event in last month………………………………….. 
Number of Hyperglycemia (high blood sugar) event in last month ………..……………………….  
Number of Diabetic ketoacidosis event in last month……………………………………………… 
Are you taking any medications, pills or drugs…………….....  If yes, please list and state dose 
………………………………………………………………………………………………….. 
Do you have any of the following?  
 Yes No   Yes  No  
Heart Disease   Liver Disease   
High Blood Pressure   Kidney Disease   
Rheumatic arthritis    Hepatitis   
Heart Murmur   Asthma   
HIV Positive /Aids    Tuberculosis (TB)   
Any allergy    Stroke   
Tumour (Cancer) History   Epilepsy   
Terminally or mentally ill   Any recent surgery   
Restriction in physical activity 
because of disease 
  Had an active infection   
Participation in exercise (aerobic or resistance) 2 times or more weekly for 20 
minutes or longer per session during the previous 6 months  
  
 
Diabetes mellitus DM 
Type of insulin…………………………………………..…………………. 
Units / day…………………………………………………….……………. 
Injections / day……………………………………………………..………. 
Blood glucose testes / day …………………………………………………. 
 
PLEASE RETURN THIS FORM TO: De Montfort University Diabetes and Exercise Group 
2012 
Participant Name…………………….. Signature…………………….Date…………………. 
 Appendix K 
Visit Measurements sheet 
 
TRIAL 1 TRIAL 2 
Sessions number  1 3 5 7 9 11 2 4 6 8 10 12 
1. Subject name/Ref Name  Ref: 
2. Date                  /         /                 /         / 
3. Food inventory sheet 
 
 
4. Temperature of the lab   
5. ADI calibration    
6. Zero all input 
 
 
7. Chest polar Attached   
8. RER at rest 5 min on (ADI)    
9. BP & HR   at rest   /          mm Hg           bpm  /       mm Hg                 bpm 
10. BG  before exercise  mmol/L mmol/L 
11. Stretching for 5 min     
12. Warm up on the bike for 5 
min (at 50-55 % HRR) 
 
 
Resistance Sets 1
st
 2
nd
 3
rd
 1
st
 2
nd
 3
rd
 
13. Exercise 1 Squat       
14. Exercise 2 Chest       
15. Exercise 3 Back       
16. Exercise 4 Triceps       
17. Exercise 5 Bicep       
 
RPE HR RPE HR 
18. After 1st  set of Resistance       
19. After 2nd  set of Resistance      
20. After 3rd  set of Resistance      
21. BG after Resistance                                             mmol/L                                             mmol/L 
22. BP & HR after Resistance /            mm Hg bpm  /          mm Hg bpm 
23. 5 minute break (attach the 3 
leads ECG, pulse rate and 
mouth piece)   
 
24. Start cardio exercise cycling  
 
 
 
RPE HR BG RPE HR BG 
25. At 10 min of Cycling 
  
    
26. At 20 min of Cycling  
 
    
27. Unattached the ECG  leads, 
HR chest polar and mouth 
piece) 
 
 
28. Stretching for 5 min 
 
 
29. BP & HR after Cycling             /            mm Hg bpm         /          mm Hg bpm 
30. BG after Cycling   
                                            mmol/L                                               mmol/L 
  
 Visits  
1
st
 6
th
 12
th
 
31.  Height    
32. Weight     
33. Body water %    
34. Body Fat %    
35. BMI    
36. Blood  Gases  
A. Blood pH 
   
B. pCO2 mmHg    
C. pO2 mmHg    
37. Electrolytes   
A. K+  mmol/L    
B. Na+ mmol/L    
C. Ca+ mmol/L    
D. Cl- mmol/L    
E. Lactate mmol/L     
38.  Lipids profile  
 
A. LDL mmol/L    
B. HDL mmol/L    
C. Total cholesterol mmol/L    
D. Triglyceride mmol/L    
39. Creatinine μmol/L    
40. HbA1c 1
st
  12
th
  
41. Waist (cm):   1
st
  12
th
  
42. Hip (cm):   1
st
  12
th
  
43. Waist/HIP Ratio:   1
st
  12
th
  
44. Blood samples for Immuno 
assay 
Acute exercise  Chronic exercise 
2
nd
 4
th
 6
th
 8
th
 12
th
 
Before 
Exercise 
After  
Resistance 
After 
Cycling  
 
 
 
 
 Appendix L 
Assessment of caloric intake 
FOOD INVENTORY INSTRUCTIONS 
It is important that you weigh and record everything that you eat and drink except water for 
theday prior to each main experimental trial. Please do not take any alcohol on these days.  
Please    (i) start a separate page for each day.             
(ii) start a separate line for each item.              
(iii) for the day before exercise, try 
to eat same food as similar as you 
can.      
Column 1  
Record meal and time and place of eating. 
Column 2  
Describe each item as accurately as possible, stating where relevant: 
(i) Type and brand 
(ii) Whether food is fresh, dried, canned, frozen, salted, smoked, etc. 
(iii) Whether food is cooked, if so give method of cooking e.g. fried, baked, etc. 
Column 3  
Record the weight of each item after cooking: 
(i) Place scales on a level surface 
(ii) place plate or container on top of scales 
(iii) press 'ON/Reset' button to turn on scales 
(iv) once zero appears, add first item of food 
(v) record weight displayed 
(vi) press reset button before weighing next item 
Wherever possible, record weights in grams. If this is not possible, record weights in 
household measures (e.g. sugar or jam in teaspoons, stating whether level, rounded, or 
heaped). 
Column 4  
Record the weight of any leftovers, such as food remaining on plate, weight of container in 
which food has been weighed, apple cores, etc. 
Columns 5 and 6   
Please leave 
blank. 
 If food consists of several items, please list each on a separate line i.e. instead of writing 'one 
cheese sandwich', record separately the weights of bread margarine, cheese, etc. 
Please remember to record all drinks, as well as food, giving weights where possible, or 
volumes if these are known. Record separately the weight of added milk and sugar.  
An example is shown overleaf.  
Food Inventory - Example 
Name:.......................................................................Date:................................................... 
1 
 
2 
 
3 4  
Time/Place Description of food/drink Weight of 
food/drink 
(g)
 
Weight of 
container/ 
leftovers (g) 
Leave 
Blank 
5 6 
Breakfast Cornflakes (Kelloggs) 28   
8:30am Milk (Sainsbury's virtually fat-
free) 
48   
Home Bread (Mothers Pride, large 
white 
76   
 sliced, toasted)    
 Flora margarine 7   
 Robinsons lemon marmalade 12   
 Coffee (instant) 2   
 Milk (whole pasteurised) 10   
     
Lunch Cheese (Cheddar) 55   
1:00pm Bread (white, crusty) 76   
Pub Butter 4   
 Chutney (2 teaspoons)    
     
Snack Coffee (instant) 2   
3:30pm Coffee-mate 6   
Office Mars Bar 35   
 Apple 76 8 (core)  
     
Dinner Turkey Fillet (frozen, grilled) 102   
6:30pm Potatoes, old, boiled 320 74  
Home   (leftover)  
 Peas (Birds Eye, frozen, boiled) 50   
 Heinz tomato ketchup 14   
 Yoghurt (Ski strawberry thick and 162 10  
 creamy)  (carton)  
 Coffee, filter 148   
 Milk (Sainsbury's virtually fat-
free) 
8   
 
